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Abstract 
 
Impaired wound healing is associated with hyperglycaemia in patients suffering from 
diabetes mellitus. Hyperglycaemia induces protein glycation and the formation of 
advanced glycation endproducts (AGEs). The accumulation of AGEs in the body leads 
to structural and functional modifications of tissue proteins. Protein glycation is 
believed to play an important role in the development of diabetic complications. Thus, 
inhibition of AGE formation may have a role in the prevention of diabetic 
complications. This thesis was set out to evaluate the potential effects of compounds 
with antiglycation activities. The investigated compounds include S-allyl cysteine 
(SAC), N-acetylcysteine (NAC), as well as the synthesised derivative known as 
compound A. The extent of glycation in the presence and absence of a number of 
inhibitors include SAC/NAC and compound A were assessed by several methods 
including fluorescence, sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE)-silver stain, western blotting and enzyme-linked immunosorbent assays 
(ELISA). 
 
Moreover, this work aimed to evaluate and quantify the potential of human adipose 
mesenchymal stem cells (hADMSCs) to release these ‘drugs’ as potential therapeutics, 
and therefore hADMSCs were primed with SAC/NAC, compound A and 
concentration analysed using high performance liquid chromatography (HPLC). The 
SAC/NAC and compound A showed protective effects against AGEs formation. 
These inhibitors reduced the cell migration and tube formation of cultured bovine 
aortic endothelial cells (BAECs) while conditioned medium from SAC/NAC- and 
compound A-loaded hADMSCs induced the cell migration and tube formation in 
BAECs. HADMSCs provide a unique opportunity for developing a novel targeting 
and drug delivery system, which could effectively deliver therapeutics to specific 
regions of wounds or other damaged tissues. The results show the potential of 
hADMSCs as a drug delivery method with potential to improve wound healing. The 
findings from the in vitro study suggest that dietary supplementation with SAC, NAC, 
and compound A may offer protection against the damage from cross-linked AGEs 
and therefore would be a potential therapeutic targeting for the development of 
diabetic complications. 
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Chapter 1 -Introduction 
1.1 Diabetes  
Diabetes mellitus (DM) refers to a collection of chronic conditions that result from 
poor insulin production or insulin resistance causing hyperglycaemia. This high blood 
sugar and lack of insulin cause metabolic disorders impacting the ability to metabolise 
proteins, lipids and carbohydrates (Association, 2015; Yazdanpanah et al., 2015). The 
pathogenesis of DM seems to be influenced by a variety of factors including 
autoimmune disease, viral infection and environmental factors as well as genetic 
factors (Fu et al., 2013; Ott et al., 2014). 
 
Over recent years, diabetes has become increasingly widespread and established. This 
is thought to be caused by several factors from the extensive increase in consuming 
diets that are very calorie-rich to sedentary lifestyles, obesity and ageing populations 
( Ott et al., Caliceti et al., 2017). In 2000, diabetes was in the top five causes of death 
indicating how common this chronic disease is. It then became mankind’s third most 
common cause of death, ranking behind cancer and cerebrovascular and 
cardiovascular diseases (Diabetes, 2011; Durstine et al., 2013). In 2015, the figure 
indicating the number of global diabetic patients was 415 million but the World Health 
Organisation predicted this number to rise up to 642 million by 2040 (Bommer et al., 
2018). 
 
Diabetes has been classified into four subtypes by the World Health Organisation and 
the National Diabetes Data Group. Type 1 refers to insulin-dependent diabetes 
mellitus (IDDM). This results from insulin deficiency due to pancreatic β–cells being 
destroyed by the autoimmune system. Around 10% of diabetes cases are IDDM. Type 
2 is non-insulin-dependent diabetes mellitus (NIDDM) and results from multiple 
factors. NIDDM is when the glucose homeostasis regulation is abnormal as a result of 
resistance to insulin or a defect in insulin secretion, or a combination of the two 
(Ozougwu et al., 2013). Type 3 is Gestational diabetes mellitus (GDM) presents due 
to physiological stress or the inability to tolerate glucose normally during pregnancy 
(Appiah et al., 2016). GDM often resolves after the baby is born (Parsons et al., 2018). 
It is also possible for Type 4 to be present as a secondary to other conditions; it can 
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occur as a result of biological events, metabolic events, various drugs/chemicals, 
genetic abnormalities and environmental factors (Yanling Wu et al., 2014). Diabetic 
complications are not unusual and often represent a large cause of illness and death. 
Such complications impact the life quality of the patient and also add strain to 
healthcare authorities (Dart et al., 2014). 
 
1.2 High blood sugar level complications for diabetes sufferers 
Diabetic complications have been recognised as being caused primarily by prolonged 
high blood sugar levels. The ̎ Diabetes Control and Complications Trial ̎ research 
group and the ̎ United Kingdom Prospective Diabetes Study ̎ both studied the 
relationship between diabetic complications and the severity and duration of 
hyperglycaemia in type 1 and type 2 diabetic patients. The studies found a significant 
relationship between them, confirming prolonged hyperglycaemia as the principal 
factor for developing complications (Giacco and Brownlee, 2010). It has also been 
found that it is possible to delay the start and advancement of complications by 
controlling the levels of glucose in the blood (Chaudhury et al., 2017).  
 
Although the links between prolonged hyperglycaemia and damage to tissues have not 
been completely understood and there are several mechanisms that could link the two. 
These possible links include hyperactivity of the sorbitol-aldose reductase pathway or 
polyol pathway that converts glucose to fructose (Yan, 2014), hyperactivity of protein 
kinase C (Feng et al., 2012; Yan, 2014), hexosamine flux increase and the role of 
protein glycation biochemically (Fattori et al., 2016b). Before looking further into 
diabetic complications, we must first understand protein glycation’s background as 
well as its biological significance and chemistry.  
 
1.3 Investigating the reaction between amino acids and reducing sugars  
The Maillard reaction, or protein glycation reaction, are the names for a well-known 
and widely studied chemical reaction between amino acids and reducing sugars that is 
accelerated by heat (Echavarría et al., 2012; Newton et al., 2012). The Maillard 
reaction was first discovered in the early twentieth century by Louis Maillard and 
began as an observation of colour formation. Since these humble beginnings, the 
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reaction now has its own research capacity and within food chemistry is considered an 
incredibly important reaction (Echavarría et al., 2012). There have been numerous 
studies on the reaction in an attempt to reveal details as to how it occurs and how it 
results in colour and flavour changes. In 1925, Mario Amadori made a discovery, 
termed the Amadori rearrangement that identified the N-glycosides as the unstable 
products of Schiff bases. In 1942, H Doob studied the influence of moisture on the 
protein glycation reaction and its ability to control colour formation. The influence of 
components including iron and copper were also recognised for their ability to enhance 
the reaction and, in contrast, sulphates sulfates did the opposite by preventing the 
reaction (FINOT, 2005; Doob Jr et al., 1942). Research groups also identified that the 
sugar and amino acid decomposition actively aromatic aldehydes by-products (Figure 
1.1) (Hellwig and Henle, 2014). The decomposition was named Strecker degradation 
in 1948 after Adolph Strecker. John Hodge studied the chemistry of non-enzymatic 
browning reactions in dehydrated foods and in 1953 presented a complete structure of 
the browning reaction (Hodge, 1953). These findings created an abundance of 
literature on the subject. It was not until the 1960s that researchers began to explore 
what the reaction generated in terms of harmful products. In 1968, this led to glycated 
haemoglobin being discovered. This caused the focus to shift from the chemistry and 
nutritional aspects of the reaction to the role it plays within the human body. A range 
of advanced glycation end products (AGEs) was identified and this has been 
characterised and linked to various conditions including diabetes and Alzheimer’s 
disease. Within Maillard reaction research, its role within medicine is thought of as a 
distinct, independent matter (Gerrard, 2006). There has been another collection of 
reaction products produced by the Maillard reaction called process-induced toxicants 
that have been identified and researched in the last couple of decades. These unwanted 
products have drawn attention to foods processed by heat and in 1990 heterocyclic 
amines were identified, followed by a 2002 discovery of acrylamide in heat-processed 
food (FINOT, 2005). 
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Figure 1.1: A graphic timeline for some of the key discoveries made in the Maillard reaction 
literature 
 
1.4 Three stages of the Maillard reaction 
The protein glycation reaction first begins with an amino compound starting a basic 
nucleophilic attack on an electrophilic centre, for example, a carbonyl moiety, and this 
causes a generation of intermediates significant in producing the changes in taste, 
colour, texture and aroma of foods (Luevano-Contreras and Chapman-Novakofski, 
2010). 
 
It is also well known that the reaction causes harmful by-products including furans, 
heterocyclic amines, acrylamide and advanced biological and dietary glycation end 
products  (Troise and Fogliano, 2013). Despite the varying routes that can occur in 
different reaction products, Hodge provided the general scheme of the Maillard 
reaction in 1953 and this continues to be understood as an accurate representation of 
the processes that occur (Hodge, 1953). The scheme of the reaction is split into three 
stages (Figure 1.2). The reaction first begins when glycosylamine forms and 
dehydrates into a Schiff base, it then slowly rearranges into a more stable product 
known as a ketosamine adduct. This product, when the reducing sugar involved is an 
aldose, is known as an Amadori Rearrangement Product. If it is ketose that is the 
reducing sugar, then it is called the Heyn’s Rearrangement Product (Hodge, 1953; 
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Newton et al., 2012). The next stage of the reaction is the transformation that occurs 
of the products that were generated earlier, and this section is dependent on the pH. If 
the pH is up to but not including 7, the rearrangement compounds will produce 3-
deoxyosone after a 1,2-enolization resulting in elimination occurring. If the sugar that 
is involved is glucose rather than ketose or aldose, then a 3-deoxyglucosone will be 
converted to 5-hydroxymethylfurfural (HMF) when dehydration occurs. If, however, 
the pH is 7 or higher, the reactions will differ. Instead, the Amadori/ Heyn’s 
rearrangement products will go through a 2,3-enolization, something that is 
irreversible. This 2,3-enolization then has two possible routes, it can branch out to 
become 1-deoxyosone or 4-deoxyosone. This route results in the generation of 
dicarbonyls, reductones and several other products. There is also a sub-reaction that 
occurs at this stage, named Strecker degradation, and this can produce aldehydes, 
carbon dioxide and aminoketones by branching between the α-dicarbonyl compounds 
and amines. The production of aldehyde by Strecker degradation, as well as the 
products created from the condensation of aminoketones, are deemed to be important 
for the aroma of food. There are many chemical reactions that occur in this second 
phase of the Maillard reaction and they include; retroaldol reactions, aldol, enolization, 
dehydration, decarboxylation and Michael additions. The late stage of this reaction 
begins with the reaction of dicarbonyl compounds with free amino groups of proteins. 
This reaction undergoes a series of complex cascades of repeated dehydrations, 
condensations, fragmentations, oxidations and cyclisation reactions within the amino-
carbonyl reaction system (Schleicher et al., 2001). The formation of dicarbonyl 
compounds appears to be the rate-determining step for the cross-linking reaction, 
which subsequently leads to the formation of an extremely heterogeneous group of 
compounds called ‘advanced glycation endproducts’(Nursten, 2005). 
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Figure 1.2: Formation of AGEs in three stages  
i.e., early, intermediate and advanced. In the early stage, sugars react with a free amino group to form 
a Schiff base which undergoes a rearrangement to a more stable product known as an Amadori product. 
In an intermediate stage, the Amadori product degrades to a variety of reactive dicarbonyl compounds. 
In the advanced stage of the glycation process, AGEs (irreversible compounds) are formed (Tsekovska 
et al., 2016). 
 
1.5 Maillard reaction during cooking 
We can see evidence of this reaction in a wide range of locations from foodstuff to 
textiles, biological systems, pharmacological preparations and soils, all allowing the 
reaction to occur at moderately low temperatures (Luevano-Contreras and Chapman-
Novakofski, 2010). However, the main focus, particularly for the food industry and 
food scientists themselves, is when the protein glycation reaction occurs during the 
processing of food with a focus on frying, roasting, baking, grilling and cooking food 
(Newton et al., 2012). The reaction causes several enhancing attributes particularly 
when it comes to the taste, aroma and texture of foods. However, it also brings 
undesired effects. Therefore, the results of the Maillard reaction can be separated into 
two groups; desired and undesired.  
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1.5.1 Flavour, colour, texture and aroma 
The Maillard reaction has been a key point of the study of scientists for decades. The 
food industry aims to provide food that is healthy and safe while also appealing in 
several ways. The Maillard reaction alters foodstuffs in various ways and the products 
that are generated include amino sugars, Strecker aldehydes, pyrroles, pyrazines, 
furanones and more. The various products that are created play a substantial role in 
the end result of the food, particularly in terms of flavours (Yu and Zhang, 2010). 
 
1.5.2 Irreversible compounds and end products 
Protein glycation, in vivo, often occurs over an extended time period when excess 
glucose or other sugars within the body react with proteins due to the Maillard 
reaction. At the start of the reaction, the process can sometimes be reversible although 
this is dependent on the concentrations of glucose that are present. The process takes 
place over time and intermediates are formed over varying periods of time spanning 
from hours to weeks. HbA1C is an example of an Amadori reaction product that takes 
only a matter of days to form; the build-up of these products leads to the next stages 
of the reaction to take place, which are more advanced. Studies have shown that it is 
the final phase of the Maillard reaction where the advanced glycation end products are 
formed alongside malanoidins (Poulsen et al., 2013) The advanced glycation end 
products require an oxidative pathway so this is through either the Wolff pathway 
(autoxidation of glucose), the Namiki pathway (Schiff base) or the Hodge pathway 
(Amadori products) (Nursten, 2005). This can also include the peroxidation of lipids. 
Typically, oxidative stress is present, and this leads to reactive dicarbonyl compounds 
being generated. These compounds include 3-deoxyglucosone, methylglyoxal (MG) 
and glyoxal. These reactive dicarbonyl compounds will often react with amino acids 
such as lysine, arginine, proteins or peptides.  
 
1.6 Identifying AGEs  
These complex, heterogeneous molecules were originally recognised by their 
fluorescent yellow-brown colouring and their capability to cross-link between amino 
groups (Singh et al., 2014). With the AGEs chemistry remaining unclear, it has been 
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determined that the majority of the structures are in vitro as opposed to the few that 
have been identified in vivo. Based on the structures’ chemical and physical 
characteristics, AGEs have been catalogued into four separate groups, these are; non-
fluorescent cross-linked, fluorescent cross-linked, non-fluorescent non-cross-linked 
and fluorescent non-cross-linked (Figure 1.3).  
 
1.6.1 Major AGE structure 
The non-fluorescent cross-linked AGEs are thought to be the major AGE structures 
which hold a fundamental role in vivo protein cross-linking. Methyl-glyoxal-lysine 
dimers (MOLD) are a common type as well as glyoxal-lysine dimers (GOLD) 
(Ahmed, 2005; Elosta et al., 2012). 
  
1.6.2 Minor AGE structure 
The fluorescent cross-linked AGEs are considered the minor structures as they account 
for no more than 1% of all of the cross-linking molecules. Some fluorescent cross-
linked structures have been identified in vitro under physiological conditions such as 
vesperlysine A- B- C, pentosidine and crossline (Elosta et al., 2012). 
1.6.3 Non-fluorescent non-cross-linked AGEs  
This collection of AGEs are made under physiological conditions from protein 
glycation. Examples include carboxyethyllysine (CEL), carboxymethyllysine (CML), 
imidazolones and pyrraline (Elosta et al., 2012) 
 
1.6.4 Fluorescent non-cross-linked AGEs 
Fluorescent non-cross-linked AGEs have been found in the blood of patients with 
diabetes. A typical example of this would be argpyrimidine (Mashilipa et al., 2011; 
Elosta et al., 2012). 
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Figure 1.3: Chemical structures of four types of AGEs:  
(A) Fluorescence cross-linking AGEs such as vesperlysine; pentosidine and crossline. (B) Non-
fluorescent cross-linking AGEs such as GOLD: glyoxal-lysine dimers and MOLD: methyl-glyoxal-
lysine dimers. (C) Fluorescent non-cross-linked AGEs such as argpyrimidine. (D) Non-fluorescent non-
cross-linked AGEs such as CEL: N-carboxyethyl-lysine; CML: N-carboxymethyllysine and pyridine. 
 
 
1.7 Regulation of the Maillard reaction through physical factors 
1.7.1 Influence of pH 
pH seems to have a very large influence on the rate of reaction as well as the 
production of reactive intermediates. The effect pH has on the Maillard reaction has 
been a particular focus for many studies due to its substantial function in controlling, 
as well as impacting, the reaction. In the early stages, pH impacts the degradation of 
the Heyn’s/Amadori rearrangement compounds as well as their progressions into the 
applicable enolization route. Studies have shown the optimum pH in terms of the 
browning rate is between 6 - 10. In aqueous systems, acidic and basic buffer solutions 
are used to control the pH and the browning will often increase as the pH increases up 
to a high of 9 or 10. A low pH yields a low development of browning (Nursten, 2005). 
pH values from 8 to 10 have been found to enhance the browning and polymerisation 
of sugar-amino acid mixtures (Ajandouz et al., 2001). A pH of between 4.6 and 8 
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almost double the glucose degradation (Martins and Van Boekel, 2005a). This is likely 
due to the reactive materials of both the amino acid and the sugar being in ideal 
alkaline conditions (Newton et al., 2012). When non-aqueous reaction materials are 
considered, switching the neutral amino acids and sugars with charged counterparts, 
can control the acidity. This is a practical option, particularly in situations such as 
pyrolytic experiments where the non-aqueous model systems are being studied. In a 
2008 study on the influence of basic and acidic sugars in modifying the Maillard 
reaction in a monosaccharide-cysteine system, it was found that a more complex 
Maillard reaction profile was formed and, compared to the neutral monosaccharides, 
the charged sugars produced more volatile compounds (Kraehenbuehl et al., 2008). 
 
1.7.2 Influence of temperature on the browning reaction  
Temperature, like pH, can have a direct influence on the Maillard and the browning 
reactions (Martins and Van Boekel, 2005a). Maillard studied how increasing the 
temperature and duration of the reaction actually increased the reaction rate. A 
temperature from 125℃ up to 160℃ is considered the optimum temperature when it 
comes to browning (Coghe et al., 2006). End product formation and the depletion of 
reactants are considered to increase with the temperature rise. The Arrhenius equation 
is heavily relied upon in kinetic studies in order to determine the influence temperature 
has on the reaction rate (Martins and Van Boekel, 2005b). An increase of 10℃ can 
cause the reaction to double in speed, however, this causes not only the rise in the 
speed of the browning process but also leads to products that are potentially harmful 
being formed. For example, a reactive carbonyl compound and asparagine reacting at 
120℃  or more cause acrylamide to be produced (Stadler et al., 2002). 
 
1.7.3 How dehydration impacts the Maillard reaction  
Water activity (aw) also plays a big role in the Maillard reaction as it takes place 
through dehydration. However, the reaction rate actually decreases when moisture 
levels are higher as well as when the moisture levels are lower due to a larger dilution 
of reactants or an increase in diffusion resistance (Ames, 1990). There have been many 
studies that have focused on controlling the water levels and activity in order to 
stabilise the reaction. Another study found that the reactions of acrylamide formation 
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and elimination were enhanced when the water activity was decreased to 0.43 from 
0.972 (Bassama et al., 2011).  
 
1.8 Reducing sugars and reactive AGEs 
AGE molecules are generated as a result of Amadori products being oxidated as well 
as by lipid peroxidation. It has been indicated in several studies that, in addition to 
glucose, there are other reducing sugars that are also involved and more reactive that 
play a part in AGE formation (Ahmad et al., 2007). Forming via non-oxidative 
glyceraldehyde-3-phosphate fragmentation, the reducing sugars that are more reactive 
also produce AGEs that are more reactive in the intercellular compartment (Brownlee, 
2005). These findings led to further studies that took place using AGE inhibitors 
thiamine and benfotiamine. Benfotiamine, a lipid-soluble precursor to thiamine, has a 
higher bioavailability and has been found to reduce diabetes-associated complications 
in terms of severity due to its ability to prevent AGEs from being produced. The 
complications that were reduced in severity included nephropathy, neuropathy, 
angiopathy and retinopathy (Balakumar et al., 2010). By administering 7 days of 
glucose exposure to the endothelial cells, the level of AGEs was alleviated 14-fold. 
The increase is likely to have resulted from glycation by the highly reactive reducing 
sugars including fructose, glucose-6-phosphate and MG (Ahmed, 2005). 
 
1.9 Biological effects of AGEs 
Several pathological conditions are generated from aggregations and alterations of a 
variety of proteins that may cause tissue damage. For instance, accumulation of AGE 
formation leads to an accumulation of AGEs in tissues (Bohlender et al., 2005). AGE-
related tissue injury occurs as a result of the cross-linking of AGEs, increased free 
radical production, blocking particular functions of proteins and cross-talk with 
receptors for glycation end products (RAGEs) and accumulation of proteins (Rojas 
and Morales, 2004).  
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1.10 Receptor for advanced glycation end products 
AGE formation activates different signalling cascades mediated by the multi-ligand 
receptor RAGE. RAGE has a mass of 45-kDa and belongs to an immunoglobulin 
superfamily (Hudson and Schmidt, 2004; Srikanth et al., 2011). RAGE is a 
transmembrane receptor composed of 394 amino acids, with one hydrophobic 
transmembrane helix consisting of 19 amino acids, and a short cytoplasmic tail of 43 
amino acids. The extracellular part of RAGE comprises V-type and C-type 
immunoglobulin domains (Figure 1.4). The V-domain is important for ligand binding 
whereas the cytosolic tail regulates RAGE-mediated intracellular signalling (Srikanth 
et al., 2011). Molecular analysis of RAGE-transfected 293 cells showed a majority of 
bands with a molecular weight of ~ 50 kDa due to post-translational processing 
(Neeper et al., 1992). RAGE is highly expressed and particularly present in organs 
such as heart, lung, and skeletal muscle and different types of cells such as endothelial 
cells, macrophages, smooth muscle cells, mesangial cells and epithelial cells, 
lymphocytes, monocytes and neurons (Basta et al., 2004). Previous studies identified 
several AGE receptors, including lactoferrin, oligosaccharyltransferase complex 
protein 48 (AGE-R1), 80K-H protein (AGE-R2), galectine-3 (AGE-3), SRA, CD-36 
and receptors for AGE (RAGEs), which act as signal transducers for AGEs (Hudson 
and Schmidt, 2004; Bohlender et al., 2005). Moreover, RAGE is localised in different 
cell types, including another form of RAGE receptor called DN-RAGE, which is a 
dominant negative form, not of full length, which lacks the cystolic tail. It is located 
inside the membrane and functionally is blunted in mediating RAGE intracellular 
signalling pathways as shown in Figure 1.4 (Hallam et al., 2010). 
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Figure 1.4: Structure of RAGE. The extracellular part of RAGE contains one of the V-type 
immunoglobulin domains, followed by two C-type immunoglobulin domains. Dominant negative 
RAGE (DN-RAGE) is located inside the membrane and is functionally blunted in regulating RAGE 
pathways (Hallam et al., 2010). 
 
1.11 Diabetes mellitus and oxidative-stress signalling pathways 
The production of AGEs is a consequence of hyperglycaemia and contributes to the 
generation of oxidative stress in several tissues (Elosta et al., 2012). Generation of 
reactive oxygen species (ROS) causes injury to cell components such as proteins, 
lipids and nucleic acids (DNA and RNA). Thus, the presence of natural, endogenous 
antioxidant enzymes such as catalase (CAT), superoxide dismutase (SOD) and 
glutathione peroxidase (GPx) is crucial to engulf ROS and maintain normal cellular 
functions. When the endogenous antioxidant system is inhibited, the restoration of 
cellular redox decreases the complications of DM (Tang et al., 2012).  
Binding AGEs to RAGEs leads to the generation of a variety of biological effects such 
as the elevated secretion of cytokinase, and inflammatory cytokines (e.g. tumour 
necrosis factor-α (TNF-α), interleukin-1α (1L-1α) and interleukin-6 (IL-6α)) 
(Bierhaus et al., 2005; Elosta et al., 2012) as well as to intercellular ROS formation. 
Initially, ROS production is triggered by the activation of the NADPH-oxidase system 
(NOX) (NOX family including NOX1, 2, 3, 4, 5 and DOX1 and DOX2) (Frey et al., 
2009; Cho et al., 2013). It was found that the development of diabetic complications 
in organs is associated with the stimulation of a glucose-metabolising pathway that is 
orchestrated by aldose reductase (AR), a key enzyme in the polyol pathway, which 
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catalyses the nicotinamide adenosine dinucleotide phosphate-dependent reduction of 
glucose to sorbitol and sorbitol dehydrogenase. In cells cultured under high glucose 
conditions, many studies have demonstrated similar AR-dependent increases in ROS 
production, confirming AR as an important factor for the pathogenesis of many 
diabetic complications. Moreover, a study carried out by Tang et al. have shown that 
AR inhibitors may be able to prevent or delay the onset of cardiovascular 
complications such as ischemia/reperfusion injury and atherosclerosis (Tang et al., 
2012). Many studies have indicated that production of ROS and elevated oxidative 
stress trigger signal transduction and change the gene expression (Cui et al., 2012; 
Cho et al., 2013; Nita and Grzybowski, 2016). Moreover, the transcription factor NF-
κB has been identified as an intercellular target of hyperglycaemia and ROS 
production (Calcutt et al., 2009).  
In addition, hyperglycaemia and oxidative stress potentiate AGE formation and 
accumulation. AGE-RAGE interaction triggers signal transduction pathways 
including mitogen-activated protein kinases (MAPK) such as p38, extracellular 
regulated (ERK)-1/2, c-Jun N-terminal kinase (JNK), Cdc42/rac, and Jak/Stat 
pathways (Figure 1.5) (Cho et al., 2013). The consequence is the generation of gene 
products, such as vascular endothelial growth factor (VEGF), vascular cell adhesion 
molecule-1 (VCAM-1) and others, which all contribute to the development of cellular 
injury and the long-term complications of diabetes mellitus (Basta et al., 2004). 
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Figure 1.5: Signal transduction pathways activated by AGE-RAGE interaction.  
Stimulation of RAGE by AGEs formation increases the production of ROS by different signalling 
pathways (Calcutt et al., 2009). 
 
 
1.12 Advanced glycation end products and complications 
The main complication types experienced by diabetic patients can be split into 
microvascular, which refers to damage to small blood vessels (including eyes, kidneys, 
neuropathy), and macrovascular, which refers to damage to larger blood vessels 
(including brain, heart and extremities) (Figure 1.6). Although there has been a large 
quantity of literature written on the topic of diabetic complications, it remains 
unknown what the root of most complications actually is. It seems that a significant 
aspect leading to complications is the raised development and build-up of AGEs 
resulting from chronic exposure to hyperglycaemia (Rhee and Kim, 2018). Equally, 
intensive management of glycaemia causes a reduced formation of AGEs and can help 
to decrease vascular complications (Ahmed, 2005; O’sullivan and Dinneen, 2009) 
Chapter 1 
 
 
35 
 
 
 
Figure 1.6: Major microvascular and macrovascular complications associated with diabetes 
mellitus.  
Diabetic complications are divided into (1) microvascular, due to damage to small blood vessels and 
include damage to eyes, kidneys and the nerves and (2) macrovascular, due to damage to larger blood 
vessels, and includes cardiovascular diseases such as heart attacks, strokes and insufficiency of blood-
flow to the legs. 
 
 
1.12.1 Complications associated with damage to smaller blood vessels 
Microvascular complications are generally what is called ‘dysfunctional alterations’ 
that occur in the microvascular bed. When looking at microangiopathy, the most often 
seen types are neuropathy, retinopathy and nephropathy (Chawla et al., 2016). To 
develop this kind of complication in a diabetic patient generally takes 10 to 15 years. 
Microangiopathy is characterised by the vascular permeability increasing and the 
basement membranes thickening, resulting in decreased blood flow, otherwise known 
as a prothrombotic state. (Chawla et al., 2016). To date, there has been no effective 
treatment for such complications in association with diabetes (Ahmed and Thornalley, 
2007). 
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1.12.1.1 Most common complications  
Among the most common complications in terms of microangiopathy is diabetic 
retinopathy, which can cause blindness if left undiagnosed and untreated. The chance 
of suffering from retinopathy rises with the amount of time diabetes has been present 
in the patient. Nearly all type 1 diabetes sufferers, and over 60% of type 2 diabetes 
patients, experience retinopathy to some degree after 20 years. Studies have shown 
that increased AGEs play a substantially important role in the growth and 
advancement of diabetic retinopathy (Fowler, 2008). The increased production of 
AGEs can also cause retinal microvascular endothelial cells to experience abnormal 
proliferative reactions resulting in an irregular expression of eNOS (endothelial nitric 
oxide synthase) (Giacco and Brownlee, 2010).  In addition to this, the production of 
AGEs also impacts the pericyte growth negatively, causing a decrease in pericytes. 
This decrease is actually the earliest hallmark (histological) of diabetic retinopathy. 
The decrease in pericytes then causes thickening of the basement membrane, 
contributing significantly to the inner blood-retinal barrier breakdown (Bianchi et al., 
2016). Diabetic retinopathy may also include neural dysfunction/ depletion due to the 
production and build-up of AGEs (Stitt et al., 2016). It appears as though growth 
factors such as transforming growth factor beta, VEGF vascular endothelial growth 
factor and growth hormone also have an impact (Fowler, 2008). A study on animals 
indicated that suppression of the VEGF is complemented by a lessened development 
of retinopathy (Fowler, 2011), thus demonstrating a link between the two. It is a matter 
of conjecture as to what the impact of increased growth factor production can have on 
the body’s response to a lack of oxygen reaching the tissues.  
 
1.12.1.2 Development of cataracts  
Diabetes and hyperglycaemia are significant risk factors in regards to developing 
cataracts; a patient who suffers from diabetes is likely to experience cataracts a whole 
decade earlier than healthy individuals (Jeng et al., 2018).  Methylglyoxal and other 
AGE precursors play a crucial part in the formation of cataracts. Lens crystallins and 
other long-lived proteins have a higher probability of glycation taking place (Fowler, 
2011). When a lens crystallin experiences glycation, it can cause oxidation, protein 
crosslinking and high molecular weight aggregates being produced which in turn 
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cause cataracts to develop (Pescosolido et al., 2016). Cataract formation in diabetic 
patients may also be significantly contributed to by the glycation of the sodium-
potassium pump and channel proteins (Williamson and Ido, 2012).  
 
1.12.1.3 Kidney damage in diabetic patients  
Diabetic nephropathy, or diabetic kidney disease, is a significant cause of the last stage 
of chronic kidney disease. A three-fold increase in the number of AGEs indicates it is 
present and the disease plays a substantial role in the increased illness and mortality 
of diabetic patients (Lim, 2014). Diabetic nephropathy is accountable for up to half of 
all end-stage renal disease cases (Haller et al., 2017). Complications that are connected 
to diabetic nephropathy include the thickening and expansion of the mesangial matrix, 
coagulation of basement membranes (specifically glomerular and tubular), leading 
over time to microvascular impairment, vascular occlusion and fibrotic conversion. 
This causes a hardening of the glomeruli in the kidneys, also referred to as scarring of 
the small blood vessels of the kidney (Kolset et al., 2012). Playing a very important 
role, the kidney is a significant site where AGE clearance takes place, however, it is 
equally a target for damage caused by AGEs (Mallipattu and Uribarri, 2014). A large 
number of AGEs that are present in diabetic nephropathy can be linked to reduced 
clearance, as opposed to an elevated formation of AGEs by glycation of proteins 
(Stinghen et al., 2015). It has been recently discovered that the renal tissues of diabetic 
patients contain increased levels of CML and pentosidine regardless of whether the 
end-stage renal disorder is present (Beisswenger et al., 2013).  
 
1.12.1.4 The impact of diabetes on the nervous system  
Over half of all diabetes sufferers experience complications relating to nerve damage; 
this is a major cause of illness and mortality (Edwards et al., 2015). It is known that 
diabetic neuropathy causes the peripheral nervous system to be damaged (Beisswenger 
et al., 2013), often impacting nerves in the patients’ legs and feet. AGEs have an 
important contribution to the development of diabetic neuropathy due to their 
biochemical pathways (Singh et al., 2014). The impact of AGEs on neuropathy has 
been widely studied, with a recent study indicating that peripheral nerve myelin that 
has been modified by AGEs is vulnerable to phagocytosis by macrophages, which 
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causes segmental demyelination. Subsequently, AGEs have an impact on the main 
axonal cytoskeletal proteins and this leads to axonal degeneration, which is an 
expression of diabetic neuropathy the degenerated axonal express in diabetic 
neuropathy (Cashman and Höke, 2015). More evidence suggests that if the expression 
levels of eNOS (the inducible form) are altered due to AGEs, then this affects the flow 
of blood to the nerves and causes a lack of oxygen to the peripheral nerves (Zhao et 
al., 2015). Despite the precise role of RAGE and AGEs interactions being unknown, 
there is a contribution to endoneurial vascular dysfunction which causes 
microangiopathy in peripheral nerves (Yagihashi et al., 2011).  
 
1.12.2 The impact of AGEs on major blood vessels 
Complications involving the macrovascular system are alterations within the body that 
impact the major blood vessels resulting in abnormalities in both function and 
structure (Chawla et al., 2016). Endothelial dysfunction, reduction of vascular 
compliance and artery wall thickening are all caused by the glycation of wall 
structures. Atherosclerosis is considered to be the highest risk factor causing 
macrovascular complications in diabetic patients, these include myocardial infarction, 
peripheral vascular disorders and stroke (Funk et al., 2012).  
 
1.12.2.1 The impact of AGEs on arteries  
Atherosclerosis is a build-up of plaque within arteries; this seems to be the result of 
multiple factors and causes limited blood flow. This is the fundamental cause of what 
is currently the number one killer of humans in the world. Studies have found links 
between the development of atherosclerosis and AGE production in patients with 
diabetes (Rai et al., 2016). It is also possible that interactions between AGEs and 
RAGEs also cause an increase in endothelial impairment, neointimal proliferation, 
delayed wound healing and increased plaque destabilisation (Hallam et al., 2010; 
Karmakar and Goswami, 2012). Therefore, it is unsurprising that the interactions 
between AGEs and RAGEs are considered to be a significant cause in the development 
of atherosclerosis in sufferers of diabetes (Singh et al., 2014). AGEs also activate 
nuclear factor-kB and protein-1 transcription factors within vascular wall cells causing 
increased expression of several atherosclerosis-related genes (Laakso, 2010). 
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1.13 Wound healing  
Wound healing occurs in three stages. The first is inflammation, followed by 
proliferation and finally maturation and remodelling (Figure 1.7). Each of the phases 
has distinct functions and characteristics. For the regulatory events to be carried out, 
there is a reliance on the cell growth factors, cytokines, chemical mediators and 
chemokines (Eming et al., 2014; You and Han, 2014). In order for the re-establishment 
of homeostasis to occur, the acute inflammatory response must begin so the tissues 
can start the healing process (Slavich and Irwin, 2014). When an injury first occurs, 
the body must react so that it can clot the blood and prevent further blood loss. This is 
done by various substances including thromboxane A2, prostacyclin and serotonin 
being released. Then the coagulation cascade is activated by signals from the exposed 
collagen, this causes haemostasis to begin as platelets cling to blood vessels that are 
damaged then a thrombin and fibrin buffer forms. The buffer plays a significant role 
in preventing micro-organisms from entering the wound, preventing further loss of 
cellular elements and to assist by creating a provisional matrix, growth factors and 
cytokine deposit, something that is vital for the later stages of wound healing 
(Demidova-Rice et al., 2012). 
 
At the start of the inflammation phase, vasodilation occurs in order to immediately 
decrease blood pressure. This is stimulated by the release of soluble factors including 
histamine, bradykinin, E and I series prostaglandins and nitric oxide. The blood flow 
is reduced by the vascular permeability increasing and this allows leukocytes, 
primarily neutrophils, to interact with the endothelium. This interaction involves 
multiple levels and events taking place including margination, rolling, adhesion, 
transmigration and targeting leukocytes so they can focus on the lesion (this occurs 
with inflammatory mediators, chemotactic activity and vascular endothelial 
membrane protein alterations (MacLeod et al., 2014). 
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Figure 1.7: Schematic representation of the phases of cutaneous wound healing 
(1) inflammation begins with (a) coagulation, platelet aggregation, and fibrin clot formation; (b) 
inflammatory events then occur through neutrophil and macrophage infiltration and phagocytosis of 
debris, apoptotic cells, and pathogens; anti-inflammatory events occur through inhibition of destructive 
inflammatory process and proliferation promotion. (2) In the proliferation phase there occurs (a) 
angiogenesis; (b) re-epithelisation (epithelial cell mitosis and transformation of fibroblasts into 
myofibroblasts), and granulation tissue formation (EMC composed of collagen, glycoprotein, 
proteoglycan, fibroblasts, and keratinocytes, under the modulation of MMP-9). (3) Maturation and 
remodelling are marked by  (a) EMC reorganisation: cell apoptosis and angiogenesis regression; and 
(b) type III collagen being replaced by type I (Yolanda et al., 2014). 
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Within hours of an injury occurring, neutrophils are enlisted and help to resolve tissue 
damage by releasing cytokines and proteases as well as other substance that is 
contained within cytoplasmic granules (Mayadas et al., 2014). The generation of 
reactive oxygen species (ROS), takes place and antimicrobial proteases are produced 
including defensins, lysozyme, lactoferrin and cathepsins. These antimicrobial 
proteases are able to destroy any microorganisms that are pathogenic or potentially 
pathogenic. As well as acting as a protection, they also release enzymes including 
elastases and collagenases that assist with tissue renewal and repair by supporting 
devitalised tissue digestion (Kolaczkowska and Kubes, 2013).  
 
Membrane metalloproteinases (MMPs) of a variety of types are produced by 
neutrophils. The principal subtypes MMP-8, MMP-9 and MMP-2 cleave collagen 
(MMP-8 splits fibrillar collagen and MMP-9 cleaves, amongst others, collagen IV). 
These types of MMPS play an important role in extracellular matrix degradation. 
Metalloproteinase tissue inhibitors are a molecular class that are produced by cells on 
the skin and restrain the MMPs’ actions. Without the regulation of the proteases and 
the inhibitors, the result could be an impaired formation of granulation tissue (Wilgus 
et al., 2013). Therefore, any migration of uncontrolled neutrophils causes activation 
of cells resulting in excessive proteases and ROS being produced. This then causes 
additional damage to tissues and unwanted extracellular matrix degradation which can 
lead to reduced tissue resistance, long-lasting inflammation with collagen deposition 
that is defective, delayed re-epithelialisation as well as limited healing and recovery 
(de Oliveira et al., 2016). There is also a release of cytokines, for example, the 
inflammatory response is triggered by IL-6 and TNF-α, which is then increased by 
additional cells and neutrophils, like macrophages, being activated. Though these are 
incredibly important for the activation of repair cells, they can also cause harmful 
effects when intensified release takes place (Eming et al., 2014). When the skin is 
healthy and intact, the cell-type present that is most abundant are macrophages and 
they perform homeostatic and sentinel functions. When there is a skin lesion present, 
the wound triggers monocytes to move from their position within the blood circulation 
through vessels to the wound site. The resident and infiltrating macrophages are 
triggered by signals and will then, determined by the distinctive functional 
phenotypes, develop into subpopulations (Murray and Wynn, 2011). Macrophages 
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have been known to demonstrate a proinflammatory phenotype termed “classically 
activated” or M1, in response to bacterial components. These M1 macrophages clean 
the debris and dead cells, defend the host, produce proinflammatory mediators (IL-12, 
IL-1, IL-6, inducible nitric oxide synthase (iNOS) and TNF-α) and perform 
phagocytosis. Macrophages can also assume a variety of “alternatively activated” or 
M2 phenotypes. In addition, chemokines will recruit more leukocytes (Galván-Peña 
and O’Neill, 2014). The IL-13, IL-4 and other cytokines will lead to M2 subset 
macrophages being formed. These assist by regulating the inflammation using 
mediators including IL-1 receptor antagonist, IL-1 type II receptor, transforming 
vasopressin endothelial growth factor (VEGF) and TGF-𝛽 to promote extracellular 
matrix synthesis, angiogenesis and fibroblast proliferation (Novak and Koh, 2013).  
 
The next stage, known as the proliferative phase, is then initiated by the cells involved 
entering apoptosis as the resolution of inflammation takes place. This phase 
(proliferative) can be separated into four essential stages, these are re-epithelisation 
(successful wound closure), angiogenesis (the formation of new blood vessels), 
granulation (tissue formation) and finally, collagen deposition. The proliferative phase 
is recognisable by concentrated cellular activity that aims to repair connective tissue 
as well as to aid in the formation of epithelium and granulation tissue (Landén et al., 
2016).  
 
The first of the four essential stages, re-epithelialisation, is when keratinocytes move 
away from the wound and the release of growth factors stimulates epithelial 
attachments that are responsible for an increase in epithelial hyperplasia and mitoses 
(Pastar et al., 2014). In order to degrade and proliferate the provisional matrix and 
produce MMPs, fibroblasts migrate to it. The fibroblasts will also produce hyaluronic 
acid, collagen, glycosaminoglycans, fibronectin for the formulation of granulation 
tissues and proteoglycans. These will fill the wounded area and encourage wound 
repair by supporting the adhesion and migration of cells as well as their differentiation 
and growth (Levinson, 2013). AGE formation is very important when it comes to 
chronic hyperglycaemia. This is because AGEs have properties that are pro-
inflammatory and pro-oxidant and, through cell surface receptor-mediated 
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interactions, they induce oxidant stress within cells and protein cross-linking (C. 
Sharma et al., 2015).  
 
In order for the new tissue to form properly in terms of oxygenation and nutrition, 
angiogenesis is vital. Growth factors including basic fibroblast growth factor (bFGF), 
platelet-derived growth factor (PDGF) and VEGF initiate the development of new 
blood vessels. Then, to dissolve the basal lamina, proteolytic enzymes are secreted. 
Following this, the angiogenic stimulus encourages endothelial cells to leave the blood 
vessels in order to multiply and go to the stimulus source. They will also assist in 
supplying oxygen for cell function maintenance (DiPietro, 2013). 
 
The production of collagen is activated from the beginning of the formation of 
granulation tissue through the production and deposition steps as well as the steps of 
digestion and reorganisation. At first, collagen fibres are not in an organised form, as 
they are shadowing a fibronectin model. In an effort to order and organise the fibres, 
they are subjected to digestion. This is through the action of enzymes that are produced 
by macrophages, fibroblasts and neutrophils (Landén et al., 2016). Then new, more 
organised, fibres are created and deposited following connective tissue which is 
adjacent, and this will initiate the next phase, remodelling (Ganeshkumar et al., 2012). 
The remodelling phase takes place when granulation tissue formation is complete. 
Cytokine expression, amplified mechanical stress and tissue development help to 
encourage fibroblasts to separate into myofibroblasts. The myofibroblasts express 
smooth muscle actin and have a contractile function that prefers the movement of the 
cells from the edge of the lesion to the centre for contraction of the wound (Penn et 
al., 2012). Collagen I is then produced in order to replace the rapidly produced 
collagen III in the extracellular matrix. Collagen I takes longer to deposit but has an 
increased tensile strength (Ganeshkumar et al., 2012). Larger fibres and a greater 
number of fibrils characterise the new collagen. The very high number of cross-links 
that are present result in larger fibre diameter and increased tensile strength developed 
by the scar (Siviero, 2013). 
 
There are multiple factors that can play a role in delaying the process of healing a 
wound including diabetes, arterial or venous insufficiency, renal disease, local 
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pressure effects, old age and trauma. Other local factors that can impair the healing of 
wounds include ischaemia, tissue hypoxia, exudates, foreign bodies, inflammatory 
process regulation disruptions, maceration of tissue, systemic factors such as a 
compromised immune system or a compromised nutritional status and infection 
(Eming et al., 2014). The rise in the number of chronic wounds being seen is 
contributed to by the rise in the number of non-communicable diseases including 
obesity, vascular disease and diabetes. There is a significant global problem with 
chronic wounds including venous, pressure ulcers and diabetic, and the considerable 
management costs that come with these. The United States has seen a $25 billion 
estimated annual figure being spent to manage the chronic wounds of the over 6 
million people who are suffering from them (King et al., 2014). The NHS of the UK 
managed over 2 million patients with a wound during 2012 – 2013, which is the same 
as 4.5% of the adult population within the UK (Guest et al., 2015).  
 
Diabetic foot ulcers are suffered by a considerable percentage of diabetic patients 
(15%), and may lead to amputation of the lower-leg (Eming et al., 2014). Wound care 
currently focuses on recognising any factors that can aggravate the wound and remove 
these in order to, hopefully, lower the inflammation and encourage the healing process 
to continue (Velnar et al., 2009). It is not unusual for these treatments to not only be 
inefficient but they can also take a long period of time and are often expensive.  More 
than half of chronic wounds are unmanageable by the conventional methods of 
treatment (Mustoe et al., 2006). Although the formation of scar tissue and fibrosis are 
very damaging and come with many consequences, there are currently no effective 
ways to treat prevent them (Mustoe et al., 2006). Despite this, the global market for 
products that are aimed at advanced wound care, specifically promoting the healing of 
chronic wounds and reducing scarring, is over $20 billion annually (Sen et al., 2009). 
 
1.13.1 The impact of diabetes on wound healing 
When AGEs are present in the wounds of diabetic patients, they result in continued 
chronic inflammation. This result in the wound is unable to progress to the next stage 
of healing (matrix deposition and remodelling) and thereby prevents healing from 
taking place (Serra et al., 2017). Small blood vessel damage and immune suppression 
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can also be present in diabetic patients and this can result in inadequate tissue 
oxygenation. All of this together can cause wounds to become chronic because of more 
ROS being created, amplified apoptosis of lymphocytes and immune deficiency (Arya 
et al., 2013). 
 
Many physiologic factors (~100) contribute to wound healing deficiencies in diabetic 
individuals (Figure 1.8). These include reduced or impaired growth factor production 
(Galkowska et al., 2006), angiogenic response (Falanga, 2005), macrophage function 
(Maruyama et al., 2007), collagen accumulation, epidermal barrier function, quantity 
of granulation tissue (Falanga, 2005), keratinocyte and fibroblast migration and 
proliferation, number of epidermal nerves (Gibran et al., 2002), bone healing, and the 
balance between the accumulation of extracellular matrix (ECM) components and 
their remodelling by MMPs (Lobmann et al., 2002). The wound healing process in 
response to injury involves activation of keratinocytes, fibroblasts, endothelial cells, 
macrophages, and platelets. Activation of these candidates is coordinated by the 
release of growth factors and cytokines to maintain healing. 
Biopsies obtained from the epidermis of patients have identified pathogenic markers 
that are associated with delayed wound healing. For example, overexpression of c-
myc and nuclear localisation of β-catenin (Stojadinovic et al., 2005) coupled with a 
decrease in, and abnormal localisation of, estimated glomerular filtration rate (eGFR), 
stimulation of the glucocorticoid pathway and inhibition of keratinocyte migration 
(Stojadinovic et al., 2005; Brem et al., 2007). At the non-healing edge (callus) of 
diabetic foot ulcers (DFUs), keratinocytes exhibit hyperproliferation, partial 
differentiation and absence of migration (Stojadinovic et al., 2005; Brem et al., 2007). 
Fibroblasts show changes in phenotypic characteristics and the inhibition of migration 
and proliferation. 
In contrast, in an adjacent non-ulcerated area, cells become physiologically impaired 
but still display the normal phenotype appearance. However, the ability of 
keratinocytes to respond to growth factors or cellular therapy is still unchanged. 
Microarray analyses of patient biopsies have confirmed that the transcription profiles 
of epithelial cells from the callus and adjacent non-ulcerated skin are distinct and well-
recognised (Brem et al., 2007). 
Chapter 1 
 
 
46 
 
 
Figure 1.8: Comparison of wound healing in healthy and diabetic people.  
In healthy individuals (left), the acute wound healing process is regulated by cytokines and chemokines 
released by keratinocytes, fibroblasts, endothelial cells, macrophages, and platelets. During wound 
healing and under hypoxic conditions, VEGF is released by macrophages, fibroblasts, and epithelial 
cells inducing the phosphorylation and activation of eNOS in the bone marrow. This results in an 
increase in NO levels, which triggers the mobilisation of bone marrow endothelial progenitor cells 
(EPCs) to the circulation. The chemokine Stromal-derived factor-1 alpha (SDF-1α) promotes the 
homing of these EPCs to the site of injury to be involved in neovasculogenesis. Impaired causing a 
limitation of EPC mobilization from the bone marrow into the circulation. A decrease in SDF-1α 
expression in epithelial cells and myofibroblasts in the diabetic wound prevents EPC homing to wounds 
and therefore limits wound healing. Hyperoxia in wound tissue (via hyperbaric oxygen therapy) 
activates many NOS isoforms, elevates NO levels, and promotes EPC mobilisation to the circulation. 
However, the local administration of SDF-1α triggers the homing of these cells to the wound site (Brem 
et al., 2007).  
 
 
Debridement is the medical removal of hyperkeratotic, infected, and nonviable tissue 
from a wound. It accelerates wound healing via a multitude of mechanisms (Saap and 
Falanga, 2002). Pathological diagnosis is essential to confirm the elimination of the 
hyperkeratotic epithelium and to determine the efficacy of debridement (Figure 1.9). 
DFU debridement should be carried out regularly until the callus or hyperkeratotic 
tissue has disappeared in the periphery of the wound and to ensure no scar or infection 
is present at the base of the wound. 
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There are many pathological factors that affect tissue repair in diabetes mellitus 
(Cunha, 2000) such as atherosclerosis, development of major vascular stenosis or 
occlusion, and renal failure. Atherosclerosis can lead to an embolism in proximal 
vessels that leads to a decrease in the blood flow and, ultimately, insufficient oxygen 
delivery and causes toe damage. In this case, angioplasty or vascular bypass should be 
performed to accelerate wound healing. The atherosclerosis complications are 
different from the manifestations in non-diabetic patients. Because the arteries are 
inflexible due to calcification, the ankle-brachial (AB) index becomes difficult to 
assess. However, a transcutaneous monitor can be used to ensure that there is enough 
local oxygen delivery for wound healing to accelerate. Also, diabetic patients may 
develop a thickened perivascular basement membrane that may contribute to the 
altered delivery of micronutrients and increase vascular permeability (Shimomura and 
Spiro, 1987). Diabetic people are more prone to the development of neuropathy and 
infectious diseases due to immunosuppression. Moreover, in diabetes and venous 
stasis disease, oedema impairs wound healing. The thickness of the basement 
membrane also slows the leukocyte migration. This ECM deposition may gather 
inflammatory cells increasing the tendency for infection (Shimomura and Spiro, 
1987). 
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Figure 1.9: Molecular basis of debridement.  
A typical diabetic patient foot ulcer is shown at the top. (i) Callus containing ulcerogenic cells 
expressing molecular markers, which are indicative of impaired wound healing. (ii) Cells presenting 
normal phenotypical characteristics but are physiologically impaired, though they can be stimulated to 
heal. After debridement, cells express c-myc (green) and nuclear β-catenin (purple) indicating the 
presence of ulcerogenic cells, which handicap wound healing, thus additional debridement becomes 
required. Weak/slow healing is also demarcated by a thicker epidermis and the presence of a nuclei-
containing cornified layer (lower left lower diagram). If the debridement is successful (lower right lower 
diagram), no staining for c-myc or β-catenin is detected and there is no formation of ulcerogenic cells 
(Brem et al., 2007). 
 
 
1.14 Recognising and measuring AGEs 
Recognised as being complex molecules, AGEs are generally difficult to detect within 
serum and tissue (Morais et al., 2013; Lobo Júnior et al., 2017). The measurement of 
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AGEs continues to be restricted to investigative laboratories as there remains a lack of 
a universally accepted method for AGE measurement (Lobo Júnior et al., 2017; Villa 
et al., 2017). There have been various methods used to observe the quantitative and 
qualitative levels of AGEs. Arguably, the main method that allows for fluorescent 
AGE detection both in vivo and in vitro is fluorescence spectroscopy (Villa et al., 
2017). Measuring the fluorescence of AGEs is a common method as it is quick and 
relatively simple to repeat data through incubating the reducing sugar and protein to 
then allowing investigation of its manifestation in diabetes mellitus (de Vos et al., 
2016). The limitations of this technique are that only AGE trend indicators are 
recognised as opposed to the actual structural AGEs themselves (de Vos et al., 2016; 
Raposeiras-Roubín et al., 2013)Matrix-assisted laser desorption ionisation time-of-
flight mass spectrometry (MALDI-TOF-MS) has been used with success in order to 
observe AGEs (Uribarri, 2017). The method is cost-effective and fast with benefits 
including very little sample work-up, excellent sensitivity, soft ionisation and high 
resolution. In order to measure protein glycation products both in vivo and in vitro, the 
technique MALDI-TOF-MS peptide mapping is used (Uribarri, 2017; Ahmed and 
Thornalley, 2007). Throughout the duration of glycation research, separation assay 
methods are used, an example of this being SDS-PAGE (Xie et al., 2011; Kishabongo 
et al., 2015)Using this method identifies oligomerisation of glycated protein with ease 
and is a technique that is frequently used. It is a financially practical and effective 
method. Enzyme-linked immunosorbent assay (ELISA) is an immunochemical 
technique that uses monoclonal and polyclonal antibodies that are particular to 
structures of defined AGEs giving the benefit of being very sensitive to AGEs and 
allowing quantitative estimation to occur (Elosta et al., 2012). 
 
1.15 Using medicinal plants for diabetes  
Naturally, derived products from plants to fungus, shells and minerals are the oldest 
practice of medicine. Even today, the majority of frequently used medications are 
derived from herbs with around one-quarter of prescription drugs containing one or 
more active ingredient derived from herbs, or even a compound that is synthetic but 
plant-mimicking (Saad and Said, 2011). Since ancient times, medicines that have been 
derived from plants, organic matter and minerals have been used to treat diabetes and 
other chronic disorders. Around 150 species are currently available commercially for 
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use as medicine around the world (out of 21,000 plants), according to the WHO 
(Raman et al., 2012). A number of recent studies have indicated that a combination of 
antioxidant nutrients, antiglycation and complementary medicine is understood as a 
simple and safe accompaniment to the traditional medications and it is hoped to inhibit 
and focus on the complications relating to diabetes (Aljohi et al., 2016). An example 
is tomato paste, which demonstrates effective inhibitory effects against glycation 
(Kiho et al., 2004) as well as autoxidative reactions (Cervantes-Laurean et al., 2006). 
Other plant medicines that contain polyphenolic molecules have demonstrated their 
ability to inhibit the production of AGEs, such as garcinol originating from Garcinia 
indica (amagishi, 2011), crisilineol originating from Thymus vulgaris (Roby et al., 
2013) and soy sauces (Mashilipa et al., 2011). There has also been a variety of 
antioxidant compounds identified to have in vitro antiglycation properties, including 
green tea extract, which has a large number of flavonoids or tannins (Panche et al., 
2016) and garlic (Allium sativum) which has high amounts of S-allyl cysteine 
(Ourouadi et al., 2016). This is similar to curcumin which has been isolated from 
turmeric (Curcuma longa) (Qader et al., 2011). There has also been a large number of 
natural compounds that have been shown to inhibit AGEs, including epigallocatechin-
3-gallate (Lee et al., 2013), caffeic acid, chlorogenic acid (Agunloye and Oboh, 2018), 
hesperidin and capsaicin (Fattori et al., 2016a). 
 
1.15.1 The origins and medicinal properties of garlic 
Believed to come from Central Asia origins, garlic (Allium sativum) belongs to the 
Alliaceae plant family. Garlic has been used for centuries as a functional food, folklore 
medicine and flavouring agent (Ourouadi et al., 2016). Similar to many other plants, 
an effective defence system is present in garlic that is composed of several different 
components that aid in boosting the immune system of humans. When garlic is injured, 
it produces allicin enzymatically in an effort to safeguard itself from fungi and insects 
(Ghani, 2010; Ourouadi et al., 2016). Due to the beneficial effects that garlic has, it is 
consumed both as it is and in the form of a supplement in numerous cultures (Ourouadi 
et al., 2016). Garlic has been known to be used medicinally for reducing triglycerides 
and serum cholesterol, inhibiting the formation of platelets and lowering blood 
pressure (Samakradhamrongthai, 2017). The healing properties that are present in 
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garlic are largely produced by the bioactive components present (Santhosha et al., 
2013). 
 
1.15.1.1 Garlic – a closer look into the key compounds 
Garlic is part of the Liliaceae family. The beneficial effects are produced by the larger 
sulphur compound concentration present, which is also responsible for the strong taste 
and flavour that is characteristic to garlic. Garlic is made up of a large percentage of 
water (65%) as well as over a quarter (28%) carbohydrate (fructans), 2.3% 
organosulphur compounds, 2% proteins (alliinase), 1.5% fibre and 1.2% free amino 
acid (arginine). The therapeutic properties and the strong smell of garlic are caused by 
an active substance called allicin (diallyl thiosulfate) (Santhosha et al., 2013; 
Macpherson et al., 2005). The substances within garlic that are biologically active can 
be separated into two units (Yongkun Ma et al., 2011). Group 1 is the sulphur 
compounds and group 2 is the sulphur-free active substances. Group 1, for example, 
alliin, ajoene and allicin, are vital flavour compounds. Alliin is an active substance 
that is biologically ineffective and sensorily inactive until cell damage occurs when it 
forms allicin, the effective garlic essential oil. Allicin is what gives garlic the 
characteristic strong smell and its important antibiotic properties. It is possible to 
modify the off-odour of garlic using certain processing methods, for example; 
steaming, roasting, using soaked water to cook it in, autoclaving, hydrostatic pressure 
treatment and fermentation (Sharma and Prasad, 2006). There is no allicin found in 
the plant when it is intact, only when garlic bulbs are crushed do the enzyme reactions 
between a precursor molecule, alliinase (enzyme) and alliin (non-protein amino acid) 
take place. Although these are all present within intact garlic, compartments separate 
them (Arzanlou and Bohlooli, 2010). Recent research has been focussed on the allicin 
of garlic, specifically on compounds containing sulphur and the benefits of this (Omar 
and Al-Wabel, 2010). The organosulphur compounds can be separated into water-
soluble and oil-soluble constituents. Water-soluble organosulphur components 
include S-allyl cysteine (SAC) (Figure 1.10) and N-acetylcysteine (NAC) (Figure 
1.11) (Santhosha et al., 2013) and oil-soluble organosulphur components include DAS 
(diallyl sulfide), DADS (diallyl disulfide) and DATS (diallyl trisulfide). NAC has a –
SH residue donor and a nucleophile (Nishikawa-Ogawa et al., 2005). Deriving from 
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gamma-glutamyl-S-allyl-L-cysteine, SAC is a major compound which is primarily 
seen in the garlic extracts from alcoholic and aqueous bases (Kodera et al., 2017). A 
study that was conducted by Yin and Cheng focused on the antimicrobial and 
antioxidant protection of NAC, DADS, S-ethyl cysteine (SEC) and DAS for 5 
inoculated pathogenic bacteria. They found that DADS and DAS both showed 
antimicrobial and antioxidant protection whereas NAC and SEC may stabilise the 
protein structure or redox status directly (Yin and Cheng, 2003). In a study of alloxan 
diabetic rats, it was found that S-allyl cysteine sulfoxide (SACS), which is an amino 
acid present in garlic that contains sulphur and is the originator of garlic oil and allicin, 
demonstrated antidiabetic effects (Ourouadi et al., 2016). A typical antidiabetic 
treatment combined with garlic has exhibited an ability to improve antihyperlipidemic 
activity as well as glycaemic control indicating that garlic could be a useful and 
suitable addition for patients managing hyperlipidaemia and diabetes (Ashraf et al., 
2011). It has also been found that garlic alcohol extract decreased uric acid, urea, 
triglycerides, cholesterol, serum glucose, Aspartate amino transferase (ALT) and 
Alanine amino transferase (AST), and when comparing treated diabetic rats with 
control diabetic rates there was an increase in serum insulin levels seen in the former 
(Eidi et al., 2006). 
 
 
Figure 1.10: S-allyl cysteine chemical structure. 
Molecular Formula: C6H11NO2S and Molecular Weight: 161.224 
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Figure 1.11: N-acetylcysteine chemical structure. 
Molecular Formula: C5H9NO3S and Molecular Weight: 163.195 
 
 
 
1.15.1.2 Use and properties of aged garlic extract  
In the last decade, there has been an increase in the popularity of garlic and the number 
of garlic products that are available in international markets. Many consumers have 
become influenced by commercially available products as a way to increase their daily 
intake of garlic by avoiding the strong smell that fresh garlic possesses (Cardelle-
Cobas et al., 2010). The development of garlic extraction has been based around its 
traditional uses. The chosen solution used for extracting often diluted alcohol or 
purified water is used to soak sliced or whole cloves of garlic for a varying period of 
time. The solution is separated, and the extract is then concentrated and ready for use. 
The produced extract contains mostly water-soluble compounds but also a small 
number of oil-soluble constituents (Mane et al., 2011; Cardelle-Cobas et al., 2010). 
An extract that is created using a method slightly different from the other garlic 
products is aged garlic extract. No heat is required when creating this, instead, slices 
of raw garlic are soaked in a 15 - 20% solution of aqueous ethanol for at most 20 
months at room temperature. Under reduced pressure, the extract is then filtered as 
well as concentrated at a low temperature. The extract has a low number of oil-soluble 
compounds but a high number of water-soluble compounds. The process of aged garlic 
extract increases the concentration of antioxidants and converts allicin and other 
unstable compounds into stable substances that promote health such as S-
allylmercaptocysteine (SAMC) and SAC (Ahmed et al., 2012). Aged garlic extract 
has anti-glycation effects, which are thought to be a result of the antioxidant compound 
SAC, which can prevent glycoxidation and autoxidative reactions that play a role in 
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the formation of AGEs. The amino groups in SAC could also prevent the formation of 
reducing sugars, dicarbonyl intermediates and Amadori products due to a reaction 
with, and blocking of, carbonyl groups thereby stopping them from carrying out 
AGEs’ conversion (Ahmad et al., 2007). Aged garlic extract is believed to be an 
excellent natural oxidant that may be able to protect the macromolecules that are 
essential for the survival of cells, limit the oxygen effects and inhibit the free radical 
processes (Goffin, 2012). There has also been particular attention to AGEs due to 
studies showing an effective antioxidant with the capacity for free radical scavenging 
(Soloviev et al., 2002). Due to its ability to be detected and its quantitative increase in 
the blood, SAC is the sole reliable marker that is used in studies concerning garlic 
consumption by humans (Steiner and Li, 2001). SAC may be used to compare a 
number of sources or for garlic preparation standardisation as it is found in many 
preparations. The sole product that is standardised for SAC is AGEs (Cardelle-Cobas 
et al., 2010). Various toxicological studies have been able to confirm the safety of use 
and consumption of aged garlic extract (Amagase et al., 2001). 
 
1.15.1.3 Recommended daily garlic intake 
The amount of garlic consumed on a daily basis has not been standardised, however, 
there are multiple suggestions from various sources. The German Commission E 
Monograph (GKEM) suggested that consuming around 4 grams or 1 to 2 cloves of 
garlic that are intact each day may result in benefits to health (Amagase et al., 2001). 
However, there is no scientific evidence that backs up this claim. A recent study 
involving dehydrated garlic powder estimated a dose each day of around 900mg. 
When we consider aged garlic extracts, the daily intake is between 1.7g and 2g per 
day and this has been successfully used in humans to lower plasma cholesterol (Steiner 
and Li, 2001). There have been several studies involving aged garlic extract that have 
found a dose each day of between 1.8g and 10g has an enhancing effect on the immune 
response and which does not cause any toxic or severe side effects (Abdullah, 1989). 
It has been noted that even in clinical studies administering high doses of the extract, 
there have been no severe or toxic side effects reported (Rahman, 2007).  
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1.16 Using synthetic compounds for diabetic complications 
Synthetic mimic compounds A, B and C were kindly supplied by Dr Alan Jones from 
the Chemistry Department at Manchester Metropolitan University, UK. These 
compounds are small molecules inhibitor – mimic of SAC and NAC. Compound A 
[(R) S-Benzyl-L-cysteine] and its molecular formula is C10H13NO2S. It is more fat-
soluble compound. Compound B [L-cysteine methyl ester hydrochloride] and its 
molecular formula is C4H10CINO2S. It is more water-soluble compound. Compound 
C [(R)-S-triphenylmethyl cysteine] and its molecular formula is C22H21NO2S. It is 
much more fat-soluble compound than compound A (Figure 1. 12). 
 
 
Figure 1.12: Structure of mimic compound A, B and C. 
 
1.17 The role of mesenchymal stem cells 
Conventionally, the term mesenchymal stem cell, or MSCs, describes a collection of 
cells known as multipotent stromal cells (Waterman and Betancourt, 2011) that have 
the ability to differentiate into a variety of cell types. Mesenchymal stem cells have 
been known by various names before MSCs including “bone marrow stromal” or 
“osteogenic” stem cells (Caplan, 1991), another later example being “stromal 
progenitor” stem cells (Bianco et al., 2008). However, those within the scientific 
community have expressed concerns regarding whether or not the MSCs are actually 
stem cells at all. This is due to there being little or no evidence to show that these cells 
are capable of self-renewing in vivo as stem cells are known to do (Dominici et al., 
2009).  In a 2005 statement from the International Society for Cellular Therapy it was 
said that, as a term, mesenchymal stem cell should be used only in cases where the 
cells are in alignment with the stem cell criteria and instead the term multipotent 
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mesenchymal stromal cells should be used to describe fibroblast-like plastic-adherent 
cells, regardless of the tissue they are isolated from. However, MSCs can continue, as 
they have been, to be used to describe both cell types/populations. Although this 
statement has been made, little has changed in the use of the term. The mesenchymal 
stem cell is a commonly used term and, in addition to this, the European consortium 
Genostem stated that there is evidence of MSCs being true stem cells as they have 
self-renewal capabilities, something that was reported during a systematic analysis of 
bone marrow-derived MSCs (Charbord et al., 2011). The feature that is most 
characteristic of these cells is the ability to differentiate into adipocytes, osteoblasts 
and chondroblasts in vitro. In fact, this differentiation ability in vitro is frequently used 
to identify MSCs (Keating, 2012).  
 
MSCs are multipotent progenitor cells that are capable of self-renewing and are able 
to differentiate themselves into several cell types (under appropriate stimuli) (Sollazzo 
et al., 2011). The mesenchymal stem cells are able to differentiate into a range of cell 
types comprising fat cells, cartilage cells and bone cells (Mittal, 2011). It is possible 
to isolate MSCs from both adult or embryonic tissues including adipose and bone 
marrow (Hima Bindu and Srilatha, 2011). In fact, these cells and similar are also 
isolated from, amongst other tissues, the placenta (Igura et al., 2004), blood (Zvaifler 
et al., 2000), umbilical cord blood (Erices et al., 2000) and trabecular bone (Sottile et 
al., 2002). An incredible property that MSCs have is the ability to institute repair when 
tissue injury is present. They do this by either increasing the number of endogenous 
cells that are capable of repairing tissue and influencing the immune response by the 
creation of a milieu (Ankeny et al., 2004) or by becoming tissue-specific cell 
phenotypes (Tadokoro et al., 2009). Recent studies have been more focused on the 
ability that MSCs possess to repair, without significant differentiation or engraftment, 
the tissues rather than studying the cell differentiation itself and this has resulted in 
concepts relating to the therapeutic effects of human adipose mesenchymal stem cells 
(hADMSCs). This new concept depends on the MSC’s capability to answer to the 
needs of damaged tissue in an immediate and specific manner as well as the ability 
secretes a mixture that is rich in soluble factors (Ma, 2010). 
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1.17.1 The use of MSCs as a mean to deliver drugs  
Delivery of drugs into the systems is traditionally carried out by applying the substance 
to the mucous membranes or skin, injection or oral administration. These are the 
conventional systems and most of them distribute the drug to the blood flow 
proportionally by using the systemic circulation of blood. This also means that the 
medication is carried through the entire body indiscriminately as opposed to tackling 
just the diseased tissues. This non-specific distribution of the substance then causes 
the patient to experience side effects (Branco and Schneider, 2009). In order to 
improve the method of drug delivery and increase efficiency, the potential of using 
delivery vehicles is being explored. To use a delivery vehicle means to encapsulate 
the drug in a specific material that will release the medicine in a way that is controlled, 
allowing the dosage to be optimised for a certain time period (Goldberg et al., 2007; 
Lee and Yuk, 2007). The abilities of MSCs to move to the inflammation sites, 
influencing immune responses and slow inflammatory responses as well as prevent 
tissue damage and assist in repairing tissue damage are unique to MSCs and all make 
them an appealing option for use as a therapy to assist in the treatment of 
inflammatory-related diseases (Newman et al., 2009). On top of this, MSCs have 
shown that they are also capable of increasing neurogenic factors, mitogenic factors, 
angiogenesis and anti-apoptotic factors (Quittet et al., 2015) in addition to being able 
to, when facilitated by micro and nanovesicles, accept and release medicines using 
endocytosis (Baglio et al., 2012).  
 
The novel idea of utilising stem cells to deliver drugs within the body has been recently 
researched, with results showing that MSCs are able to effectively accept and release 
treatments (Andrews, 2015). The concept of using these cells as a drug delivery system 
has been proven by many preclinical studies. Tumour can be regarded as a kind of 
wounds that never heal and continuously generate various inflammatory cytokines 
(Li et al., 2019).  Indeed, MSCs that are either de novo mobilized or exogenously 
administered have been found to migrate to tumour cells and adjacent tissue sites 
(Clavreul et al., 2017). In view of this property, Chulpanova et al. (2018) reported 
that MSCs have the characteristics of tumor tendency and avoidance of immune 
clearance; thus, it is promising that MSCs are utilized as vectors for the delivery of 
antitumor treatments. Additionally, BM-MSCs have been used for clinical trials to 
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treat  damaged tissues of  neurological diseases, spinal infarction, and myocardial 
infarction which difficult to heal by normal tissue regeneration (Squillaro et al., 2016; 
Lukomska et al., 2019). However, the clinical studies have concentrated on 
unmodified human mesenchymal stem cells. For the cells to be additionally modified 
may assist in the amount of therapeutics that the cells generate, or encourage 
therapeutics not usually found within the naive cells to be produced. It is possible to 
modify MSCs using non-genetic and genetic techniques, including pre-differentiation 
of the cells in growth factor-containing media. A clinical study has used adipose-
derived insulin-producing MSCs as a treatment for type 1 diabetes (Bose et al., 2018; 
Takahashi et al., 2019). 
 
 The use of MSCs as a delivery vehicle in therapeutic and diagnostic situations is an 
attractive option as they are readily available, safe, can travel to the specific 
tumorigenesis and injury sites and have a small immunogenicity profile (Prasad et al., 
2011). However, there are studies to be carried out and challenges to master before the 
use of MSCs clinically to deliver drugs within the body. One such challenge is how to 
effectively load the drug on the cell. The cells need to be altered to manufacture high 
levels of the agent or loaded with enough drugs to produce healing effects without 
having a negative impact of the viability of the cell or the necessary properties needed 
for effective delivery of the drugs, for example, the migration potential of the cell. 
Studies carried out on animals have shown it is possible to generate modified and still 
therapeutically effective MSCs, and it will be down to the human clinical trials to 
determine if these outcomes can be effectively translated. Another necessary challenge 
is to develop a method for the drug to be released effectively. This would require 
mechanisms that start the release from the MSCs in order to enter or access the target 
cell. Overall, the use of MSCs as a drug delivery system is a promising prospect. The 
use of these cells in this way will become widespread only if an effective loading and 
release of drugs at the right times and locations can be developed and ensured (Todd 
et al., 2011).  
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1.17.2 The role MSCs play in healing wounds  
Skin plays a vitally important role for our bodies; from actively synthesising vitamin 
D, preventing dehydration, providing a protective barrier, being a site for active 
immune surveillance and being a thermoregulatory and sensory organ (Lee et al., 
2006). Epidermis and dermis make up the skin. Distinct layers are present in the 
epidermis, and these layers mirror the sequential differentiation of keratinocytes while 
they move to the outer cornified layers from the basal layer as terminal differential 
sets in and they lose the capability of proliferation. Once they are in the outermost 
layers, they will be shed (Wikramanayake et al., 2014). Healing of wounds that are 
present on the skin surface is an intensely coordinated effort with an organised 
succession of processes taking place in order to effectively restore the tissue with the 
desired functions and integrity. It is when these processes are interrupted that a non-
healing, or chronic, wound can develop (Eming et al., 2014). A chronic wound is one 
that has persisted for a minimum period of three months, and commonly classified as 
being diabetic, pressure ulcer or vascular (Pang et al., 2017; Hu et al., 2018).  
 
There are multiple chronic wound therapies that have been developed, although the 
success rates have been varied (Eming et al., 2014). One type of therapy that has 
caught interest and shown promise for use in enhancing tissue regeneration is using 
stem cells. Using MSCs as a wound treatment results in the increased formation of 
granulation tissue, increased angiogenesis and it speeds up the rate of wound closure. 
However, it is not the MSCs replacing the damaged cells by differentiating that causes 
the positive outcomes, it is instead the MSCs ability to produce therapeutic properties 
agent by the secretion of soluble factors. This secretion actually helps to regulate the 
cells’ responses to a cutaneous wound (Hocking and Gibran, 2010; Hocking, 2012). 
Angiogenesis is promoted, cell death reduced and the formation of scars at the area of 
the injury reduced with the MSCs cytokine and growth factor secretion (Ankrum and 
Karp, 2010). On top of this, immunosuppressive factors are released by MSCs and 
these aid in preventing the increase of immune cells including natural killer cells, B-
cells and T-cells (Matthay et al., 2010). Administering exogenous MSCs to wounds 
helps to speed up the closure of the wound, increase angiogenesis and increase the 
formation of granulation tissue (Hocking and Gibran, 2010). It is also suggested, by a 
further study, that the secretions from MSCs are able to produce such results due to 
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their ability to regulate the responses to an injury by the main cell types that are present 
within the wound, which are keratinocytes, endothelial cells, macrophages and dermal 
fibroblasts (Hocking and Gibran, 2010). In another study, topical allogeneic MSCs 
were used to treat full-thickness wounds that resulted in less inflammation and 
enhanced healing. These results were likely to be due to the immunosuppressive 
factors within the wound that were released and prevented the increase of immune 
cells (Kim et al., 2013). A recent study found that MSCs used on bioengineering 
scaffolds encouraged an enhancement of re-epithelialisation. This is characterised by 
the enhanced formation of blood vessels, a reappearance of hair follicles, multi-
layered epidermis and sebaceous glands (Formigli et al., 2015). In a study on animals, 
adipose MSCs were used on an acellular dermal matrix and this resulted in improved 
angiogenesis, enhanced healing of the wound and they played a role in the newly-
formed vasculature (Huang et al., 2012).  
 
It appears as though MSCs are an effective therapy when it comes to wound healing 
as well as the healing of scars, despite the warnings about their source or identity (Hu 
et al., 2018). Bone marrow mesenchymal stem cells (BMSCs) in vitro could have 
limits in terms of long-term potential for differentiation and growth  (Barry and 
Murphy, 2004). Due to this, it is vital to identify other MSC sources in humans that 
can be used for therapies to heal wounds. Various MSCs including dermal, adipose-
derived stromal cells, MSCs from the umbilical cord and from the amniotic fluid have 
all been involved within the preclinical investigations into the healing of wounds 
(Böttcher-Haberzeth et al., 2014). The dermal MSCs and adipose-derived stromal 
cells (ASCs) can be harvested using procedures that are minimally invasive and the 
cells are abundant within skin and fat. The use of these cells presents an ethical 
alternative to other more controversial harvest sites, which makes them a great 
alternative. The use of dermal MSCs and ASCs show promise as, when compared with 
BMSCs, they exhibit the similar immunogenicity, differentiation potential and 
biological characteristics (Driskell et al., 2011). In studies based on wound healing, 
adipose-derived stem cells (ASCs) display promising outcomes in vitro (Collawn et 
al., 2012) and, in animals, in vivo (Kato et al., 2017) and they are being tested in 
clinical trials for their ability to help heal ulcers and burn wounds. A high level of 
success has been seen with the healing of chronic radiation wounds using human ASCs 
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taken from the debridement of the burned artificial dermis (Akita et al., 2010). It was 
shown in a study that the paracrine factors’ secretion from Amniotic fluid MSCs (AF-
MSCs) was related to cell survival and proliferation was enhanced by hypoxia (Jun et 
al., 2014). In addition to this, hypoxic conditioned medium taken from human 
amniotic fluid MSCs (AF-MSC-hypo CM) improved the in vitro migration of dermal 
fibroblasts and enhanced the in vivo wound healing by the PI3K/AKT and TGF-
β/SMAD2 pathways. It has been shown that murine full-thickness wound margins 
injected with human MSCs resulted in reduced tissue fibrosis and accelerated wound 
closure. The TSG-6 released by MSCs was found to suppress TNF-α-mediated 
inflammation as well as switching the synthesis of TGF-b3 and TGF-b1 from 
promoting scars to instead being anti-fibrogenic. This reduces the differentiation of 
myofibroblasts and suppresses excessive collagen deposition, similar to what is seen 
in foetal wound healing (Qi et al., 2014). These clinical studies are very promising and 
show that using MSCs as a base for therapies is both potentially effective and safe, 
with no suggestion that the use of one MSCs tissue of origin is more advantageous in 
wound healing than another of a different origin (Maxson et al., 2012). 
 
As opposed to a direct structural contribution, paracrine signalling of trophic 
mediators (Garg et al., 2014) by releasing stromal cell-derived factor-1, keratinocyte 
growth factor, VEGF, epidermal growth factor, matrix metalloproteinase-9 and 
insulin-like growth factor, MSCs are able to promote the formation of new vessels, 
recruit endogenous progenitor cells and direct the differentiation, extracellular matrix 
formation and proliferation of cells during the repair of wounds (Rustad et al., 2012; 
Garg et al., 2014). The secretion MSCs produces prostaglandin E2 that also helps to 
regulate inflammation and fibrosis while also promoting the healing of tissues as well 
as reducing scarring (Hu et al., 2014). Myeloid cells such as macrophages (Oh et al., 
2014), granulocytes (Chen et al., 2014) and monocytes (Chiossone et al., 2016) 
display proinflammatory activity which is suppressed by MSCs. An MSC-conditioned 
medium acts as a chemo-attractant when it comes to macrophages, through producing 
macrophage inflammatory protein-1 α and β (Wu et al., 2010). The MSCs also alter a 
macrophage’s phenotype so it is more of an anti-inflammatory M2 phenotype which 
is characterised by an upregulation of interleukin-12 and other similar anti-
inflammatory cytokines as well as TNF-α and an increase in phagocytic ability 
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(Maggini et al., 2010). MSCs also show bactericidal properties as they secrete an 
antimicrobial substance as well as increase phagocytosis by immune cells and enhance 
bacteria killing (Mei et al., 2010) (Figure 1.13). 
 
The therapeutic benefits of MSCs are mostly a result of their capability of secreting 
cytokines that are pro-regenerative, which makes them a potentially successful option 
for chronic wound treatment (Garg et al., 2014). There are currently studies and tests 
being carried out using stem cells obtained from various sources to discover their 
abilities in the regeneration of tissue and in wound healing. These clinical and 
preclinical trials have proven that therapy using stem cells is a safe and tolerable option 
(Kirana et al., 2012), and have also shown the therapies to have positive results. 96 
critical limb ischemia patients were studied by Prochazka et al. demonstrating that 
using autologous MSCs as a treatment can reduce the number of amputations to major 
limbs seen within the follow-up of 120 days compared with the standard treatment (Li 
et al., 2014; Procházka et al., 2010). In addition to this, MSCs aid in the rate of wound 
closure and therefore enhance healing of the wound (Rodriguez-Menocal et al., 2015). 
MSCs derived from human bone marrow have been shown to increase the rate of 
wound closure by encouraging keratinocyte and fibroblast migration in vitro (Walter 
et al., 2010). Similarly, MSCs derived from murine bone marrow increase the 
migration of dermal fibroblasts which accelerate the closure of a wound (Smith et al., 
2010). Another study demonstrated that skin fibroblasts that are cultured with media-
conditioned MSCs derived from human umbilical cord blood (UCB-MSCs) showed a 
significant elevation in the ability to migrate (Jinfeng et al., 2016). 
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Figure 1.13: The involvement of MSCs in healing cutaneous wounds.  
The mesenchymal stem cells help to enhance healing in many ways, from encouraging the migration 
of fibroblasts and keratinocytes, increasing the density of microvessels, enhancing the thickness of 
regenerated epidermis as well as decreasing the number of inflammatory cells. Each factor that is 
influenced by MSCs plays a role in an aspect of healing including; increased angiogenesis, enhanced 
wound closure, reduced inflammation, enhanced skin regeneration and the regulation of ECM 
remodelling. Paracrine signalling helps to mediate these effects (Lee et al., 2016). 
 
 
1.17.3 Ability of MSCs to express pro-angiogenic factors 
Angiogenesis is enhanced by MSC during the process of wound healing. Using MSCs 
derived from the human umbilical cord to treat rat wounds showed an increase in 
VEGF, microcirculation in the cutaneous wound and microvessel density (Liu et al., 
2014). A study using stem cells derived from rat adipose cells that were implanted into 
wounds of rats showed MSCs had the ability to contribute to the vasculogenesis of 
wound healing by differentiation directly into vascular endothelial cells (Nie et al., 
2011). This same result has also been seen in similar studies and trials (Lu et al., 2008). 
The same MSCs were also responsible for secreting greater levels of hepatocyte 
growth factor and pro-angiogenic cytokine VEGF (Nie et al., 2011). Another study 
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indicated that injected MSCs from murine bone marrow lowered the resistance of the 
arteriolar vasculature and, in murine skin that is recuperating from ischaemia, there 
were enhancements seen in the functional capillary density. The important finding of 
that particular study was that the MSCs had the ability to express pro-angiogenic 
cytokines including VEGF. 
 
1.17.4 The impact of MSCs on immune modulation 
Successful healing of wounds requires inflammation to be resolved, and poor healing 
is often the result of chronic inflammation (Xu et al., 2012). The wounds’ 
inflammatory response is regulated by the MSCs, which supports the healing process. 
MSCs derived from human umbilical cord transplanted into cutaneous rat wounds, 
resulted in a significantly reduced amount number of inflammatory cells as well as 
pro-inflammatory cytokines such as TNF-α and interleukin (Liu et al., 2014). The 
wounds also demonstrated a quicker recovery time along with a faster rate of healing. 
A study showed that MSCs derived from murine bone marrow co-cultured with human 
dermal fibroblasts reduced intercellular adhesion molecule 1 mRNA levels. It is 
thought that intercellular adhesion molecule 1 mediates the binding of leukocytes to 
dermal fibroblasts, which indicates a role within inflammation. A reduction of the 
expression of this by fibroblasts could aid in resolving inflammation throughout the 
wound repair process (Couture et al., 2009). Jeon et al. studied the activity of 
antioxidants seen in fibroblasts that had been exposed to MSCs conditioned media 
derived from the human umbilical cord, which demonstrated that MSCs promoted 
glutathione peroxidase and superoxide dismutase synthesis. The ability to detoxify is 
significant at wound sites as superoxide detoxification helps to promote the proper 
healing of the wound (Schäfer and Werner, 2008). In addition to this, the 
detoxification of hydrogen peroxide is also an important factor for the VEGF 
upregulation within skin wounds, indicating pro-angiogenic effects (Jeon et al., 2010).  
 
The extracellular matrix remodelling by MSCs has shown that they are able to enhance 
ECM events within the healing of wounds (Ojeh and Navsaria, 2014). The expression 
of MMP-1 is inhibited by conditioned MSCs from human umbilical cord blood, which 
indicates that the stem cells suppress destruction of the collagenous matrix, play a role 
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in the regeneration of fibroblasts as well as preserve the matrix (Jeon et al., 2010).  
Within the study there was also an increase in collagen product and fibroblast elastin, 
adding to the wound healing enhancement factors. MSCs derived from human adipose 
cells were used alongside the wound healing assay in vitro and showed a significant 
increase in human adult keratinocyte (HaCaT) cell proliferation as well as dermal 
fibroblasts, and an enhancement in the overall healing of the wound (Lee et al., 2012). 
The dermal fibroblasts’ ability to contract collagen lattices was enhanced by the 
MSCs, which indicates that MSCs are able to induce the transformation of fibroblasts 
into myofibroblasts. 
 
1.17.5 Skin regeneration improvements with the application of MSCs  
The redevelopment of normal skin function and architecture is essential for optimal 
wound healing. There have been several studies that have shown MSCs are able to 
produce this level of regeneration (Ojeh and Navsaria, 2014). A study carried out by 
Luo et al. (2010) observed the impact of MSCs derived from human umbilical cord 
blood on mice suffering from severe combined immunodeficiency. The study found 
that the wounds healed at a significantly enhanced rate, the epidermis regenerated 
more thickly, the cell number in the regenerated skin was increased, the healing tissue 
was produced with increased regular fibre alignment and an increased number of 
dermal ridges were seen. In addition to this, the wound also developed normal skin 
appendages including sweat glands and hair follicles. These positive results showed 
that MSCs may enhance the quality of wound healing, enhance the physiology of the 
skin that is regenerated and accelerate the rate of healing too. A skin model of in vitro 
human keratinocyte-MSCs was used in another study to show that the MSC-cultured 
keratinocytes create epidermis that is well differentiated and multi-layered (Ojeh and 
Navsaria, 2014). The study also indicated that MSCs have the ability to control the 
production of ECM by the expression of collagen. The accelerations of wound closure, 
enhanced re-epithelialisation, increased angiogenesis, moderation of inflammation, 
regulation of extracellular matrix remodelling and the promotion of granulation tissue 
formation, on MSCs administration has displayed many benefits on the healing of 
cutaneous wounds and the regeneration of skin. Paracrine signalling seems to mediate 
these beneficial effects (Lee et al., 2012). 
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1.18 Uses method of analysis with chromatography 
There are several types of chromatography techniques including thin layer 
chromatography, gas chromatography, supercritical fluid chromatography and, the 
focus of this section, high performance liquid chromatography (HPLC). The HPLC 
method is most often used to separate and determine pesticide residues in foods and 
other mixtures (Torres et al., 1996). The analysis of a sample is carried out by 
separating the analytes using a sample mixture known as the mobile phase. The 
analytes interact within the HPLC column when high pressure is applied and the 
solution separates between the mobile phase and stationary phase. The solution 
separation that occurs varies depending on how the sample components interact and 
their affinity for the stationary and mobile phases. The separation will first occur with 
the component that has the least affinity for the chromatographic packing material, or 
stationary phase (Snyder et al., 2012). 
 
The general structure of the HPLC method includes a mobile phase reservoir, a high-
pressure pump, injector system, stationary phase column, the detector and a data 
acquisition system (Figure 1.14). It is also possible to carry out reverse- phase HPLC 
using a specialised instrument, such as an Agilent Technologies integrated Agilent HP 
Series 1100 Liquid Chromatography equipment. This needs to be fitted with the 
necessary degasser, auto-injector, and a single channel as well as a 230nm tunable 
ultraviolet absorbance detector, in order to be effective. A sample is introduced to the 
HPLC analysis system using the injector, and this can be done automatically or by 
injection valves. The use of automated devices for injection is common, particularly 
in sophisticated systems that are used for the analysis of 100 samples or fewer. The 
core of any HPLC system is the column which is filled with chromatic packing 
material such as silica or polymer. This material is what is referred to as the stationary 
phase. The stationary phase material has regularly- shaped and -sized particles, and is 
necessary to effect separation. It is vital to the analysis as the particles help to retain 
neutral, ionic, polar and non-polar molecules within the column. The common 
chromatic packing material is silica, which offers great polar selectivity and has 
dominant areas for analyte interactions in the form of active adsorption sites of silanol 
(Si-O-H). Analyte detection is carried out by using a low detection level such as UV, 
fluorescence, mass spectrometry or diode array and a suitable detector. The most 
Chapter 1 
 
 
67 
 
extensively used low detection level in HPLC analysis is UV as it is cost-effective, 
and some compounds within the samples are able to absorb one or more wavelengths 
of light in the UV range. Conventionally, a UV detector can measure absorbance at 
just one wavelength, whereas a diode array detector (DAD) is able to measure 
absorbance at multiple wavelengths. A DAD is able to show the spectrum of sample 
components, providing more means of identification than when using one UV 
wavelength alone. When using UV, the absorption intensity by each component is 
recorded via an electronic signal that is generated for the chromatogram. The data 
system is then used to structure and show the collected data such as the peak area and 
retention time. The software optimises the development of the method by increasing 
the validation of accuracy and precision. The data software can also be used to make 
predictions as well as decisions to improve separation and the conditions of the 
analysis (Snyder et al., 2012).  
 
 
 
 
Figure 1.14: Diagram of the general structure of an HPLC system 
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1.18.1 Selection and developing of the chromatography method  
There are multiple considerations to take into account when beginning method 
development. The analytical method is used to determine the target component within 
the sample so it is important to think about the analysis objective, the sample nature 
and the HPLC equipment that is available. The best-suited detector for the specific 
analysis also needs to be determined, for example, consideration of which component 
needs to be measured and whether a single detection method or qualitative analysis 
will be required (Snyder et al., 2012). The chromatographic separation should start the 
method development process as it requires the selection of HPLC method and deciding 
the most suitable experimental conditions. There are many approaches to the method 
that are used, especially in modern analysis. Many now choose reverse-phase HPLC 
as the preferred method and this is increasingly being considered to be the best 
technique because of its reduced run-time and high resolution. Reverse-phase HPLC 
also offers the possibility of manipulating the conditions to reproduce retention time 
(Majors and Przybyciel, 2002). This tends to depend on the composition of the sample 
itself when deciding which chromatography technique is best suited. There are 
important factors that can affect the analysis, for example, column temperature which 
can influence on retention time, selectivity and peak separation, but the column 
temperature can cause problems too (Dolan, 2002). It is not just temperature that can 
have an impact on the separation and analysis efficiency, the size of the particles, 
length and mobile phase flow rate can also have an impact (Wang et al., 2003; Snyder 
et al., 2012). 
 
 
 
 
 
 
Chapter 1 
 
 
69 
 
1.19 Aims and objectives  
The aims and objectives of this study were:  
 To investigate and compare the ability of SAC/NAC (The key component of 
aged garlic extract) and synthesised compounds A, B and C mimics of SAC 
and NAC to inhibit the formation of methylglyoxal-derived AGE cross-links 
in vitro.  
 To develop an HPLC method for the separation and quantification of NAC to 
test the effectiveness of drug loaded hADMSCs on wound healing in vitro. 
 To examine the effect of SAC/NAC and compound A as well as SAC/NAC- 
and compound A-primed MSCs CM on  angiogenesis in vitro 
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Chapter 2 – Materials and methods 
2.1 Materials 
 Acetic acid (Fisher Scientific International, Loughborough, UK) 
 Acetonitrile (Fisher, St Louis, MO, USA) 
 Acrodisc® 32mm syringe filter with 0.2 µm membrane (Pall Corporation, 
UK) 
 Acrylamide/Bis solution (BIO-RAD, Hertfordshire, UK) 
 Advanced glycation endproducts ELISA Kit (Human) (OKEH00348) 
(Aviva Systems Biology, San Diego, USA) 
 Affinity Pak™ Detoxi-Gel™ endotoxin removing gel column (Thermo 
Scientific, USA) 
 Ammonium persulphate, APS (Sigma-Aldrich, Heidelberg, UK) 
 Antibiotics: Penicillin-Streptomycin solution containing L-glutamine (PSG) 
in 0.9% NaCl (Sigma-Aldrich, Heidelberg, UK) 
 Anti-MG AGEs antibody, Rabbit polyclonal to AGEs antibody (Abcam, 
Cambridge, UK) 
 Anti-Tubulin antibody, Mouse monoclonal to tubulin antibody (Abcam, 
Cambridge, UK) 
 Bio-Rad protein essay Kit (Bio-Rad Laboratories, Hertfordshire, UK) 
 Bovine aortic endothelial cells, secondary cell line (Cell and Molecular 
Biology Research Laboratory, Manchester Metropolitan University, UK) 
 Bovine serum albumin, BSA (Sigma-Aldrich, Hertfordshire, UK) 
 Bromophenol blue (Serva, Feinbiochemica, Heidelberg, Germany) 
 Coomassie Brilliant Blue (BDH, UK) 
 Cryotubes (Scientific Laboratory Supplies, UK) 
 Cryovials (Nunc Corporation, Roskilde, Denmark) 
 Deionised water (Local store, Manchester, UK) 
 Detoxi-gel endotoxin removal columns (Thermo Scientific, USA) 
 D-glucose (Sigma-Aldrich, Heidelberg, UK) 
 Dialysis membrane (Medical International, UK) 
 Dialysis tubes (Visking, UK) 
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 Digital multi-channel pipettes (Eppendorf, Germany) 
 Dimethyl sulfoxide (DMSO) (Sigma-Aldrich, Heidelberg, UK) 
 Dulbecco’s Modified Eagle Medium (Sigma-Aldrich, Heidelberg, UK) 
 Eppendorf tubes (Scientific Laboratory Supplies, UK) 
 Ethanol (Fisher Scientific International, Loughborough, UK) 
 E-toxic kit for endotoxin measurement (Sigma-Aldrich, Heidelberg, UK) 
 Fibroblast growth factor-basic (FGF-2) (R & D Systems, USA) 
 Foetal bovine serum (FBS) (Sigma-Aldrich, Heidelberg, UK) 
 Glycerol (Sigma-Aldrich, Heidelberg, UK) 
 Glycine (Sigma-Aldrich, Heidelberg, UK) 
 Hydrochloric acid (Sigma-Aldrich, Heidelberg, UK) 
 Isopropanol (Sigma-Aldrich, Heidelberg, UK) 
 Liquid nitrogen (BOC Cryospeed Thermolyne, Surrey, UK) 
 Lysozyme from chicken egg white (Sigma-Aldrich, Heidelberg, UK)  
 Matrigel™ basement membrane reduced (Becton Dickinson, San Jose, UK) 
 2-Mercaptoethanol (Sigma-Aldrich, Heidelberg, UK) 
 Methanol (Fisher Scientific International, Loughborough, UK) 
 Methylene blue stain (Sigma-Aldrich, Heidelberg, UK) 
 Methylglyoxal, MG (Sigma-Aldrich, Heidelberg, UK) 
 N-acetyl-L-cysteine, NAC (Wakunaga Pharmaceutical Company, Japan) 
 Nitrocellulose membrane (Scientific Laboratory Supplies, UK) 
 N, N, N′, N′-tetramethylethylenediamine (TEMED) (Sigma-Aldrich, 
Heidelberg, UK) 
 Phosphate buffered saline, PBS (Lonza, USA) 
 Pipette tips (Sarstedt AG & Co, Germany) 
 Polyclonal Goat Anti-rabbit Immunoglobulin/Horseradish peroxidase, 
HRP (Dako, Glostrup, Denmark) 
 Protein essay Kit (Bio-Rad Laboratories, Germany) 
 Protein molecular weight marker for SDS – PAGE (Sigma-Aldrich, 
Heidelberg) 
 Rabbit anti-Mouse (Murine) IgG (Dako, Glostrup, UK) 
 Radioimmunoprecipitation assay buffer (Sigma-Aldrich, Heidelberg, UK) 
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 S-allyl cysteine, SAC (Wakunaga Pharmaceutical Company, Japan) 
 Silver stain kit (BIO-RAD, California, USA) 
 Six-well plates, polystyrene, flat bottom, sterile (Corning Life Sciences, 
USA, supplied by Fisher Scientific, UK) 
 Skimmed milk powder (Local store, Manchester, UK) 
 Sodium azide (Sigma-Aldrich, Heidelberg, UK) 
 Sodium chloride, NaCl (Sigma-Aldrich, Heidelberg, UK) 
 Sodium dodecyl sulfate, SDS (BDH, Poole, UK) 
 Sodium phosphate dibasic (Sigma-Aldrich, Heidelberg, UK) 
 Sodium phosphate monobasic (Sigma-Aldrich, Heidelberg, UK) 
 Sterile bijoux (SLS, Nottingham, UK) 
 Sterile needle (BD Plastipak, UK) 
 Sterile universal containers (SLS, Nottingham, UK) 
 Tissue culture flasks (T-25, and T-75) (Scientific Laboratory Supplies, UK) 
 Tris (hydroxymethyl) methylamine (Fisher Scientific, UK) 
 Trypan blue dye (Sigma, Heidelberg, UK) 
 Trypsin 10X (Sigma-Aldrich, Heidelberg, UK) 
 Tween- 20 (TBST) (Sigma-Aldrich, Heidelberg, UK) 
 
2.2 Equipment 
 Autoclaves (Lab Impex Research, UK) 
 Automated Cell Counter TC10™ (Bio-Rad, California, USA) 
 Autovortex mixer SA1 (Stuart Scientific Co, UK) 
 Blotter (Semi-Phor, Hoefer Scientific Instrument, London, UK) 
 Centrifuge (Eppendorf and Laborzentrifugen 3K10, Sigma, Hertfordshire, 
UK) 
 ChemiDoc™ Touch Imaging System (Bio-Rad Laboratories Ltd, UK) 
 CO2 incubator (Lab Impax Research, London, UK) 
 Electrophoresis unit Mini-Protean® 3 (Bio-Rad, California, USA) 
 ELISA plate reader model 354 (Thermo Life Sciences, UK) 
 Freezer -80°C (Juan Quality System, London, UK) 
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 Fridge (Scientific Laboratory Supplies, UK) 
 Haemocytometer chamber (Weber Scientific International Ltd, UK) 
 High performance liquid chromatography (HPLC) column (Zorbax 
Columns, PN, USA) 
 Ice maker (Borolab Ltd, Abingdon, UK) 
 Image J software analyser (free online software) 
 Incubator model E4C (Phillip Harris, UK) 
 Laminar flow hood tissue culture grade (Walker Safety Cabinets Ltd, 
London, UK) 
 LTE IP 30 incubator (Scientific Laboratory Supplier, UK) 
 Magnetic stirrer hotplate (Stuart Scientific Co, Abingdon, UK) 
 Microplate reader, 96-well (Spectramax, Finland) 
 Microscope (Nikon TMS) 
 MiniRocker-Shaker, PMR30, (Grant-Bio, Cambridge, UK) 
 PH meter AGB-75 (Medical Scientific Instruments, England) 
 Pipettes 0.5-10, 2-20,100-200,100-1000µl (Scientific Laboratory Supplies 
Ltd, UK) 
 Power supply PS-251-2 (Sigma-Aldrich, Heidelberg, UK) 
 Sigma laboratory centrifuge 3K10 for cell culture use (Howe, Germany) 
 Single threshold coulter counter (Beckman Coulter, UK) 
 Spectrophotometer, Biochrom WPA Biowave II (Pharmaxia Biotech, 
Cambridge, UK) 
 Trans-blot SD semi-dry transfer (Bio-Rad, California, USA) 
 Water bath (Grant Instruments Ltd, UK) 
 
2.3 Buffer solutions 
 Ammonium persulphate (10%): 100mg APS was dissolved in 1ml of 
dH2O. The solution was prepared and used fresh 
 Blocking buffer (1%): 1g BSA was dissolved in 100ml of Tris-buffered-
saline and Tween-20 (TBST). The pH was adjusted to 7.4 and the buffer 
was stored at 4°C for one week 
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 Destaining buffer: 250ml Methanol was dissolved in 70ml of acetic acid 
and the volume was made up to 1L with dH2O. The buffer was stored at 
room temperature 
 Electrophoresis buffer: 12.02g Tris-base, 4g SDS and 57.68g glycine were 
dissolved in 2 L of dH2O. The buffer was stored at room temperature 
 Milk (5%): 5.0g Skimmed milk powder was dissolved in 100ml of TBST 
buffer. The pH was adjusted to 7.4 and the solution was stored at 4°C for 
one week 
 Radioimmunoprecipitation assay (RIPA) buffer: 50mM Tris-HCl, 0.25% 
(w/v) SDS, 1% Triton X-100,0.15M NaCl, 1mM EDTA, 1% (w/v) sodium 
deoxycholate, 2.5mM sodium pyrophosphate, 1mM 
sodiumorthovanadate, 1mM β-glycerophosphate, 1μg/ml pepstatin and 
0.5mM PMSF, pH 7.2. The solution was stored at -20°C 
 Reconstitution of FGF-2: Sterile phosphate-buffered saline was added to 
the vial in order to prepare a working stock solution (≥ 100g/ml). The 
carrier-free protein was immediately used upon reconstitution to avoid loss 
of activity 
 Sample buffer: 1.5g Tris-base, 20ml glycerol, 4g SDS, 10ml 2-
mercaptoethanol and 0.004g of bromophenol blue was dissolved in 100ml 
of dH2O filtered and stored at -20°C. Prior to use, the pH was adjusted to 
6.8 
 Separation buffer: 45.5g Tris-base and 1g of SDS were dissolved in 
dH2O.The pH was adjusted to 8.8 with HCl and made to the final volume 
of 250ml. The buffer was stored at room temperature 
 Sodium phosphate buffer (0.1M, pH 7.4): the acid component of the buffer 
(sodium dihydrogen phosphate) and the basic component (sodium 
hydroxide) were weighed out in a certain ratio according to the Henderson 
Hasselbalch equation. The desired volume was then accordingly adjusted 
with dH2O and the solution was mixed. The pH of the buffer was adjusted 
to 7.4. Sodium azide was added to the mixture to prevent any bacterial 
growth. The buffer was stored at 4°C 
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 Stacking buffer: 15g Tris-base and 1g of SDS were dissolved in dH2O. 
The pH was adjusted to 6.8 with HCl and volume adjusted to 250ml. The 
buffer was stored at room temperature 
 Staining buffer: 2.5g Coomassie brilliant blue was dissolved in 500ml 
methanol and 100ml acetic acid. The volume was made up to 1L with 
dH2O and then filtered. The staining solution was stored at room 
temperature 
 Towbin buffer: 1.51g Tris-base, 7.2g glycine, 0.167g SDS were dissolved 
in 400ml of dH2O and 75ml methanol. The pH adjusted to 8.3 and volume 
adjusted to 50ml with dH2O.The buffer was kept at room temperature 
 Tracking dye buffer: 1mg Bromophenol blue was added to 0.1ml of 
glycerin and mixed with 0.9ml dH2O 
 Tris-buffered saline and Tween-20 (TBS-Tween) buffer: 2.422g Tris-base, 
16.36g NaCl, and 2ml Tween 20 mixed and made up to 2L with dH2O. 
The pH was adjusted to 7.4 with HCl and the buffer was kept at room 
temperature 
 Treatment buffer: SDS (0.1g), and 0.1ml of 2-mercaptoethanol were added 
to 1 ml of stacking buffer (pH 6.8) and 2ml of glycerine and the volume 
was made up to 10ml with dH2O 
 
2.4 Methods 
2.4.1 Methods for in vitro protein glycation  
2.4.1.1 Preparation of AGEs 
This methodology was described by Mashilipa et al. (2011). Briefly, BSA or 
lysozyme was incubated with 0.1M MG in sodium phosphate buffer (0.1M, pH 
7.4) at 37°C for different time intervals (1 and 3 days). The prospective inhibitors 
SAC and NAC (provided by the Wakunaga Pharmaceutical Company, Japan), and 
mimic compounds A, B and C (chemically synthesised small molecule inhibitors 
which mimic of SAC/NAC, kindly supplied by Dr Alan Jones, Chemistry Dept., 
Manchester Metropolitan University, UK), were introduced into the incubation 
mixture simultaneously. BSA or lysozyme was incubated alone under the same 
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conditions as negative controls. All experiments were carried out in triplicate and 
repeated at least twice. The results represent one of the experiments. 
 
2.4.1.2 Measurement of cross-linked AGEs using SDS – PAGE 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) was 
used to determine the degree of cross-linking of glycated proteins. The Mini-
Protean®3 apparatus (Bio-Rad, UK) was used to cast vertical slab gels and run 
SDS-PAGE. The cross-linking efficiency was assessed using 12% SDS-PAGE 
according to the method of Laemmli (Laemmli, 1970). The glass plate sandwiches 
were assembled with gaskets and clips in place. The acrylamide gel was prepared 
by mixing 3.3ml 40% bis-acrylamide with 4.8 ml dH2O and 2.5ml separating 
buffer in a universal tube. 100μl 10% APS solution was added followed by 10μl 
TEMED solution. The 5ml of the resolving gel solution was added to the sandwich 
and a few drops of isopropanol were added on top of the gel, which was left to 
polymerise for 30 minutes. Isopropanol was washed off after the gel polymerised 
and rinsed with plenty of dH2O (Table 2.1).  
 
Table 2.1: Preparation of separating gel 
 
 
 
 
 
 
 
 
 
 
The stacking gel solution was prepared in a fresh universal tube by combining 
1.45ml 40% bis-acrylamide with 6.1ml dH2O, and 2.5ml stacking buffer. 100μl 
APS was added followed by 10µl TEMED solution, 3ml of the stacking gel 
solution was added onto the top of the resolving gel. Combs was quickly inserted 
and allowed to polymerise for up to 30 minutes. The stacking gel was left to 
Material Volume 
ddH2O 4.2ml 
40% Acrylamide 3.3ml 
Separating buffer 2.5ml 
10% APS 100μl 
TEMED 10μl 
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polymerise for a minimum of 30 minutes. Slowly the combs, clamps, and gaskets 
were then removed taking care not to damage the wells, and the gel plates inserted 
into the electrophoresis chamber (Table 2.2). 
 
Table 2.2: Preparation of stacking gel  
Material Volume 
ddH2O 6.1ml 
40% Acrylamide 1.4ml 
Stacking buffer 2.5ml 
10% APS 100μl 
TEMED 10μl 
 
 
The chamber was subsequently filled with electrode buffer. A total of 500ml 
electrode buffer was used to fill the tank. 1μl of glycated protein was mixed with 
9μl of treatment buffer and blocked at 100°C for 10 minutes. Protein marker was 
loaded into the first well of each gel and 3μl tracking dye loaded in the rest of the 
wells. Then, 10μl of the appropriate sample was loaded to the rest of the wells. 
Electrophoresis was carried out at 65V until the blue band reached the separating 
gel (approximately after 45 minutes). Then the voltage was increased to 200V and 
run for further approximately 60 minutes. After running, the gels were stained 
with Coomassie Brilliant Blue staining or silver staining to detect the proteins. 
 
2.4.1.3 Coomassie Brilliant Blue staining  
After electrophoresis, the running buffer was discarded, and the gels were 
removed from the gel cassette sandwiches. Gels were stained for two hours in a 
staining buffer containing 0.25% (w/v) Coomassie blue R, 10% (v/v) acetic acid 
and 50% (v/v) methanol. After two hours of staining, gels were de-stained in a de-
staining buffer, containing 25% (v/v) methanol and 7% (v/v) acetic acid. The de-
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staining buffer was changed several times with fresh de-staining solution until the 
gel was clear. 
 
2.4.1.4 Silver stain 
Following SDS-PAGE, silver staining was carried out according to the 
manufacturer’s recommendations using the silver stain kit from Bio-Rad. Briefly, 
the gel was fixed with gentle agitation in a solution of 40% (v/v) methanol, 10% 
(v/v) acetic acid and 50% dH2O (v/v) fixative enhancer concentrate for 30 minutes 
minimum. Pour the fixative and add 10% (v/v) Oxidizer with 90% dH2O (v/v) for 
5 minutes. After decanting the oxidiser solution, the gel was rinsed in 400ml 
deionised dH2O for 15 minutes with three changes of water after every 10 minutes. 
Then, the gels were incubated in 10% silver reagent for 20 minutes and rinsed 
quickly with water for a maximum of 30 seconds. The gel was then stained in the 
staining and developing solution for 30 seconds or until a brown or smoky 
precipitate appeared. The solution was quickly poured off and fresh developer 
added until the desired intensity was obtained. The staining reaction was stopped 
by placing the gel in a 5% (v/v) solution of acetic acid. This was followed by 
rinsing the gel in deionised dH2O for 5 minutes. 
 
2.4.1.5 Preparation of bovine serum albumin-derived advanced glycation 
end products (BSA-AGEs) 
Bovine serum albumin (10mg/ml) was incubated with 0.5M glucose in 0.1M 
sodium phosphate buffer containing 3mM sodium azide, pH 7.4 at 37°C for four 
weeks. The glycated albumin was subsequently extensively dialysed with dH2O 
at 4°C. Endotoxin was removed by using Detoxi-Gel resin columns according to 
the method described below. The formation of BSA-AGEs was assessed by their 
characteristic fluorescence emission spectra at 420nm after excitation at 350nm 
using a luminescence spectrometer. Prior to the addition to cell cultures, BSA-
AGEs were dissolved in DMEM and were filtered through a sterile 0.2μm filter. 
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2.4.1.6 Endotoxin removal from BSA-AGEs 
Endotoxins were removed from the dialysed BSA-AGE samples using the Detoxi-
Gel endotoxin removing gel. The Detoxi-Gel resin column underwent 
regeneration through wash cycles with five resin-bed volumes using 1% sodium 
deoxycholate and basal media. BSA-AGEs were added to and were allowed to run 
into, the column. The flow of the column was stopped when the AGE sample filled 
the resin-bed from top to bottom. Following this, incubation was carried out for 2 
hr at room temperature prior to samples being collected. In an attempt to achieve 
greater efficiency with a gravity-flow column, the samples emerged from the 
column after the void volume was collected. 
 
2.4.1.7 Determination of endotoxin content in BSA–AGE solutions 
Bovine serum albumin-derived advanced glycation end product samples were 
analysed to detect the remaining Endotoxin content using an E-toxic kit (Sigma, 
UK). Samples, water and endotoxin standards (100μl) were added to the 
endotoxin-free glass test tubes. Subsequently, E-toxic working solution (100μl) 
was added to each tube by inserting a pipette to just above the contents, and the 
lysate was then allowed to flow down the side of the tube. The tubes were mixed 
gently and covered with Parafilm and incubated for 1 hour at 37°C. Following 
incubation, the tubes were gently inverted 180 degrees and observed for evidence 
of gelation. The formation of a hard gel was considered to be a positive test. All 
other results including soft gels, turbidity, and increased viscosity or clear liquid 
were considered to be negative. Notably, the amount of endotoxin level (EU/ml) 
was calculated using the following formula:  
Endotoxin (EU/ml) =1/ (Highest dilution of sample found positive × Lowest 
concentration of Endotoxin standard found positive) 
 
2.4.1.8 Glycated protein dialysis 
To remove unbound sugars (glucose or MG) before the protein assay, glycated 
proteins were subjected to extensive dialysis against dH2O by making a tight knot 
at one end of the tubing. Protein samples were delivered into the dialysis tubing 
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and then the other end of the tube was closed carefully. The dialysis bag was 
placed into a 2litre beaker containing dH2O. A few drops of chloroform were 
added to prevent any contamination. Dialysis was carried out by stirring the 
samples at 4ºC with 4 - 5 changes over two days until equilibrium was reached. 
At the end of dialysis, the dialysed samples were transferred into clean tubes and 
stored at -20ºC until used.  
  
2.4.1.9 Imaging SDS-PAGE gels 
The gels were photographed using a ChemiDoc™ Touch Imaging System (Bio-
Rad, UK). All the bands were compared within the same gel. Integrated Density 
(I.D) was measured to analyse the one-dimensional electrophoretic gels and 
computed using the following formula:  
Integrated Density = N x (mean – background) 
Where N is the number of pixels in the selection and the background is the modal 
grey value (most common pixel value) after smoothing the histogram. Sufficient 
background was included in the selection to avoid errors. 
 
2.4.1.10 Percentage inhibition of cross-linked AGEs 
This was calculated using the following formula:  
100 (I.D without inhibitor - I.D with inhibitor) / I.D without inhibitor. 
 
2.4.1.11 Measurements of fluorescent AGEs 
The formation of AGEs was assessed by their characteristic fluorescence emission 
spectra at 460nm after excitation at 350nm using a fluorescence plate reader 
(Thermo Life Sciences, UK) operating at room temperature. Glycated samples 
were thawed at 4˚C and each sample was diluted in 1.8ml of dH2O to give a 
solution with a final concentration of 1mg/ml. Fluorescent measurements were 
carried out on a plate reader. Fluorescence intensity standards were used to the 
manufacturer’s protocol. Sodium phosphate buffer was used to calibrate the 
instrument and monitor its performance. A water blank was used to zero the 
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instrument. Fluorescence of AGE was expressed in arbitrary units (AU) per mg of 
protein. 
2.4.1.12 Measurement of cross-linked AGE by Western blotting 
The glycated proteins (AGEs) were separated using 12% SDS-PAGE, and the 
proteins were transferred to a nitrocellulose membrane (NCM) according to the 
method described previously (Towbin et al., 1979). After blotting, the membrane 
was blocked for 1 hour in blocking buffer (1% BSA, w/v) on a shaker at room 
temperature. Then, the membrane was incubated with primary antibody (rabbit 
anti-AGE antibody, at 1:1000 dilution in 1% BSA, w/v) on a shaker at 4°C 
overnight. The following day, the membrane was washed five times with TBST 
buffer on a shaker at room temperature for 10 minutes per wash. The membrane 
was then incubated with a secondary antibody [Polyclonal Goat anti-Rabbit IgG-
horseradish peroxidase (HRP)] diluted in 5% (w/v) milk solution (1:2000) and 
incubated for 1 hour on a shaker at room temperature. After one hour, the 
secondary antibody was discarded, and the membrane was washed five times for 
10 minutes each wash in new changes of TBST buffer. The glycated proteins were 
then detected by using the enhanced chemiluminescence (ECL) solution and 
photographed using a ChemiDoc™Touch Imaging System for image analysis. 
 
2.4.1.13 Measurement of AGEs using ELISA 
For rapid detection and quantification of AGEs, enzyme-linked immunosorbent 
assay (ELISA) was performed using an Aviva Systems Biology AGE ELISA kit 
(Human). Briefly, a series of BSA-AGE standards were prepared as showed in 
table 2.3.  Glycated-BSA samples were diluted to 10μg/ml in sample diluent. To 
each well of a 96-well plate, 100μl sample and the standards were incubated in 
duplicate for 2 hours at 37°C. After incubation, the samples and the standards were 
discarded and the wells were washed with 300μl of 1× washing buffer. Then 100μl 
of 1× Biotinylated AGEs detector antibody was added to each well and incubated 
at 37°C for 60 minutes. After that, the liquids from each well were discarded, and 
the wells washed three times with 300μl of 1× washing buffer. A 100μl of 1× 
Avidin-HRP conjugate was added to each well and incubated for 1 hour at 37°C. 
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After that, the wells were washed 5 times with 300μl of 1× washing buffer, then 
90μl of TMB substrate solution added and incubated at 37°C for up to 30 minutes. 
The enzymatic reaction was stopped by adding 50μl of stop solution to the wells, 
and the absorbance at 450nm measured using a microplate reader (Lin et al., 
2002). Table 2.3 shows the volume of the standard to dilute the buffer. 
 
Table 2.3: Volume of the standard to dilute and sample diluent buffer required to establish 
the standard curve 
 
2.4.2 Methods for cell culture techniques 
All cell culture experiments were carried out in a sterile environment and 
performed in a Class II microbiological safety cabinet (Labcaire SC-R 
Recirculating Class II, North Somerset, UK). Ethanol [70% volume/volume (v/v) 
in dH2O] was used for cleaning all surface before commencing work. Only sterile 
Standard 
Number 
Standard to 
Dilute 
Volume of 
Standard 
to Dilute 
(μl) 
Volume 
of 
Sample 
Diluent 
Buffer 
(μl) 
Total 
Volume 
(μl) 
Final 
Concentration 
1 
50,000 pg/ml 
Reconstituted 
AGE standard 
600 0 600 50,000 pg/ml 
2 50,000 pg/ml 300 300 600 25,000 pg/ml 
3 25,000 pg/ml 300 300 600 12,500 pg/ml 
4 12,500 pg/ml 300 300 600 6,250 pg/ml 
5 6,250 pg/ml 300 300 600 3,125 pg/ml 
6 3,125 pg/ml 300 300 600 1,650 pg/ml 
7 1,560 pg/ml 300 300 600 780 pg/ml 
8 NA 0 300 300 0 
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plastics were used, and all media were pre-warmed by placing them in a 37 ºC 
water bath for 30 minutes before use. All cell incubations were performed in a 
Nuaire DH Autoflow CO2 Air-Jacketed Incubator (Triple Red Laboratory 
Technology, Buckinghamshire, UK). Liquid, media and supernatants were 
discarded using an aspirator (IBS Integra Biosciences Vacusafe Comfort, Chur, 
Switzerland). All solutions used for cell culture were prepared with H2O from an 
Elgastat option 4 water purifier (Elga Ltd., High Wycombe, UK). 
 
2.4.2.1 Preparation of cell culture medium for BAECs 
Pre-warmed sterile FBS was de-complemented at 65 – 70ºC for approximately 45 
min and other reagents were mixed as described below (Table 2.4).  
 
Table 2.4: Preparation of cell culture medium supplemented with 0.1 – 15% of FBS 
  
2.4.2.2 Cell culture techniques for BAECs 
Bovine aortic endothelial cells were obtained from Dr Sabina Matou (Manchester 
Metropolitan University) and previously characterised as EC by the presence of 
the Von Willebrand factor. They were seeded into T-75 flasks and cultured in 
DMEM medium composed of 10% (v/v) FBS, 2mM L-glutamine and 1% 
antibiotics (100U/ml penicillin and 100μg/ml streptomycin). The culture flasks 
were maintained at 37°C in a dH2O humidified atmosphere of 95% air and 5% 
CO2-incubator. Following confluence, the cells were subcultured at 1:3 split and 
cultured in fresh flasks or frozen in liquid nitrogen for later use. Passage numbers 
between 4 – 12 were used for the experiments. 
Reagents 0.1% FBS 0.5% FBS 2.5% FBS 10% FBS 
DMEM 98.9ml 98.5ml 96.5ml 89ml 
FBS 0.1ml 0.5ml 2.5ml 10ml 
PSG 1ml 1ml 1ml 1ml 
Chapter 2 
 
 
84 
 
2.4.2.3 Sub-culture of BAECs 
Bovine aortic endothelial cells (1.5 × 105 – 5 × 105) were seeded in T-75 flasks 
with 12ml of growth medium (10% FBS DMEM, v/v) and incubated in a dH2O 
humidified atmosphere of 95% air and 5% CO2-incubator for 24 hours. The 
growth medium was changed every three days. Upon reaching confluence, the 
growth medium was discarded from the T-75 flask. Then, the cells were washed 
with 10ml of sterile, warm PBS three times and incubated with 5ml of 1× trypsin 
solution for 5 minutes at 37°C. When the cells were detached (with a brief check 
under the phase contrast microscope), 5ml of growth medium was immediately 
added to the flask to stop the trypsinisation. The cell suspension was centrifuged 
at 200 5 minutes at room temperature. After discarding the supernatant, the cell 
pellet was re-suspended in 1 ml fresh growth medium, and then split at a ratio of 
1:3 before being seeded in fresh T-75 flasks, which corresponded to a new 
passage. 
 
2.4.2.4 Preparation of freezing medium 
The freezing medium was composed of 90% FBS and 10% dimethyl sulfoxide 
(DMSO), a cryo-protector agent. Briefly, 1ml of DMSO in 9ml of FBS were 
mixed and kept at -20°C until use. The fresh freezing medium was prepared or 
defrosted shortly before use. 
 
2.4.2.5 Freezing of cells 
The trypsinised cells taken from the flask were centrifuged at 300×g for 5 minutes; 
the supernatant was then removed, and the cell pellet was re-suspended in 250 µL 
of complete medium with the addition of 750 µL of 10% (v/v) DMSO (freezing 
medium). One ml of the medium containing approximately 2.5×106 of cells was 
kept in a 1.5ml cryovial labelled with the cell passage, number and date. Cryovials 
containing cells were kept at -20°C for 30 minutes. then the cryovial was 
transferred into a -80°C freezer overnight. After 24 hours, the cryovial was 
transferred to liquid nitrogen (-190°C) and the location was recorded. 
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2.4.2.6 Thawing of cells 
A cryo-tube containing the frozen BAECs were taken out from liquid nitrogen and 
decontaminated by spraying with 70% (v/v) ethanol. During the thawing process, 
the cells were defrosted at 37°C under sterile conditions until liquid but still cold 
to prevent any cell toxicity effect of the DMSO. The cells were re-suspended in 1 
ml of warm, fresh complete medium. Subsequently, the cells were seeded in a T-
25 flask and incubated at 37°C in a humidified atmosphere of 95% air and 5% 
CO2 incubator.  
2.4.2.7 Cell counting 
A TC10™ automated cell counter (Bio-Rad, UK) was used for counting the cells. 
From sub-culturing of BAECs, 20μl of 1ml cell suspension was added into an 
Eppendorf tube containing 20μl of trypan blue dye. The sample was then loaded 
onto a dual-chamber slide. The slide was inserted into the TC10 cell counter and 
the counting of the cells automatically started. As a final point, the total cell count 
was obtained from the screen. 
 
2.4.2.8 Protein extraction 
BAECs (2 × 105/ml) were seeded in complete medium in a 6-well plate (Corning  
Life Sciences, USA) (2ml /well), together with various concentrations of MG 
(300μM), alone and together with the SAC/NAC, and compound A (0.001μg/ml, 
0.01μg/ml, 0.05μg/ml, 0.1μg/ml, 0.5μg/ml, 1μg/ml and 2μg/ml) and incubated at 
37°C in a humidified atmosphere of 95% air and 5% CO2 incubator. After 3 days 
incubation, the medium was discarded, and the cells were washed with cold PBS 
three times. Ice-cold RIPA buffer (300μl) was added to lyse the cells. The plate 
was put on ice for one minute, and the cells were scraped using a cell scraper. The 
cell lysate was collected and transferred into a 0.5ml microcentrifuge tube and 
incubated on ice for 20 minutes. Then, protein samples were stored at -20°C for 
later use. 
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2.4.2.9 Protein estimation 
The protein concentration was determined using protein assay (Bio-Rad 
Laboratories, Germany). Briefly, 10μl of protein sample was added and completed 
with 90μl of dH2O in a bijou. After that, 2ml of Bio-Rad protein assay (1:4 
dilution) was added in each bijou. A standard curve was prepared by BSA at 
1mg/ml as a standard protein and measured by the absorbance at 595nm. The data 
outlining the reading of each protein sample and the standard curve required for 
protein estimation are shown in Table 2.5. 
 
Table 2.5: The volume of BSA, dH2O and Bio-Rad solution required to establish the 
standard curve 
 
BSA Standard (μg)  
BSA volume added 
(1μg/µl) 
Volume of dH2O 
(µl) 
Volume of 
diluted Bio-Rad 
reagent (ml) 
 0  0 100 2 
 
5  5 95 2 
 
10  10 90 2 
 20  20 80 2 
 
40  40 60 2 
 
 
2.4.2.10 Cell migration – wound healing assay 
Thermanox plastic coverslips (Nunc™) were placed into each well of a 24-well 
plate. Approximately, 6×104 BAECs /ml were added to each well in complete 
growth medium (15% FBS) and incubated for 24 – 48 hours. When confluence 
was attained, the medium was then replaced with DMEM containing 0.1% (v/v) 
FBS and the cells were then incubated for a further 24 – 48 hours. After removing 
the medium, cells were pre-incubated with Mitomycin C (10μg/ml) for 3hrs to 
arrest the proliferation phase. Coverslips containing cells were washed with warm 
PBS (3 – 4 times) and the wound was made using a sterile razor blade to produce 
straight-edged cuts. The wounded cell monolayer was washed with warm sterile 
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PBS three times in order to remove cellular debris and dislodged cells, then placed 
in a fresh 24-well plate containing serum- poor medium (SPM) (0.1% (v/v) FBS). 
Different concentrations of glucose, BSA-AGEs, SAC/NAC and compound A 
were applied respectively and incubated for a further 24 hours. Untreated cells in 
SPM were used as controls. Cells treated with FGF-2 (25ng/ml) were used as 
positive controls. After 24 hours of incubation, the coverslips were rinsed 3 times 
in PBS, fixed in 100% ethanol for 5 mins, then the ethanol was removed, and 
subsequently, the wells allowed to dry at room temperature. The cells were stained 
with methylene blue for 1 minute before being washed with dH2O and left to dry 
at room temperature. Finally, the cells were examined under the microscope and 
pictures were taken using phase contrast microscopy (10× magnification) for 5 
random areas of each coverslip. The picture analysis was performed using Image-
J software. 
 
2.4.2.11 Matrigel™ tube formation assay  
A tube formation assay was performed in order to assess the ability of BAECs to 
form vascular structures, which are important in new vessel formation. One day, 
prior to performing the assay, a matrigel matrix was incubated on ice overnight. 
On the day of the assay, a 96-well plate was coated with 50μl of growth factor-
reduced Matrigel™ and incubated at 37°C for 1 hour. BAECs (8×103cells) were 
mixed respectively in 50μl of medium ± different concentrations of inhibitor 
(glucose, BSA-AGEs, SAC/NAC and compound A), and 500µl of growth 
medium (15% FBS, v/v) were added in order to cover each cell/matrigel spot. 
Cells containing FGF-2 (25ng/ml) were used as positive controls. After 7 hours 
incubation, 4% (v/v) paraformaldehyde (PFA) was added to fix the endothelial 
tube-like structures in the well. Under an optical microscope (10 × magnification), 
closed areas surrounded by endothelial tube-like structures were counted in 3 - 5 
areas from each well. 
 
2.4.2.12 Preparation of cell growth medium for human adipose-derived 
mesenchymal stem cells (hADMSCs) 
Human adipose-derived mesenchymal stem cells (hADMSCs) were kindly 
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provided by Professor Giulio Alessandri and Professor Valentina Cocce (Istituto 
Neurologico "Carlo Besta"). Resume the cells from liquid nitrogen and put the 
cells in a T-25 flask containing 5 ml stem cell growth media (SCM) and incubated 
for 4 hours. Then, the medium was changed with the fresh growth medium. Cells 
were grown in SCM composed of 80% Iscove’s modified Dulbecco’s medium 
(IMDM; Sigma-Aldrich) containing 5% foetal bovine serum (FBS; Sigma-
Aldrich), 10% NeuroCult medium (Stem Cell Technologies) and 10% endothelial 
basal medium (EBM; Lonza) in a humidified incubator with 5% CO2 at 37∘C. 
 
2.4.2.13 Subculture of stem cells MSCs  
When cells reached confluency, MSCs was performed using Trypsin-EDTA 
(0.25% Trypsin, 0.02% EDTA; Sigma-Aldrich) for 5 minutes at 37°C in the 
incubator. Once the cells were detached, 5ml of growth medium was added to 
inactivate the enzyme reaction and then the Trypsin-EDTA solution with the cell 
suspension was transferred into a centrifuge tube. The flask was rinsed out with 3 
– 5ml of PBS and that was transferred into the same centrifuge tube (Jouan 
CR422). This minimised cell loss. The cell suspension was then centrifuged at 
300×g for 5 minutes. The supernatant was discarded leaving behind 200 – 500μl 
supernatant to re-suspend the cells and then split at a ratio of 1:3 before seeded in 
fresh T-75 flasks, which corresponded to a new passage.  
 
2.4.2.14 Cytotoxicity of the compounds on hADMSCs 
The toxicity of SAC/NAC and compound A on hADMSCs was determined in a 
24-hour alamarBlue assay (cytotoxicity test; Life Technologies). Briefly, 96-well 
plates containing cells in growth medium were set up. Sub-confluent cultures 
(2×105 /ml) of hADMSCs were exposed to different concentrations of SAC/NAC 
(0.0076 – 500μg/ml) and compound A (0.12 – 250μg/ml) and the final volume 
was made up to 100μl in each well. After a 24-hour incubation, 20μl/well of Cell 
Titer-Blue® Reagent was added. The cells were incubated for a further 4 hours. 
then, fluorescence emission spectra were recorded at 560nm after excitation at 
590nm. 
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2.4.3 High performance liquid chromatography (HPLC) analysis 
The flow rate was 1.0 ml/min (using LC-FC-B) with an injection volume of 1μl. 
The fluorimeter was operated at an excitation wavelength of 330nm and an 
emission wavelength of 380nm. The stationary phase (Eclipsex DB. C18, 4.6mm 
× 25cm, particle size: 3μm) used in the study was obtained from HiChrom Limited 
(Reading, UK). The column was fitted with a guard cartridge (ACE 3 C18) and 
maintained at an isothermal temperature of 22°C with an Agilent HP Series 1100 
column oven with a programmable controller (Agilent Technologies, 
Wokingham, UK). Detection of the analyte was performed using a suitable 
detector. In this study, a diode array detector (DAD), which can measure the 
absorbance at several wavelengths, was used (λ ex = 330nm and λ em = 376nm). 
 
2.4.3.1 Preparation of the mobile phase 
The mobile phase for HPLC analysis was prepared from the organic solvent of 
water-acetonitrile (50:50, v/v) and was adjusted to a pH of 3.75 through the 
addition of 0.1ml of acetic and phosphoric acids. The N-(1-pyrenyl) maleimide 
(NPM) derivatives were eluted from the column isocratically at a flow-rate of 
0.45ml/min. The water used for the preparation of the mobile phase was supplied 
from an Elga Purelab Option deioniser model LA613.  
 
2.4.3.2 Preparation of calibration solution 
For calibration studies, a calibration standard stock solution of NAC (500μg/ml) 
was weighed accurately into a 10.0ml clear glass volumetric flask and diluted to 
volume with dH2O to give a solution containing the components at 1mg/ml. This 
solution was then further diluted with dH2O to prepare the diluted calibration 
standard working solutions (500, 400, 300, 200 and 100μg/ml) of each analyte in 
a volume of μl.  
 
2.4.3.3 Sample preparation and derivatisation  
Conditioned medium from hADMSCs was derivatised with NPM, which reacts 
with free sulfhydryl groups to form fluorescent derivatives. Acetonitrile (250μl) 
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and 500μl of 1.5mM NPM solution in acetonitrile were added to diluted samples 
(250μl). The resulting solution was mixed and then incubated at room temperature 
for 5 min. At the conclusion of the incubation period, 10µl of 50% (v/v) acetic 
acid was added to stop the reaction. Filtration through a 0.2μm acrodisc was 
performed and the derivatised samples were injected onto a 3μm C18 column in a 
reversed-phase HPLC system (Figure 2.1). 
 
 
Figure 2.1: Reaction of NPM with thiols to form fluorescent adducts.  
(Ogony et al., 2006). 
 
2.5 Statistical analysis 
Data was reported as the mean ± standard deviation (SD). Students t-test was 
performed to test the statistical significance. Values were considered significant 
with a p-value below 0.005. All the values (mean, SD and p-value) were calculated 
using Microsoft® Excel 2016. Statistical significance between groups was tested 
by t-tests and one-way analysis of variance (one-way ANOVA). The analysis was 
performed by the statistical package IBM SPSS Statistics for Windows, version 
22.0 (IBM). 
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Chapter 3 – Results 
3.1 AGE formation of lysozyme induced by MG 
3.1.1 Lysozyme glycation by MG after 24 hours 
After 1 day of incubation, glycation of lysozyme by MG produced cross-linked AGEs 
and the formation of dimers with an approximate molecular weight of 28.7 kDa, as 
indicated by the protein marker ladder shown in Figure 3.1, lane 1. Compare to 
lysozyme control (Figure 3.1, lane 2), the effect of MG on cross-linked AGE formation 
is clearly visible by their ability to reduce electrophoretic mobility in a dose-dependent 
manner (Figure 3.1, lanes 3-6).  
 
 
Figure 3.1: SDS-PAGE gel showing lysozyme glycation by MG after 24 hours. 
Gel showing lysozyme (10mg/ml) with or without MG. Molecular Weight Marker (lane 1), lysozyme 
incubated alone (lane 2) or in the presence of MG,40mM (lane 3), 60mM (lane 4), 80mM (lane 5) and 
100mM (lane 6), respectively. The gel shows evidence of dimer formation caused by protein cross-
linking in 0.1M sodium phosphate buffer the pH 7.4 at 37 °C  for 24 hours. The cross-linked AGEs 
were analysed using SDS-PAGE and stained with silver stain. The results shown here are representative 
of three independent experiments.  
 
 
Image analysis of the gel was performed, and the results based on the integrated 
density of each band are presented in Figure 3.2. MG (40 - 100mM). After 1 day of 
incubation with MG, the formation of cross-linked AGEs was evident and occurred in 
a dose-dependent manner. Glycation of 10mg/ml lysozyme by MG at 60mM caused 
significant (p<0.05) production of AGE dimers while at 80 - 100mM caused 
significant (p<0.01) production of AGE dimers compared to the lysozyme control. 
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Figure 3.2: Lysozyme glycated by different concentrations of MG after 24 hours. 
Bar chart showing evidence of dimer formation with an increased band density of lysozyme glycated 
by MG (40 - 100mM) compared to control (=1.0). Each value represents the mean  ±  SD (n = 3), 
*p<0.05 and **p<0.01. 
 
 
3.1.2 Lysozyme glycation by MG after 72 hours 
After three days of incubation, glycation of lysozyme by MG produced cross-linked 
AGEs and the formation of dimers and trimer bands as indicated by comparison with 
the protein marker ladder shown in Figure 3.3, lane 1. Compare to lysozyme control 
(Figure 3.3, lane 2), glycated lysozyme (Figure 3.3, lanes 3 - 6) showed reduced 
electrophoretic mobility with an increased intensity of the dimer bands of approximate 
molecular weight of 28.7 kDa at a concentration of 100mM in a dose-dependent 
manner.  
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Figure 3.3: SDS-PAGE gel showing lysozyme glycation by MG after 72 hours. 
Gel showing lysozyme (10mg/ml) with or without MG. Molecular Weight Marker (lane 1), lysozyme 
incubated alone (lane 2) or in the presence of MG, 40mM (lane 3), 60mM (lane 4), 80mM (lane 5) and 
100mM (lane 6), respectively, and showing evidence of dimer and trimer formation caused by protein 
cross-linking in 0.1M sodium phosphate buffer pH 7.4 at 37 °C for 72 hours. The cross-linked AGEs 
were analysed using SDS-PAGE and stained with silver stain. The results shown here are representative 
of three independent experiments.  
 
 
Figure 3.4 shows that glycation of 10mg/ml lysozyme by MG (60 - 80mM) caused a 
significant (p<0.01) production of AGEs compared to the lysozyme control.  In 
addition, at a concentration of 100mM, there was significant (p<0.001) inhibition of 
dimers cross-linked AGE formation. The cross-linked AGE production was more than 
14-fold greater when lysozyme was incubated with 100mM MG as compared to 
40mM MG.  
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Figure 3.4: Lysozyme glycated by MG after 72 hours. 
Bar chart showing evidence of dimer formation with an increased band density of lysozyme glycated 
by MG (40 - 100mM) compared to control (=1.0). Each value represents the mean ± SD (n = 3), 
**p<0.01 and ***p<0.001.   
 
 
3.2 Detection of AGEs 
3.2.1 Detection of AGEs by fluorescence 
Fluorescence modifications were investigated as an index of alterations in protein 
structure and conformation. The effect of MG (0 – 10mM) on fluorescent AGE 
production over 72 hours of lysozyme glycation was determined from the specific 
fluorescence intensity. Lysozyme alone was used as the reference compound at a 
concentration of 10mg/ml. In contrast with the control, the fluorescent intensity of 
lysozyme incubated with MG showed a significant increase (p<0.05). The results 
show that AGE production increased in a dose-dependent manner. The effect 
determined for lysozyme incubated for 3 days with 10mM MG was more than twenty-
fold greater as compared to control and two-fold greater than the effect observed with 
1mM MG (Figure 3.5). 
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Figure 3.5: Effect of MG on fluorescent AGE formation. 
Lysozyme (10mg/ml) was incubated with or without of MG (0 -10mM) in 0.1M sodium phosphate 
buffer pH 7.4 at 37°C for 72hours. Each value represents the mean ± SD (n = 3), *p<0.05. 
 
3.2.2 Detection of AGEs by SDS-PAGE-silver stain 
3.2.2.1 The effect of SAC on MG-derived AGE formation 
Glycation of lysozyme by MG produces cross-linked AGEs and the formation of 
dimers bands as indicated by comparison with the protein ladder. Glycated lysozyme 
(Figure 3.6, lane 3) was used as the control and clearly showed reduced electrophoretic 
mobility with higher molecular weight compared with native lysozyme (Figure 3.6, 
lane 2). The molecular weight of glycated lysozyme was approximately twice that of 
the original lysozyme as determined by protein molecular ladder (Figure 3.6, lane 1). 
SAC inhibited AGE formation causing a reduction in the intensity of the dimerised 
lysozyme band of approximate molecular weight of 28.7 kDa (Figure 3.6, lanes 4 –
10). 
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Figure 3.6: SDS-PAGE gel showing the effect of SAC on MG-derived AGE formation. 
Gel showing lysozyme (10mg/ml) with or without SAC. Molecular Weight Marker (lane 1), lysozyme 
incubated alone (lane 2), in the presence of 100mM MG (lane 3) or MG in the presence of SAC, 
0.001µg/ml (lane 4), 0.01µg/ml (lane 5), 0.05µg/ml (lane 6), 0.1µg/ml (lane 7), 0.5µg/ml (lane 8), 
1µg/ml (lane 9) and 2µg/ml (lane 10), respectively. The gel shows evidence of dimer formation caused 
by protein cross-linking in 0.1M sodium phosphate buffer pH 7.4 at 37 °C for 72 hours. The cross-
linked AGEs were analysed using SDS-PAGE and stained with silver stain. The results shown here are 
representative of three independent experiments.  
 
 
Image analysis of the gel was performed and the results based on the integrated density 
of each band are presented in Figure 3.7. The percentage inhibition of SAC compared 
to the control was used to evaluate the protective effect of SAC on MG-derived cross-
linked AGEs in vitro. In comparison to the control, SAC showed significant (p<0.05) 
inhibition on cross-linked AGE formation in vitro only at concentration of 0.01µg/ml 
while at 0.05 - 0.1µg/ml (p<0.01). In addition, SAC at a concentration of 0.5 - 2µg/ml, 
showed highly significantly (p<0.001) inhibition of cross-linked AGE formation. This 
inhibitory effect occurred in a dose-dependent manner with a maximum inhibition of 
79% in samples containing 2µg/ml of SAC. 
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Figure 3.7: The effect of SAC on MG-derived AGE formation. 
Bar chart showing decreased band density of dimer formation of lysozyme glycated by MG in the 
presence of SAC compared to control (=1.0). Each value represents the mean ± SD (n = 3) of three 
independent experiments, *p<0.05 ,**p<0.01 and ***p<0.001.  
 
 
3.2.2.2 The effect of NAC on MG-derived AGE formation 
Figure 3.8 shows the effect of NAC on the formation of cross-linked AGEs. Lysozyme 
incubated in the presence of MG produced cross-linked AGE, as is apparent from the 
analysis of this gel, to cause the formation of dimers. Glycated lysozyme (Figure 3.8, 
lane 3) was used as the control and clearly showed reduced electrophoretic mobility 
with higher molecular weight compared with native lysozyme (Figure 3.8, lane 2). The 
molecular weight of glycated lysozyme was approximately twice that of the original 
lysozyme as determined by comparison with the protein marker ladder (Figure 3.8, 
lane 1). Like SAC, inhibition of dimer formation by NAC showed a reduction in the 
intensity of the dimerised lysozyme band of approximate molecular weight of 28.7 
kDa (Figure 3.8, lanes 4 - 10).  
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Figure 3.8: SDS-PAGE gel showing the effect of NAC on MG-derived AGE formation. 
Gel showing lysozyme (10mg/ml) with or without NAC. Molecular Weight Marker (lane 1), lysozyme 
incubated alone (lane 2), in the presence of 100mM MG (lane 3) or MG in the presence of NAC, 
0.001µg/ml (lane 4), 0.01µg/ml (lane 5), 0.05µg/ml (lane 6), 0.1µg/ml (lane 7), 0.5µg/ml (lane 8), 
1µg/ml (lane 9) and 2µg/ml (lane 10), respectively. The gel shows evidence of dimer formation caused 
by protein cross-linking in 0.1M sodium phosphate buffer pH 7.4 at 37 °C for 72 hours. The cross-
linked AGEs were analysed using SDS-PAGE and stained with silver stain. The results shown here are 
representative of three independent experiments.  
 
 
The results obtained from the preliminary analysis of the effect of NAC on cross-
linked AGE formation are presented in Figure 3.9. The percentage inhibition 
compared to the control was used to evaluate the effect of NAC on MG-derived cross-
linked AGEs in vitro. In comparison to the control, NAC showed significant (p<0.01) 
inhibition of cross-linked AGE formation between the concentrations of 0.1, 0.5, 1 
and 2μg/ml. The percentage inhibition was 43%, 49%, 59% and 65%, respectively and 
this inhibitory effect occurs in a dose-dependent manner. 
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Figure 3.9: The effect of NAC on MG-derived AGE formation. 
Bar chart showing decreased band density of dimer formation of lysozyme glycated by MG in the 
presence of NAC compared to control (=1.0). Each value represents the mean ± SD (n= 3) from three 
independent experiments, **p<0.01 and ***p<0.001. 
 
 
3.2.2.3 The effect of SAC/NAC on MG-derived AGE formation 
The synergetic effect of both SAC and NAC (SAC/NAC) was also tested to determine 
their role in the inhibition of cross-linked AGEs. Incubation of lysozyme with MG 
produced cross-linked AGEs and the formation of dimers and trimers band. The 
glycated lysozyme (Figure 3.10, lane 3) was used as the control and clearly showed 
reduced electrophoretic mobility with a higher molecular weight as compared to native 
lysozyme (Figure 3.10, lane 2). The molecular weight of glycated lysozyme was 
approximately twice that of the original lysozyme, as determined by comparison with 
the protein marker ladder (Figure 3.10, lane 1). SAC (Figure 3.10, lanes 4 and 7), NAC 
(Figure 3.10, lanes 5 and 8) and SAC/NAC (Figure 3.10, lanes 6 and 9) inhibited AGE 
formation causing a reduction in the intensity of the dimerised lysozyme band of 
approximate molecular weight of 28.7 kDa.  
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Figure 3.10: SDS-PAGE gel showing the effect of SAC/NAC on the formation of cross-linked 
AGEs. 
Gel showing lysozyme (10mg/ml) with or without SAC, NAC and SAC/NAC. Molecular Weight 
Marker (lane 1), lysozyme incubated alone (lane 2), in the presence of 100mM MG (lane 3) or MG in 
the presence of 0.25μg/ml of SAC, NAC and SAC/NAC (lanes 4 - 6), respectively and 0.5μg/ml of 
SAC, NAC and SAC/NAC (lanes 7 - 9), respectively. The gel shows evidence of dimer and trimer 
formation caused by protein cross-linking in 0.1M sodium phosphate buffer pH 7.4 at 37 °C for 72 
hours. The cross-linked AGEs were analysed using SDS-PAGE and stained with silver stain. The results 
shown here are representative of three independent experiments.  
 
 
The percentage inhibition compared to the control was used to evaluate the effect of 
these inhibitors on AGE formation in vitro. The effects of different concentrations of 
SAC, NAC and SAC/NAC on AGE formation were compared with each other. The 
results showed that SAC, NAC at a concentration of 0.25 - 0.5μg/ml significantly 
(P<0.01) inhibited AGE formation and the maximum percentage inhibitions for both 
inhibitors were 65%. Therefore, the inhibitory effects of SAC/NAC significantly 
inhibited AGE formation at the concentration of 0.25μg/ml (P<0.01) and 0.5μg/ml 
(P<0.001). This inhibitory effect occurred in a dose-dependent manner with a 
maximum inhibition of 76% that was higher than those of SAC and NAC at a 
concentration of 0.5µg/ml (Figure 3.11).  
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Figure 3.11: The effect of SAC/NAC on the formation of cross-linked AGEs. 
Bar chart showing decreased band density of dimer formation of lysozyme glycated by MG in the 
presence of SAC, NAC and SAC/NAC compared to control (=1.0). Each value represents the mean ± 
SD (n = 3). **p<0.01 and ***p<0.001. 
 
 
3.2.2.4 Comparison between mimic compounds A, B and C on MG-derived AGE 
formation 
 The effect of three mimic compounds A, B and C were also tested to determine their 
role in the inhibition of cross-linked AGEs. Incubation of lysozyme with MG 
generated cross-linked AGEs that caused the formation of dimer bands with an 
approximate molecular weight of 28.7 kDa. The glycated lysozyme (Figure 3.12, lane 
3) was used as the control and clearly showed reduced electrophoretic mobility with a 
higher molecular weight as compared to native lysozyme (Figure 3.12, lane 2). The 
molecular weight of glycated lysozyme was approximately double that of the original 
lysozyme, as determined by comparison with the protein marker ladder (Figure 3.12, 
lane 1). Compound A (Figure 3.12, lanes 4, 7 and 10), compound B (Figure 3.12, lanes 
5, 8 and 11) and compound C (Figure 3.12, lanes 6, 9 and 12) inhibited AGE formation 
causing a reduction in the intensity of the dimerised lysozyme band. 
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Figure 3.12: SDS-PAGE gel showing the effect of compounds A, B and C on MG-induced cross-
linked AGE formation. 
Gel showing lysozyme (10mg/ml) with or without compounds A, B and C. Molecular Weight Marker 
(lane 1), lysozyme incubated alone (lane 2), in the presence of 100mM MG (lane 3) or MG in the 
presence of 10μg/ml of compound A, B and C (lanes 4 - 6), 5μg/ml of compound A, B and C (lanes 7 
- 9) and 0.5μg/ml of compound A, B and C (lanes 10 - 12), respectively. The gel shows evidence of 
dimer formation caused by protein cross-linking in 0.1M sodium phosphate buffer pH 7.4 at 37 °C for 
72 hours. The cross-linked AGEs were analysed using SDS-PAGE and stained with silver stain. The 
results shown here are representative of three independent experiments.  
 
 
Figure 3.13 compares the effects of three concentrations of these inhibitors on AGE 
formation. The percentage inhibition compared to the control was used to evaluate the 
effect of compounds A, B and C on MG-derived cross-linked AGEs in vitro.  The 
results show that all the inhibitors were effective in reducing MG-derived cross-linked 
AGEs in vitro. Compound A produced a significant (p<0.01) inhibition on AGE 
formation at 0.5μg/ml while at concentrations of between 5-10μg/ml, the inhibition 
was more significantly (p<0.001). The percentage inhibitions were 64% and 77%, 
respectively. Compounds B and C showed significant inhibition (p<0.01) of AGE 
formation at all concentrations. The maximum percentage inhibitions of compound B 
were 65% and for compound C 58%.  Therefore, the inhibitory effect of all inhibitors 
occurred in a dose-dependent manner. At all concentrations tested, compound A 
showed a stronger inhibitory effect than compounds B and C on the in vitro formation 
of cross-linked AGEs. Therefore, compound A was used in future experiments.  
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Figure 3.13: The effect of compounds A, B and C on MG-induced cross-linked AGE formation. 
Bar chart showing decreased band density of the dimer formation of lysozyme glycated by MG in the 
presence of compounds A, B and C compared to control (=1.0). Each value represents the mean ± SD 
(n = 3), **p<0.01 and ***p<0.001. 
 
 
3.2.2.5 The effect of compound A on MG-induced AGE formation 
Lysozyme (10mg/ml) was incubated with 0.1M MG and compound A (0.01 - 2μg/ml) 
for 72 hours, the glycated lysozyme was tested by SDS-PAGE-silver stain to 
determine their role in the inhibition of cross-linked AGEs. Incubation of lysozyme in 
the presence of MG produced cross-linked AGEs that present as dimers and trimers. 
Glycated lysozyme with MG (Figure 3.14, lane 3) was used as the control and clearly 
showed reduced electrophoretic mobility with the higher molecular weight as 
compared to native lysozyme (Figure 3.14, lane 2). The molecular weight of glycated 
lysozyme was approximately twice that of the original lysozyme as determined by 
comparison with the protein marker ladder (Figure 3.14, lane 1). The inhibition of 
dimer formation by compound A showed a reduction in the intensity of the dimerised 
lysozyme band of approximate molecular weight of 28.7 kDa (Figure 3.14, lanes 4 – 
9). 
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Figure 3.14: SDS-PAGE gel showing the effect of compound A on MG-induced cross-linked 
AGE formation. 
Gel showing lysozyme (10mg/ml) with or without compound A. Molecular Weight Marker (lane 1), 
lysozyme incubated alone (lane 2), in the presence of 0.1M MG (lane 3) or MG in the presence of 
compound A,  2μg/ml (lane 4), 1μg/ml (lane 5), 0.5μg/ml (lane 6), 0.1μg/ml (lane 7), 0.05μg/ml (lane 
8) and 0.01μg/ml (lane 9), respectively. The gel shows evidence of dimer formation caused by protein 
cross-linking in 0.1M sodium phosphate buffer pH 7.4 at 37 °C for 72 hours. The cross-linked AGEs 
were analysed using SDS-PAGE and stained with silver stain. The results shown here are representative 
of three independent experiments.  
 
The results obtained from the preliminary analysis of the effect of compound A on 
cross-linked AGE formation in vitro are presented in Figure 3.15. The percentage 
inhibition compared to control was used to evaluate the effect of this inhibitor on AGE 
formation in vitro. The effect of different concentrations of compound A on AGE 
formation was compared with each other and with the control. Compound A showed 
significant (p<0.05) inhibition on AGE formation at concentrations of between 0.01-
0.05μg/ml while at 0.1 - 2μg/ml the significance was (p<0.01) with maximum 
percentage inhibitions of 79%. This inhibitory effect occurred in a dose-dependent 
manner with a maximum inhibition of 77% in the sample containing 2μg/ml. 
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Figure 3.15: The effect of compound A on MG-induced cross-linked AGE formation. 
Bar chart showing decreased band density of dimer formation of lysozyme glycated by MG in the 
presence of compound A compared to control (=1.0). Each value represents the mean ± SD (n = 3), 
*p<0.05, **p<0.01 and ***p<0.001.   
 
 
3.2.2.6 The effect of SAC/NAC and compound A on MG-induced cross-linked 
AGE formation 
This experiment was designed to compare in parallel the effects of SAC/NAC and 
compound A on the cross-linked AGE formation in vitro. Incubation of lysozyme 
(10mg/ml) with 0.1M MG produced cross-linked AGEs that cause the formation of 
dimers, trimers and tetramers bands. The glycated lysozyme (Figure 3.16, lane 3) was 
used as the control and clearly showed reduced electrophoretic mobility with a higher 
molecular weight as compared with native lysozyme (Figure 3.16, lane 2). The 
molecular weight of glycated lysozyme was approximately twice that of the original 
lysozyme as determined by comparison with the protein marker ladder (Figure 3.16, 
lane 1). Silver staining showed the presence of both SAC/NAC (Figure 3.16, lanes 4, 
6, 8, 10 and 12) and compound A (Figure 3.16, lanes 5, 7, 9, 11 and 13) inhibited AGE 
formation causing a reduction in the intensity of the dimerised lysozyme band of 
approximate molecular weight of 28.7 kDa. 
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Figure 3.16: SDS-PAGE gel showing the effect of SAC/NAC and compound A on MG-induced 
cross-linked AGE formation. 
Gel showing lysozyme (10mg/ml) with or without SAC/NAC and compound A (0.01-1μg/ml). 
Molecular Weight Marker (lane 1), lysozyme incubated alone (lane 2), in the presence of 0.1M MG 
(lane 3) or MG in the presence of SAC/NAC and compound A, 1μg/ml (lane 4 - 5), 0.5μg/ml (lane 6 - 
7), 0.1μg/ml (lane 8 -9), 0.05μg/ml (lane 10 - 11) and 0.01μg/ml (lane 12 - 13), respectively. The gel 
shows evidence of dimer, trimer and tetramer formation caused by protein cross-linking in 0.1M sodium 
phosphate buffer pH 7.4 at 37 °C for 72 hours. The cross-linked AGEs were analysed using SDS-PAGE 
and stained with silver stain. The results shown here are representative of three independent 
experiments.  
 
 
The results obtained from the preliminary analysis of the percentage inhibition of 
different concentrations of SAC/NAC and compound A on cross-linked AGE 
formation are shown in Figure 3.17. The effects of different concentrations of 
SAC/NAC and compound A on AGE formation were compared with each other and 
with the control. The results showed that both inhibitors significantly (p<0.05) 
inhibited AGE formation at the concentration of 0.05μg/ml while highly significant 
(p<0.01) inhibition at concentrations of between (0.1 - 1μg/ml) with maximum 
percentage inhibition were 61% and 65%, respectively. Thus, the inhibitory effect of 
SAC/NAC and compound A occurred in a dose-dependent manner. 
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Figure 3.17: The effect of SAC/NAC and compound A on MG-induced cross-linked AGE 
formation. 
Bar chart showing decreased band density of dimer formation of lysozyme glycated by MG in presence 
of SAC/NAC and compound A compared to control (=1.0). Each value represents the mean ± SD (n= 
3), *p<0.05,**p<0.01 and ***p<0.001. 
 
 
3.2.2.7 Effect of SAC/NAC-primed hADMSCs CM on MG-induced cross-linked 
AGE formation 
Lysozyme (10mg/ml) was incubated with 0.1M MG in the presence of 500μg/ml 
SAC/NAC-loaded hADMSCs CM for four days and the conditioned medium released 
from hADMSCs was collected for each day and replaced with fresh medium. The 
collected medium (days 1 - 4) were tested by SDS-PAGE-silver stain to determine its 
role on the inhibition of cross-linked AGEs. Incubation of MG with lysozyme 
produced sufficient cross-linked AGEs that cause the formation of dimers bands. The 
glycated lysozyme (Figure 3.18, lane 3) was used as the control and clearly showed 
reduced electrophoretic mobility with a higher molecular weight as compared to native 
lysozyme (Figure 3.18, lane 2). The molecular weight of glycated lysozyme was 
approximately twice that of the original lysozyme as determined by comparison with 
the protein marker ladder (Figure 3.18, lane 1). SAC/NAC-primed hADMSCs CM; 
day 1 (Figure 3.18, lane 4), day 2 (Figure 3.18, lane 5), day 3 (Figure 3.18, lane 6) and 
day 4 (Figure 3.18, lane 7). These inhibited AGE formation causing a reduction in the 
intensity of the dimerised lysozyme band with an approximate molecular weight of 
28.7 kDa. 
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Figure 3.18: SDS-PAGE gel showing the effect of SAC/NAC-primed hADMSCs CM on MG-
induced cross-linked AGE formation. 
Gel showing lysozyme (10mg/ml) with or without SAC/NAC-primed hADMSCs CM. Molecular 
Weight Marker (lane 1), lysozyme incubated alone (lane 2), in the presence of 0.1M MG (lane 3) or 
MG in the presence of SAC/NAC-loaded hADMSCs CM, day 1 (lane 4), day 2 (lane 5), day 3 (lane 6) 
and day 4 (lane 7), respectively. The gel shows evidence of dimer formation caused by protein cross-
linking in 0.1M sodium phosphate buffer pH 7.4 at 37 °C. The cross-linked AGEs were analysed using 
SDS-PAGE and stained with silver stain. The results shown here are representative of three independent 
experiments.  
 
 
Figure 3.19 compares the results obtained from the effect of four days of the collected 
medium of this inhibitor of AGE formation. At days (1 - 3), SAC/NAC-primed 
hADMSCs CM showed significant (p<0.05) inhibition of AGE formation in a dose-
dependent manner. The percentage inhibitions were 41%, 28% and 17%, respectively.  
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Figure 3.19: The effect of SAC/NAC-primed hADMSCs CM on MG-induced cross-linked AGE 
formation. 
Bar chart showing decreased band density of dimer formation of lysozyme glycated by MG in presence 
of SAC/NAC-primed hADMSCs CM compared to control (=1.0). Each value represents the mean ± 
SD (n = 3), *p<0.05 and ***p<0.001. 
 
 
3.2.2.8 Effect of compound A-primed hADMSCs CM on MG-induced cross-
linked AGE formation 
Lysozyme (10mg/ml) was incubated with 0.1M MG in the presence of 250μg/ml 
compound A-loaded hADMSCs CM for four days and the conditioned medium 
released from hADMSCs was collected for each day and replaced with fresh medium. 
The collected medium (days 1 - 4) were tested by SDS-PAGE-silver stain to determine 
its role on the inhibition of cross-linked AGEs. Incubation of MG with lysozyme 
produced sufficient cross-linked AGEs to cause the formation of dimers bands (Figure 
3.20, lane 3) was used as the control and clearly showed reduced electrophoretic 
mobility with a higher molecular weight as compared to native lysozyme (Figure 3.20, 
lane 2). The molecular weight of glycated lysozyme was approximately twice that of 
the original lysozyme as determined by comparison with the protein marker ladder 
(Figure 3.20, lane 1). These were compound A-primed hADMSCs CM for; day 1 
(Figure 3.20, lane 4), day 2 (Figure 3.20, lane 5), day 3 (Figure 3.20, lane 6) and day 
4 (Figure 3.20, lane 7) and they inhibited AGE formation causing a reduction in the 
intensity of the dimerised lysozyme band with an approximate molecular weight of 
28.7 kDa.  
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Figure 3.20: SDS-PAGE gel showing the effect of compound A-primed hADMSCs CM on MG-
induced cross-linked AGE formation. 
Gel showing lysozyme (10mg/ml) with or without compound A-primed hADMSCs CM. Molecular 
Weight Marker (lane 1), lysozyme incubated alone (lane 2), 0.1M MG (lane 3) or MG in the presence 
of compound A-loaded hADMSCs CM, day 1 (lane 4), day 2 (lane 5), day 3 (lane 6) and day 4 (lane 
7), respectively. The gel shows evidence of dimer formation caused by protein cross-linking in 0.1M 
sodium phosphate buffer pH 7.4 at 37°C. The cross-linked AGEs were analysed using SDS-PAGE and 
stained with silver stain. The results shown here are representative of three independent experiments.  
 
The percentage of inhibition compared to controls was used to evaluate the protective 
effect of four days of the collected medium of this inhibitor on AGE formation. Figure 
3.21 compares the effect of different collected media of compound A on AGE 
formation. Like SAC/NAC, compound A-primed hADMSCs CM at days (1 - 3) 
showed significant (p<0.05) inhibition of AGE dimer formation in a dose-dependent 
manner. The percentage inhibitions were 47%, 37% and 26%, respectively.  
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Figure 3.21: The effect of compound A-primed hADMSCs CM on MG-induced cross-linked 
AGE formation. 
Bar chart showing decreased band density of dimer formation of lysozyme glycated by MG in the 
presence of compound A CM compared to control (=1.0). Each value represents the mean ± SD (n =3), 
*p<0.05 and ***p<0.001.  
 
 
3.2.2.9 Effect of SAC/NAC- and compound A- loaded hADMSCs CM on MG-
induced cross-linked AGE formation. 
Figure 3.22 compares the effect of SAC/NAC- and compound A-primed hADMSCs 
CM (days 1 - 4) on AGE formation. Incubation of 0.1M MG with (10mg/ml) lysozyme 
produced sufficient cross-linked AGEs to cause the formation of dimers and trimerise. 
Glycated lysozyme (Figure 3.22, lane 3) was used as the control and clearly showed 
reduced electrophoretic mobility with a higher molecular weight as compared to native 
lysozyme (Figure 3.22, lane 2). The molecular weight of glycated lysozyme was 
approximately twice that of the original lysozyme as determined by comparison with 
the protein marker ladder (Figure 3.22, lane 1). Like the individual effect of each 
SAC/NAC- and compound A-primed hADMSCs CM, both of SAC/NAC- and 
compound A-primed hADMSCs CM exhibited the inhibitory effects on AGE 
formation after 4 days’ incubation in conditioned media. SAC/NAC- (Figure 3.22, 
lanes 4, 6, 8 and 10) and compound A- primed hADMSCs CM (Figure 3.22, lanes 5, 
7, 9 and 11) inhibited AGE formation causing a reduction in the intensity of the 
dimerised lysozyme bands with an approximate molecular weight of 28.7 kDa. 
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Figure 3.22: SDS-PAGE gel showing the effect of SAC/NAC- and compound A-primed 
hADMSCs CM on MG-induced cross-linked AGE formation. 
Gel showing lysozyme (10mg/ml) with or without SAC/NAC- and compound A-primed hADMSCs 
CM. Molecular Weight Marker (lane 1), lysozyme incubated alone (lane 2), in the presence of 0.1M 
MG (lane 3) or MG in the presence of SAC/NAC- and compound A- primed hADMSCs CM, day 1 
(lane 4 - 5), day 2 (lane 6 - 7), day 3 (lane 8 - 9) and day 4 (lane 10 - 11), respectively. The gel shows 
evidence of dimer and trimer formation caused by protein cross-linking in 0.1M sodium phosphate 
buffer of pH 7.4 at 37 °C. The cross-linked AGEs were analysed using SDS-PAGE and stained with 
silver stain. The results shown here are representative of three independent experiments.  
 
As a result, the effects of SAC/NAC- and compound A-loaded hADMSCs CM 
occurred in a dose-dependent manner. SAC/NAC- and compound A-loaded 
hADMSCs CM showed a significant (p<0.05) inhibition at days 1-3 in a dose-
dependent manner. The maximum percentage of inhibitions were 40% and 44%, 
respectively. On the other hand, no significant inhibition was found at day 4. The 
inhibition was dose-dependent (Figure 3.23). 
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Figure 3.23: The effect of SAC/NAC- and compound A-primed hADMSCs CM on MG-induced 
cross-linked AGE formation. 
Bar chart showing decreased band density of dimer formation of lysozyme glycated by MG in presence 
of SAC/NAC- and compound A- primed hADMSCs CM compared to control (=1.0). Each value 
represents the mean ± SD (n = 3), *p<0.05, ***p<0.001.  
 
 
3.2.3 Detection of AGEs by Western blot 
3.2.3.1 Protein determination 
The protein contents of different samples were determined using the Bradford method 
in order to compare the concentrations of MG obtained from the cell samples. Protein 
standard curves using albumin protein with a known concentration of BSA is a 
frequently used protein standard. A calibration curve was plotted from serial dilutions 
of BSA corresponding to protein concentrations of 0 – 60μg/ml. A protein 
concentration for each cell sample was read from the calibration curve and expressed 
relative to the BSA standard in μg of protein. The BSA standard curve showed a linear 
correlation between the protein concentration and the absorbance at 595nm using a 
spectrophotometer (Figure 3.24). 
 
Chapter 3 
 
 
114 
 
 
Figure 3.24: Calibration graph of protein estimation for Western blot analysis. 
 
3.2.3.2 The effect of MG on BAEC glycation after 24 hours. 
In order to validate the inhibitory effect of SAC/NAC and compound A on AGE 
formation, the immunological characterisation was performed by Western blotting 
analysis using an anti-MG antibody. This experiment was performed to optimise the 
incubation time corresponding to the MG glycation effects on BAECs for 24 hours 
was assessed by Western blot analysis. Glycated bands were measured at 72.0 kDa 
(upon the anti-MG-AGE antibody) (Figure 3.25A, lane 1), untreated BEACs were 
used as controls (Figure 3.25A, lane 2) or in presence of (1 - 300μM) MG (Figure 
3.25A, lanes 3 - 8), respectively. Tubulin was used as a loading control (Figure 3.25B). 
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Figure 3.25: SDS-PAGE gel showing the effect of MG on BAEC glycation after 24 hours. 
Representative Western blot of proteins from BAECs incubated with MG. (A) Molecular Weight 
Marker (lane 1), untreated BEACs control (lane 2) or in presence of MG 1μM (lane 3), 10μM (lane 4), 
50μM (lane 5), 100μM (lane 6), 200μM (lane 7) and 300μM (lane 8), respectively. (B) Tubulin. The 
samples were separated by SDS-PAGE and the gels were transferred to nitrocellulose membranes and 
protein detected using an anti-MG AGE antibody. The results are a representative example of three 
independent experiments.  
 
The relative density of protein expression was analysed using Image-J. After 24 hours 
of incubation, there were no clear bands and there is some evidence of partial 
glycation. However, Band intensity of protein cross-linking showed a non-significant 
increase as compared to control (Figure 3.26). 
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Figure 3.26: The effect of MG on BAEC glycation after 24 hours. 
Bar chart showing the relative protein glycated by MG (72.0 kDa) (control = 1.0) from Figure 3.25. 
The experiment was repeated at least three times.  
  
3.2.3.3 The effect of MG on BAEC glycation after 72 hours. 
BAEC were incubated with MG for 72 hours and the relative density of protein 
expression was analysed using the free software Image J. After 3 days’ incubation, 
MG produced sufficient cross-linked AGEs at an approximate molecular weight of 
72.0 kDa with respect to anti- MG AGE antibody (Figure 3.27A, lane 1). However, 
incubation of BAECs with different concentrations of MG caused the formation of 
AGEs and an increased band intensity at concentrations in a dose-dependent manner 
(Figure 3.27, lanes 3-8) compared to untreated cells (Figure 3.27, lane 2). This 
suggests that the incubation time was good and that carbonyl groups were bound to 
the protein. Tubulin was used as a loading control (Figure 3.27B).  
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Figure 3.27: SDS-PAGE gel showing the effect of MG on BAEC glycation after 72 hours. 
Representative Western blot of protein from BAECs incubated with MG. (A) Molecular Weight Marker 
(lane 1), untreated BAECs (lane 2) or in presence of MG 1μM (lane 3), 10μM (lane 4), 50μM (lane 5), 
100μM (lane 6), 200μM (lane 7) and 300μM (lane 8), respectively. (B) Tubulin. The samples were 
separated by SDS-PAGE and the gels were transferred to nitrocellulose membranes and protein detected 
using an anti-MG AGE antibody. The results are a representative example of three independent 
experiments.  
 
 
As can be seen in Figure 3.28, the results show that after three days, Incubation of 
BAECs with MG at concentrations of between 10 - 100μM caused significant 
(p<0.05) production of AGE formation compared to the control and was more 
significant (p<0.01) at concentrations of 200 - 300μM. The cross-linked AGE 
production was more than 16-fold greater when BAECs were incubated with 300μM 
MG compared to control and 14 -fold greater when 100μM MG was used. Therefore, 
300μM MG and 3 days’ incubated were applied to the rest of the experiments.  
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Figure 3.28: The effect of MG on BAEC glycation after 72 hours. 
Bar chart showing the relative protein glycated by MG (72.0 kDa) (control = 1.0) from Figure 3.27. 
The experiment was repeated at least three times. *P<0.05, **p<0.01 and ***p<0.01. 
  
3.2.3.4 The effect of MG on BAEC glycation after 120 hours. 
BAEC were incubated with MG for 120 hours and the relative density of protein 
expression was analysed using free software Image J. Glycation was measured as 
indexed by the presence of the 72.0 kDa with respect to anti- MG AGE antibody 
(Figure 3.29A, lane 1), untreated BEACs were used as controls (Figure 3.29A, lane 2) 
or in presence of MG (1 - 300μM) (Figure 3.29A, lane 3-8), respectively. Tubulin was 
used as a loading control (Figure 3.29B). 
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Figure 3.29: SDS-PAGE gel showing the effect of MG on BAEC glycation after 120 hours. 
Representative Western blot of protein from BAECs incubated with MG. (A) Molecular Weight Marker 
(lane 1), untreated BEAC (lane 2) or in present of MG, 1μM (lane 3), 10μM (lane 4), 50μM (lane 5), 
100μM (lane 6), 200μM (lane 7) and 300μM (lane 8), respectively. (B) Tubulin. The samples were 
separated by SDS-PAGE and the gels were transferred to nitrocellulose membranes and protein detected 
using an anti-MG antibody. The results are a representative example of three independent experiments.  
 
After 5 days’ incubation, the results show that decreased band intensity in most of the 
samples due to the hydrolysis of the AGEs, suggesting that the incubation time was 
too long (Figure 3.30).  
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Figure 3.30: The effect of MG on BAEC glycation after 120 hours. 
Bar chart showing the relative protein glycated by MG (72.0 kDa) (control = 1.0) from Figure 3.29. 
The experiment was repeated at least three times, *P<0.05 and ***P<0.001. 
 
 
3.2.3.5 The effect of SAC/NAC on BAEC glycation.  
BAECs were incubated with SAC/NAC and the relative density of protein expression 
was analysed using free software Image J. Glycation was measured as indexed by the 
presence of the 72.0 kDa with respect to anti- MG AGE antibody (Figure 3.31A, lane 
1), untreated BEACs were used as controls (Figure 3.31A, lane 2), 300μM MG (Figure 
3.31A, lane 3) or MG in the presence of SAC/NAC (Figure 3.31A, lanes 4 - 9), 
respectively. Tubulin was used as a loading control (Figure 3.31B). 
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Figure 3.31: SDS-PAGE gel showing the effect of SAC/NAC on BAEC glycation. 
Representative Western blot of protein from BAECs incubated with MG and SAC/NAC for 3 days. (A) 
Molecular Weight Marker (lane 1), untreated BEACs negative control (lane 2), treated BEACs with 
300μM MG positive control (lane 3) or MG in present of SAC/NAC, 0.01μg/ml (lane 4), 0.05μg/ml 
(lane 5), 0.1μg/ml (lane 6), 0.5μg/ml (lane 7), 1μg/ml (lane 8) and 2μg/ml (lane 9), (B) Tubulin. The 
samples were separated by SDS-PAGE and the gels were transferred to nitrocellulose membranes and 
protein detected using an anti-MG antibody. The results are a representative example of three 
independent experiments.  
 
 
As can be seen in Figure 3.32, SAC/NAC inhibited AGEs formation in vitro in a dose-
dependent manner. The intensity of each band was calculated and the percentage of 
inhibition of each band was assessed by comparing it with the value of the control. 
Following 3 days’ incubation, SAC/NAC significantly (p<0.05) inhibited AGE 
formation between the concentrations of 0.1, 0.5 and 1μg/ml. The percentages of 
inhibition were 24%, 35% and 46%, respectively. At 2μg/ml, SAC/NAC inhibited 
AGE formation even more significantly (p<0.01) and the percentage inhibition was 
66%. 
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Figure 3.32: The effect of SAC/NAC on BAEC glycation. 
Bar chart showing the relative protein glycated by MG (72.0 kDa) (control = 1.0) from Figure 3.31. 
The experiment was repeated at least three times, *P<0.05, **p<0.01 and ***p<0.001.  
  
3.2.3.6 The effect of compound A on BAEC glycation.  
BAECs were incubated with compound A and the relative density of protein 
expression was analysed using free software Image J. Glycation was measured as 
indexed by the presence of the 72.0 kDa with respect to anti- MG AGE antibody 
(Figure 3.33A, lane 1), untreated BEACs were used as controls (Figure 3.33A, lane 
2), 300μM MG (Figure 3.33A, lane 3) or MG in the presence of compound A (Figure 
3.33A, lanes 4 - 9), respectively. Tubulin was used as a loading control (Figure 3.33B). 
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Figure 3.33: SDS-PAGE gel showing the effect of compound A on BAEC glycation. 
Representative Western blot of protein from BAECs incubated with MG and compound A for 3 days. 
(A) Molecular Weight Marker (lane 1), untreated BEACs negative control (lane 2), treated BEACs with 
300μM MG positive control (lane 3) or MG in present of mimic compound A, 0.01μg/ml (lane 4), 
0.05μg/ml (lane 5), 0.1μg/ml (lane 6), 0.5μg/ml (lane 7), 1μg/ml (lane 8) and 2μg/ml (lane 9), 
respectively. (B) Tubulin. The samples were separated by SDS-PAGE and the gels were transferred to 
nitrocellulose membranes and protein detected using an anti-MG antibody. The results are a 
representative example of three independent experiments.  
 
 
Figure 3.34 shows that compound A effectively inhibited AGEs formation in vitro. 
The intensity of each band was calculated and the percentage of inhibition of each 
band was assessed by comparing it with the value of the control. Results show that 
compound A significantly (p<0.01) inhibited AGE formation between the 
concentrations 0.1 and 0.5μg/ml. The percentages of inhibition were 64% and 76%, 
respectively. Further analysis showed that a more significant (p<0.001) inhibition was 
detected at 1 - 2μg/ml where the percentage of inhibition were 89% and 93%, 
respectively and the inhibition was dose-dependent. 
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Figure 3.34: The effect of compound A on BAEC glycation. 
Bar chart showing the relative protein glycated by MG (72.0 kDa) (control = 1.0) from Figure 3.33. 
The experiment was repeated at least three times, **p<0.01 and ***p<0.001.  
 
 
3.2.3.7 The effect SAC/NAC and compound A on BAEC glycation.  
BAEC were incubated with MG in the presence of SAC/NAC and compound A and 
the relative density of protein expression was analysed using free software Image J. 
Glycation was measured as indexed by the presence of the 72.0 kDa with respect to 
anti- MG AGE antibody (Figure 3.35A, lane 1), untreated BEACs were used as 
controls (Figure 3.35A, lane 2), 300μM MG (Figure 3.35A, lane 3) or MG in the 
presence of SAC/NAC and compound A (Figure 3.35A, lanes 4 - 13), respectively. 
Tubulin was used as a loading control (Figure 3.35B). 
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Figure 3.35: SDS-PAGE gel showing the effect of SAC/NAC and compound A on BAEC 
glycation. 
Representative Western blot of protein from BAECs incubated with MG in the presence of   SAC/NAC 
and compound A for 3 days. (A) Molecular Weight Marker (lane 1), untreated BEACs negative control 
(lane 2), treated BEACs with 300μM MG positive control (lane 3) or MG in present of SAC/NAC and 
compound A, 0.01μg/ml (lane 4 - 5), 0.05μg/ml (lane 6 - 7), 0.1μg/ml (lane 8 - 9), 0.5μg/ml (lane 10 - 
11) and 1μg/ml (lane 12 -13), respectively. (B) Tubulin. The samples were separated by SDS-PAGE 
and the gels were transferred to nitrocellulose membranes and protein detected using an anti-MG 
antibody. The results are a representative example of three independent experiments.  
 
 
The results obtained from the preliminary analysis of the effect of SAC/NAC and 
compound A on AGE formation are shown in Figure 3.36. All inhibitors showed 
variable reducing power as demonstrated by their effectiveness in reducing AGE 
formation. The intensity of each band was calculated and the percentage of inhibition 
was detected by comparing it with the control value. SAC/NAC at concentrations 
between 0.05-0.1μg/ml significantly (p<0.05) inhibited AGE formation and the 
percentage inhibitions were 23% and 33%, respectively. At 0.5μg/ml, the inhibition 
was more significant (p<0.01) and the percentage inhibition increased to 49%. In 
addition, 1μg/ml of SAC/NAC inhibited AGE formation by 60% (p<0.001). 
Compound A at 0.05μg/ml significantly (p<0.05) inhibited AGE formation by 29% 
while between 0.1 - 0.5μg/ml, the inhibition was more significant (p<0.01) and the 
percentages inhibition increased to 37% and 50%, respectively. At a concentration of 
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1μg/ml, the percentage inhibition was 60% (p<0.001). Thus, the results clearly 
indicate that increasing concentrations of both inhibitors have a higher reducing 
power.  
 
  
Figure 3.36: The effect of SAC/NAC and compound A on BAEC glycation. 
Bar chart showing the relative protein glycated by MG (72.0 kDa) (control = 1.0) from Figure 3.35. 
The experiment was repeated at least three times, *P<0.05, **p<0.01 and ***p<0.001.  
 
 
3.2.3.8 The effect of SAC/NAC- and compound A-loaded hADMSCs CM on 
BAEC glycation. 
MSCs were incubated with MG and 500μg/ml of SAC/NAC-primed hADMSCs CM 
or with MG and 250μg/ml of compound A-primed hADMSCs CM for four days. The 
released conditioned medium for each day was collected and replaced by fresh 
medium. BAECs were incubated with MG and conditioned medium and the relative 
density of protein expression was analysed using free software Image J. Glycation was 
measured as indexed by the presence of the 72.0 kDa with respect to anti- MG AGE 
antibody (Figure 3.37A, lane 1), untreated BEACs were used as controls (Figure 
3.37A, lane 2), 300μM MG (Figure 3.37A, lane 3) or MG in the presence of 
SAC/NAC- and compound A- loaded hADMSCs CM (Figure 3.37A, lanes 4 - 11), 
respectively. Tubulin was used as a loading control (Figure 3.37B). 
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Figure 3.37: SDS-PAGE gel showing the effect of SAC/NAC- and compound A- loaded 
hADMSCs CM on BAEC glycation. 
Representative Western blot of protein from BAECs incubated with MG and SAC/NAC- and compound 
A-loaded hADMSCs CM (day 1 - 4). Molecular Weight Marker (lane 1), untreated BEACs negative 
control (lane 2), treated BEACs with 300μM MG positive control (lane 3) or MG in present of 
SAC/NAC- and compound A-loaded hADMSCs CM, day 1 (lanes 4 - 5), day 2 (Lanes 6 - 7), day 3 
(Lanes 8 - 9) and day 4 (lanes 10 - 11), respectively. (B) Tubulin. The samples were separated by SDS-
PAGE and the gels were transferred to nitrocellulose membranes and protein detected using an anti-
MG antibody. The results are a representative example of three independent experiments.  
 
Figure 3.38 shows the effect of CM on BAECs. The percentage inhibition compared 
to control was used to evaluate the inhibitory effect of both inhibitors on AGE 
formation. The results show that SAC/NAC- and compound A- CM significantly 
(p<0.05) inhibited the formation of AGE at days 1 and 2. The maximum percentage 
of AGE inhibition was 44% and 45%, respectively. On the other hand, CM containing 
inhibitors did not show any inhibition of AGE formation at days 3 and 4.  
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Figure 3.38: The effect of SAC/NAC and compound A loaded hADMSCs CM on BAEC 
glycation. 
Bar chart showing the relative protein glycated by MG (72.0 kDa) (control = 1.0) from Figure 3.37. 
The experiment was repeated at least three times, * P<0.05 and ***p<0.001.  
 
 
3.2.4 Detection of AGEs by ELISA 
3.2.4.1 Standardisation of ELISA for measurement of AGE 
A universal standard calibrator to identify AGE was available using an AGE ELISA 
kit (Human). The standard curve was generated by plotting the mean replicate relative 
OD450 of each standard serial dilution point vs. the respective standard protein 
concentrations from 0-50ng/ml. The absorbance of samples was read from the 
calibration curve and expressed relative to a BSA-AGE standard in AGE ng of protein. 
Each sample was analysed in triplicate on the plate. The standard curve of BSA-AGE 
showed a linear correlation between the glycated protein concentration and the 
absorbance at 450nm (Figure 3.39). 
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Figure 3.39: Standard curve of BSA-AGE. 
 
 
3.2.4.2 The effect of SAC/NAC and compound A on AGE levels  
A sandwich ELISA technique was used to detect AGE levels in vitro using a 
polyclonal anti-AGEs antibody in an attempt to validate the inhibitory effect of 
SAC/NAC and compound A on AGE formation.  After 3 days’ incubation, the 
concentration of AGE in BAEC was measured from untreated cells (negative control), 
cells treated with 300μM MG (positive control) or MG treated with SAC/NAC (Figure 
3.40, A) and compound A (Figure 3.40, B). The results showed that the effect of 
SAC/NAC significantly (p<0.05) inhibited AGEs’ formation at concentrations of 
between 0.1-2μg/ml, while compound A also showed significant inhibition (p<0.05) 
at concentrations between 0.05 - 2μg/ml. Therefore, AGE levels (U) in control cells 
(2.31 ± 0.07U) was significantly higher than in samples containing inhibitors and 
inhibition of AGEs occurred in a dose-dependent manner (Figure 3.40). 
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Figure 3.40: Interaction of SAC/NAC and compound A on MG induced AGEs’ production. 
BAECs were incubated with 300µM MG and with or without (A) 0.01 - 2μg/ml SAC/NAC and (B) 
0.01 - 2μg/ml compound A for 3 days. The bar graph shows the inhibition effect of both inhibitors on 
AGEs. The AGE levels, in 0.1ml of BSA-AGE diluted to 1μg/ml, were defined as 1 unit (U). The bar 
chart was made from the average of two independent experiments, *P<0.05 and ***p<0.001. 
  
 
3.3 Cytotoxicity study of SAC/NAC using CellTiter-Blue® Cell Viability Assay  
This study tested the toxicity of the SAC/NAC and compound A solution on 
hADMSCs. The results showed the maximum doses of SAC/NAC (Figure 3.41A) and 
compound A (Figure 3.41B), that did not affect cell viability, were 500 and 250μg/ml, 
respectively using the alamarBlue assay. Based on these results, maximum 
concentrations of SAC/NAC (500μg/ml) and compound A (250μg/ml), were 
employed in the current study. The effects of different concentrations of both 
SAC/NAC and compound A on hADMSCs viability are presented in Figure 3.41. The 
results showed that no significant inhibition of hADMSCs viability was found with 
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the inhibitors at all the concentrations. However, the inhibitors seemingly produced 
no cytotoxic effect. 
 
 
 
Figure 3.41: The effect of SAC/NAC and compound A on hADMSCs viability using the 
alamrBlue assay. 
hADMSCs (2 × 105/ml) were seeded in 96-well plates and incubated with (A) SAC/NAC (0.0076 – 
500μg/ml) and (B) compound A (0.122 - 250μg/ml). After 24 hours of incubation, the cell suspension 
(100μl) was mixed with 20μl/well of CellTiter-Blue® Reagent and incubated for 4 hours before 
recording the fluorescence. Emission spectra were recorded at 560nm after excitation at 590nm using 
a Labsystems Fluoroskan Ascent plate reader. This experiment was done twice.  
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3.4 Cell Angiogenesis Assay  
3.4.1 Effect of glucose on BAEC migration 
Since cell migration is an essential process for angiogenesis (Griffioen and Molema, 
2000), it was believed necessary to evaluate the effects of increased glucose levels on 
BAEC migration in vitro using a denudation injury model. To determine the effects of 
different concentrations of glucose treatment on cell migration (Figure 3.42), 
representative photomicrographs of the migration of untreated cells (1), cells treated 
with FGF-2 (2) or 15 - 100mM glucose (3 - 7) were evaluated. Due to the cell 
proliferation assay was not performed, images were only show the cell migration 
experiment. Pictures taken at time 0 and then after 24 hours to capture the differences 
in the number of cells which had migrated. In comparison to controls, the migration 
of cells in glucose concentrations of between 25 - 50mM were decreased significantly 
(p<0.05) with the distance reduced ranging between 8.0 ± 2.0 and 6.0 ± 1.5mm. The 
migration of wounded cells in the presence of glucose at concentrations of between 75 
- 100mM were significantly decreased (p<0.01) with the maximum distance reduced 
to 3.0 ± 2.0mm. The inhibition was in a dose-dependent manner (Figure 3.43). 
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Figure 3.42: Photomicrographic showing the effect of glucose on BAEC wound healing. 
Photomicrographs 24 hours following wounding showing the effect of glucose on BAEC (1 × 106/ml) 
migration were taken using phase contrast microscopy (magnification × 100). Untreated cells cultured 
in 2.5% FBS (1), FGF-2 (25ng/ml) used as a positive control (2) or areas (3 – 7) show cells exposed to 
different concentrations of glucose (15 - 100mM). The number of migrated cells in the denuded area 
was counted in 5 random areas per slide and averaged accordingly. This panel is representative of at 
least two independent experiments.  
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Figure 3.43: Effect of glucose on BAEC wound healing. 
Bar graph showing the effect of different concentrations of glucose on BAEC migration. The number 
of migrated cells in the denuded area was counted in 5 random areas per slide and averaged accordingly. 
The results are presented as mean ± S.D. (n=3), *P<0.05 and ** P<0.01, significantly different from 
control. 
 
 
3.4.2 Effect of glucose on tube formation  
As BAEC migration processes to the formation of microvascular tubes in vitro, assays 
for the tube-like structure of endothelial cells have been developed and used to study 
this crucial step of angiogenesis. The cells take only several hours to associate with 
each together and form micro-tubes. To test the effects of glucose on tube formation, 
an in vitro a Matrigel assay was used (Figure 3.44). Representative photomicrographs 
show tube formation in untreated cells without FBS (1), untreated cells cultured in 
2.5% FBS (2), cells treated with FGF-2 (3) or with 15 - 100mM glucose (4 - 8) are 
shown. Compared to untreated cells (negative control), FGF-2 was used as a positive 
control. Pictures were taken after 7 hours to capture the differences in the number of 
tubes formed. As shown in Figure 3.45, the capillary tube formation of BAECs was 
markedly and dose-dependently inhibited by the addition of glucose. BAECs exposed 
to glucose at concentrations of 25mM showed significant (p<0.05) inhibition of 
BAECs’ closed areas with a percentage inhibition of 69% compared with control. 
Significant inhibition was shown at concentrations of between (50 - 100mM) with the 
percentage inhibition ranging from 81% - 93% compared with control (p<0.01). This 
inhibition occurred in a concentration-dependent manner. These results suggest that 
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high glucose-treated cells failed to form networks and showed impaired tube 
formation.  
 
Figure 3.44: Photomicrographic showing the effect of glucose on BAEC tube formation. 
Photomicrographs showing the effect of glucose on BAEC (1 × 106/ml) tube formation in Matrigel. 
Negative control (untreated cells) without FBS (1), untreated cells cultured in 2.5% FBS (2), FGF-2 
(25ng/ml) used as a positive control (3) or areas (4 – 8) show cells exposed to different concentrations 
of glucose (15 - 100mM). After 7 hours, tubes had formed and the number of closed areas was counted 
from 5 random fields of 3 wells of a 96-well plate (magnification × 100). This panel is a representative 
example of at least two independent experiments. 
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Figure 3.45: Effect of glucose on BAEC tube formation. 
Bar graph showing the effect of different concentrations of glucose on BAEC tube formation. The 
results are presented as mean ± S.D. (n=3), * P<0.05 and ** P<0.01, significantly different from 
control. 
 
 
3.4.3 Effect of SAC/NAC in the presence of glucose on BAEC wound healing 
As mentioned previously, glucose at high concentrations inhibited BAEC migration. 
This experiment was designed to determine whether SAC/NAC altered the effects of 
75mM glucose on the migration of BAECs (Figure 3.46). Representative 
photomicrographs of the migration of untreated cells cultured in 2.5% FBS (1), cells 
treated with FGF-2 (2), 75mM glucose (3) or 0.01 - 2μg/ml SAC/NAC combined with 
75mM glucose (4 - 9) are shown. Images were taken at time 0 and then after 24 hours 
to capture the differences in the number of cells which had migrated. In comparison 
to controls, the results showed the addition of SAC/NAC significantly inhibited cell 
migration at all concentrations (p<0.05) with the maximum distance reduced to 3.0 ± 
0.5mm. The results suggested that SAC/NAC did not protect against the anti-
migratory effect of glucose and the inhibition was dose-dependent (Figure 3. 47). 
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Figure 3.46: Photomicrographic showing the effect of SAC/NAC in the presence of glucose on 
BAEC wound healing. 
Photomicrographs 24 hours following wounding showing the effect of SAC/NAC with 75mM of 
glucose on BAEC (1 × 106/ml) migration were taken using phase contrast microscopy (magnification 
× 100). Untreated cells cultured in 2.5% FBS (1), FGF-2 (25ng/ml) used as a positive control (2), 75mM 
glucose (3) or areas (4 – 9) show cells exposed to different concentrations of SAC/NAC (0.01 - 2µg/ml) 
with 75mM glucose. The number of migrated cells in the denuded area was counted in 5 random areas 
per slide and averaged accordingly. This panel is representative of at least two independent experiments. 
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Figure 3.47: Effect of SAC/NAC in the presence of glucose on BAEC wound healing. 
Bar graph showing the effect of different concentrations of SAC/NAC with 75mM of glucose on BAEC 
migration. All treatments were compared with the control (2.5% FBS). The number of migrated cells 
in the denuded area was counted in 5 random areas per slide and averaged accordingly. The results are 
presented as mean ± S.D. (n=3), * P<0.05 and ** P<0.01, significantly different from control. # P<0.05 
and ## P<0.01, significantly different from glucose (75mM). 
 
  
3.4.4 Effect of SAC/NAC in the presence of glucose on BAEC tube formation  
To determine whether SAC/NAC altered the effects of 75mM glucose on endothelial 
cells capillary tube formation (Figure 3.48), representative photomicrographs are 
shown of the tube formation in untreated cells without FBS (1), untreated cells 
cultured in 2.5% FBS (2), cells treated with FGF-2 (3), 75mM glucose (4) or 0.01-
2µg/ml SAC/NAC combined with 75mM glucose (5 - 10) are shown. Compared to 
the untreated cells (negative control), FGF-2 was used as a positive control. Pictures 
were taken after 7 hours to capture the differences in the number of tubes formed.  As 
shown in Figure 3.49, in comparison to controls, the addition of SAC/NAC 
significantly inhibited tube formation at all concentrations with the percentage 
inhibition ranging from 86% - 97% compared with control (p<0.01). The results 
indicated that SAC/NAC has no protective effect on the tube formation and the 
inhibition was dose-dependent.  
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Figure 3.48: Photomicrographic showing the effect of SAC/NAC in the presence of glucose on 
BAEC tube formation. 
Photomicrographs showing the effect of SAC/NAC with 75mM of glucose on BAEC (1 × 106/ml) tube 
formation in Matrigel (magnification × 100). Negative control (untreated cells) without FBS (1), 
untreated cells cultured in 2.5% FBS (2), FGF-2 (25ng/ml) used as a positive control (3), 75mM glucose 
(4) or areas (5 – 10) show cells exposed to different concentrations of SAC/NAC (0.01 - 2μg/ml) with 
75mM glucose. After 7 hours, tubes had formed and the number of closed areas was counted from 5 
random fields of 3 wells of a 96-well plate. This panel is a representative example of at least two 
independent experiments.  
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Figure 3.49: Effect of SAC/NAC in the presence of glucose on BAEC tube formation. 
Bar graph showing the effect of different concentrations of SAC/NAC with 75mM of glucose on BAEC 
tube formation. The results are presented as mean ± S.D. (n=3), ** P<0.01, significantly different from 
control. ##P<0.01, ### P<0.001 and #### P<0.0001, significantly different from 75mM glucose. 
 
 
3.4.5 Effect of compound A in the presence of glucose on BAEC wound healing 
Figure 3.50 shows representative photomicrographs of the migration of untreated cells 
cultured in 2.5% FBS (1) or cells treated with FGF-2 (2), 75mM glucose (3) or 0.01 -
2μg/ml compound A combined with 75mM glucose (4 - 9) are shown. The images 
were taken at time 0 and then after 24 hours to capture the differences in a number of 
cells that had migrated. In comparison to controls, the results showed the addition of 
compound A at concentrations of between 0.01 - 0.5µg/ml significantly (p<0.05) 
inhibited the cell migration while at the concentration of 1 - 2µg/ml, there were more 
significant inhibition (p<0.01) with the maximum distance being reduced to 2.0 ± 
0.9mm. The results suggested compound A did not protect against the anti-migratory 
effect of glucose and the inhibition was dose-dependent (Figure 3.51). 
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Figure 3.50: Photomicrographic showing the effect of compound A in the presence of glucose on 
BAEC wound healing. 
Photomicrographs 24 hours following wounding showing the effect of compound A with 75mM of 
glucose on BAEC (1 × 106/ml) migration were taken using phase contrast microscopy (magnification 
× 100). Untreated cells cultured in 2.5% FBS (1), FGF-2 (25ng/ml) used as a positive control (2), 75mM 
glucose (3) or areas (4 - 9) shows cells exposed to different concentrations of compound A (0.01 - 
2μg/ml ) with 75mM glucose. The number of migrated cells in the denuded area was counted in 5 
random areas per slide and averaged accordingly. This panel is representative of at least two 
independent experiments. 
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Figure 3.51: Effect of compound A in the presence of glucose on BAEC wound healing. 
Bar graph showing the effect of different concentrations of compound A with 75mM of glucose on 
BAEC migration. All treatments were compared against the positive control (2.5% FBS). The number 
of migrated cells in the denuded area was counted in 5 random areas per slide and accordingly averaged. 
The results are presented as mean ± S.D. (n=3), * P<0.05 and ** P<0.01, significantly different from 
control. # P<0.05, and ## P<0.01, significantly different from 75mM glucose. 
 
 
3.4.6 Effect of compound A in the presence of glucose on BAEC tube formation  
Using the Matrigel assay, the influence of mimic compound A treated with high 
glucose (75mM) on BAEC tube formation was also investigated (Figure 3.52). 
Representative photomicrographs of the tube formation in untreated cells without FBS 
(1), untreated cells cultured in 2.5% FBS (2), cells treated with FGF-2 (3), 75mM 
glucose (4) or 0.01 - 2µg/ml compound A combined with 75mM glucose (5 - 10) are 
shown. Compared to the untreated cells (negative control), FGF-2 was used as a 
positive control. Images were taken after 7 hours to capture the differences in the 
number of tubes formed. In comparison to controls, the addition of compound A 
significantly (p<0.01) inhibited tube formation at concentrations (0.01 - 2µg/ml) with 
the maximum percentage inhibition of 98%. The results indicated that compound A 
has no protective effect on the tube formation and the inhibition was dose-dependent 
(Figure 3.53). 
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Figure 3.52: Photomicrographic showing the effect of compound A in the presence of glucose on 
BAEC tube formation. 
Photomicrographs showing the effect of compound A with 75mM of glucose on BAEC (1 ×106/ml) 
tube formation in Matrigel (magnification × 100). Negative control (untreated cells) without FBS (1), 
untreated cells cultured in 2.5% FBS (2), FGF-2 (25ng/ml) used as a positive control (3), 75mM glucose 
(4) or areas (5 - 10) shows cells exposed to different concentrations of compound A (0.01 - 2μg/ml) 
with 75mM glucose. After 7 hours, tubes had formed and the number of closed areas was counted from 
5 random fields of 3 wells of a 96-well plate. This panel is a representative example of at least two 
independent experiments. 
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Figure 3.53: Effect of compound A in the presence of glucose on BAEC tube formation. 
Bar graph showing the effect of compound A with 75mM of glucose on BAEC tube formation. The 
results are presented as mean ± S.D. (n=3), ** P<0.01, significantly different from control. ##P<0.01, 
### P<0.001 and #### P<0.0001, significantly different from 75mM glucose. 
 
 
3.4.7 Effect of BSA-AGEs on BAEC wound healing 
This study was designed to determine the effect of BSA-AGEs on endothelial cells. 
Following 24 hours of incubation (Figure 3.54), representative photomicrographs 
were taken of the migration of untreated cells cultured in 2.5% FBS (1), cells treated 
with FGF-2 (2) or 15 - 50μg/ml BSA-AGEs (3 - 6) are shown. Images were taken at 
time 0 and then after 24 hours to capture the differences in the number of cells which 
had migrated. In comparison to controls, BSA-AGEs markedly (p<0.05) decreased 
cell migration across the middle line at concentrations of between 15 - 35μg/ml with 
the distance migrated being reduced to between of 8.0  2.0 - 6.0  3.0mm. The 
distance migrated showed a more significant reduction to 3.0  0.9mm (p<0.01) when 
the cells were treated with 50μg/ml BSA-AGEs and the inhibition was dose-dependent 
(Figure 3.55). 
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Figure 3.54: Photomicrographic showing the effect of BSA-AGEs on BAEC wound healing. 
Photomicrographs 24 hours following wounding showing the effect of different concentrations of BSA-
AGEs on BAEC (1 × 106/ml) cell migration were taken using phase contrast microscopy (magnification 
× 100). Untreated cells cultured in 2.5% FBS (1), FGF-2 (25ng/ml) used as a positive control (2) or 
areas (3 – 6) show cells exposed to different concentrations of BSA-AGEs (15 - 50μg/ml). The number 
of migrated cells in the denuded area was counted in 5 random areas per slide and averaged accordingly. 
This panel is representative of at least two independent experiments.  
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Figure 3.55: Effect of BSA-AGEs on BAEC wound healing. 
Bar graph showing the effect of different concentrations of BSA-AGEs on BAEC migration. The 
number of migrated cells in the denuded area was counted in 5 random areas per slide and averaged 
accordingly. The results are presented as mean ± S.D. (n=3), * P<0.05 and ** P<0.01, significantly 
different from controls.  
 
 
3.4.8 Effect of BSA-AGEs on BAEC tube formation 
Using the Matrigel assay, the effect of BSA-AGEs on BAEC tube formation was also 
investigated (Figure 3.56). Representative photomicrographs of the tube formation in 
untreated cells without FBS (1), untreated cells cultured in 2.5% FBS (2), cells treated 
with FGF-2 (3) or 15 - 50μg BSA-AGEs (4 - 7) are shown. Compared to the untreated 
cells (negative control), FGF-2 was used as a positive control. Images were taken after 
7 hours to capture the differences in a number of tubes formed. The results showed 
that AGEs suppressed tube formation of endothelial cells effectively (p<0.01) at a 
concentration of 25μg/ml with percentage inhibition of 69% while the inhibition was 
significantly greater (p<0.001) at concentrations of between 35 - 50μg/ml with 
percentage inhibition ranging of between 75% - 79%. Thus, the results demonstrated 
the suppressive effect of BSA-AGEs on BAEC tube formation in a dose-dependent 
manner (Figure 3.57).  
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Figure 3.56: Photomicrographic showing the effect of BSA-AGEs on BAEC tube formation. 
Photomicrographs showing the effect of different concentrations of BSA-AGEs on BAEC (1 × 106/ml) 
tube formation in Matrigel (magnification × 100). Negative control (untreated cells) without FBS (1), 
untreated cells cultured in 2.5% FBS (2), FGF-2 (25ng/ml) used as a positive control (3) or areas (4 – 
7) show cells exposed to different concentrations of BSA-AGEs (15 - 50μg/ml). After 7 hours, tubes 
had formed and the number of closed areas was counted from 5 random fields of 3 wells of a 96-well 
plate. This panel is a representative example of at least two independent experiments.  
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Figure 3.57: Effect of BSA-AGEs on BAEC tube formation. 
Bar graph showing the effect of different concentrations of BSA-AGEs on BAEC tube formation. The 
results are presented as mean ± S.D. (n=3), ** P<0.01 and *** P<0.001, significantly different from 
controls. 
 
 
3.4.9 Effect of SAC/NAC in the presence of BSA-AGEs on BAEC wound healing 
Since AGEs at high concentrations were shown as a potent inhibitor of BAEC 
migration, it was interesting to test whether SAC/NAC is able to reverse the effects of 
a high concentration of BSA-AGEs (50μg/ml) on the migration of BAECs (Figure 
3.58). Representative photomicrographs of the migration of untreated cells cultured in 
2.5% FBS (1), cells treated with FGF-2 (2), 50μg/ml BSA-AGEs (3) or 0.01 - 2μg/ml 
SAC/NAC combined with 50μg/ml BSA-AGEs (4 - 9) are shown. Images were taken 
at time 0 and then after 24 hours to capture the differences in the number of cells that 
had migrated. The addition of SAC/NAC not only suppressed the inhibitory effect of 
BSA-AGEs on BAEC migration but significantly induced cell migration at 
concentrations of 1μg/ml (p<0.05) and 2μg/ml (p<0.01). At the same time, the 
maximum distance migrated increased to 16.0  2.0mm. The results suggested that the 
migration of endothelial cells was promoted in a dose-dependent manner (Figure 
3.59). 
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Figure 3.58: Photomicrographic showing the effect of SAC/NAC in presence of BSA-AGEs on 
BAEC wound healing. 
Photomicrographs 24 hours following wounding showing the effect of different concentrations of 
SAC/NAC with BSA-AGEs on BAEC (1 × 106/ml) migration were taken using phase contrast 
microscopy (magnification × 100). Untreated cells cultured in 2.5% FBS (1), FGF-2 (25ng/ml) used as 
a positive control (2), 50μg/ml BSA-AGEs (3) or areas (4 – 9) show cells exposed to different 
concentrations of SAC/NAC (0.01 - 2μg/ml) with 50μg/ml BSA-AGEs. The number of migrated cells 
in the denuded area was counted in 5 random areas per slide and averaged accordingly. This panel is 
representative of at least two independent experiments. 
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Figure 3.59: Effect of SAC/NAC in the presence of BSA-AGEs on BAEC wound healing. 
Bar graph showing the effect of different concentrations of SAC/NAC with 50μg/ml BSA-AGEs on 
BAEC migration. The number of migrated cells in the denuded area was counted in 5 random areas per 
slide and averaged accordingly. The results are presented as mean ± S.D. (n=3), *P<0.05 and **P<0.01, 
significantly different from control. ##P<0.01 and ##P<0.001, significantly different from BSA-AGEs 
(50µg/ml). 
 
 
3.4.10 Effect of SAC/NAC in the presence of BSA-AGEs on BAEC tube formation 
As shown in the previous results, AGEs at high concentrations of 35-50μg/ml were 
shown to be a potent inhibitor of BAEC tube formation (Figure 3.56). Therefore, 
experiments were performed to check whether SAC/NAC was able to reverse the 
effects of a high concentration of BSA-AGEs (50μg/ml) on tube formation (Figure 
3.60). Representative photomicrographs of the tube formation in untreated cells 
without FBS (1), untreated cells cultured in 2.5% FBS (2), cells treated with FGF-2 
(3), 50μg/ml BSA-AGEs (4) or 0.01 - 2μg/ml SAC/NAC combined to 50μg/ml BSA-
AGEs (5 - 10) are shown. Compared to the untreated cells (negative control), FGF-2 
was used as a positive control. Images were taken after 7 hours to capture the 
differences in the number of tubes formed.  The results showed that addition of 
SAC/NAC suppressed the inhibitory effect of BSA-AGEs on BAEC tube formation 
and significantly induced tube formation at concentrations of between 1 - 2μg/ml in a 
dose-dependent manner (p<0.05) with percentage inhibition ranging from 37.0% - 
36.0% compared to the control (Figure 3.61). 
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Figure 3.60: Photomicrographic showing the effect of SAC/NAC in the presence of BSA-AGEs 
on BAEC tube formation. 
Photomicrographs showing the effect of different concentrations of SAC/NAC with 50μg/ml BSA-
AGEs on BAEC (1 × 106/ml) tube formation in Matrigel (magnification × 100). Negative control 
(untreated cells) without FBS (1), untreated cells cultured in 2.5% FBS (2), FGF-2 (25ng/ml) used as a 
positive control (3), 50μg/ml BSA-AGEs (4) or areas (5 – 10) show cells exposed to different 
concentration of SAC/NAC (0.01 - 2μg/ml) with 50μg/ml BSA-AGEs. After 7 hours, tubes had formed 
and the number of closed areas was counted from 5 random fields of 3 wells of a 96-well plate. This 
panel is a representative example of at least two independent experiments.  
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Figure 3.61: Effect of SAC/NAC in the presence of BSA-AGEs on BAEC tube formation. 
Bar graph showing the effect of different concentrations of SAC/NAC with 50μg/ml BSA-AGE on 
BAEC tube formation. All treatments were compared to the control (2.5% FBS). The results are 
presented as mean ± S.D. (n=3), *P<0.05 and **P<0.01, significantly different from control. ##P<0.01 
and ###P<0.001, significantly different from BSA-AGEs (50µg/ml). 
 
 
3.4.11 Effect of compound A in the presence of BSA-AGEs on BAEC wound 
healing 
Figure 3.62 shows representative photomicrographs of the migration of untreated cells 
cultured in 2.5% FBS (1), cells treated with FGF-2 (2), 50μg/ml BSA-AGEs (3) or 
0.01 - 2μg/ml compound A combined with 50μg/ml BSA-AGEs (4 - 9) are shown. 
Images were taken at time 0 and then after 24 hours to capture the differences in the 
number of cells that had migrated. In comparison to controls, the presence of 
compound A significantly (P<0.01) induced cells migration at concentrations of 
between 0.5 - 2μg/ml. Consistently, BAECs treated with compound A showed a 
similar effect as SAC/NAC in promoting cell migration, with the maximum distance 
migrated being 17.0  2.0mm. The results suggested that the migration of endothelial 
cells was promoted in a dose-dependent manner (Figure 3.63). 
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Figure 3.62: Photomicrographic showing the effect of compound A in the presence of BSA-
AGEs on BAEC wound healing. 
Photomicrographs 24 hours following wounding showing the effect of different concentrations of 
compound A with BSA-AGEs on BAEC (1 × 106/ml) migration were taken using phase contrast 
microscopy (magnification × 100). Untreated cells cultured in 2.5% FBS (1), FGF-2 (25ng/ml) used as 
a positive control (2), 50μg/ml BSA-AGEs (3) or areas (4 – 9) show cells exposed to different 
concentration of compound A (0.01 - 2μg/ml) with 50μg/ml BSA-AGEs. The number of migrated cells 
in the denuded area was counted in 5 random areas per slide and averaged accordingly.  This panel is 
representative of at least two independent experiments.  
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Figure 3.63: Effect of compound A in the presence of BSA-AGEs on BAEC wound healing. 
Bar graph showing the effect of different concentrations of compound A with 50μg/ml BSA-AGEs on 
BAEC migration. The number of migrated cells in the denuded area was counted in 5 random areas per 
slide and averaged accordingly. The results are presented as mean ± S.D. (n=3), **P<0.01, significantly 
different from control. ##P<0.01 and ###P<0.001, significantly different from BSA-AGEs (50μg/ml). 
 
 
3.4.12 Effect of compound A in the presence of BSA-AGEs on BAEC tube 
formation 
This study was designed to determine whether compound A was able to reverse the 
effects of a high concentration of BSA-AGEs (50μg/ml) on tube formation (Figure 
3.64). Representative photomicrographs of tube formation in untreated cells without 
FBS (1), untreated cells cultured in 2.5% FBS (2), cells treated with FGF-2 (3), 
50μg/ml BSA-AGEs (4) or 0.01 - 2μg/ml compound A combined to 50μg/ml BSA-
AGEs (5 - 10) are shown. Compared to the untreated cells (negative control), FGF-2 
used as a positive control to prove the cells’ ability to respond. Images were taken after 
7 hours to capture the differences in the number of tubes formed. The results showed 
that addition of compound A protect against the inhibitory effect of BSA-AGEs on 
BAEC tube formation and significantly induced tube formation at concentrations of 
between 0.5 - 2μg/ml (p<0.05) with the percentage inhibition ranging between 41 - 
32%. The results suggested that compound A promoted tube formation in a dose-
dependent manner compared to controls (Figure 3.65).  
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Figure 3.64: Photomicrographic showing the effect of compound A in the presence of BSA-
AGEs on BAEC tube formation. 
Photomicrographs showing the effect of different concentrations of compound A with BSA-AGEs on 
BAEC (1 × 106/ml) tube formation in Matrigel (magnification × 100). Negative control (untreated cells) 
without FBS (1), untreated cells cultured in 2.5% FBS (2), FGF-2 (25ng/ml) used as a positive control 
(3), 50μg/ml BSA-AGEs (4) or areas (5 – 10) show cells exposed to different concentration of 
compound A (0.01 - 2μg/ml) with 50μg/ml BSA-AGEs. After 7 hours, tubes had formed and the number 
of closed areas was counted from 5 random fields of 3 wells of a 96-well plate. This panel is a 
representative example of at least two independent experiments. 
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Figure 3.65: Effect of compound A in the presence of BSA-AGEs on BAEC tube formation. 
Bar graph showing the effect of different concentrations of compound A with 50µg/ml BSA-AGEs on 
BAEC tube formation. The results are presented as mean ± S.D. (n=3), *P<0.05 and **P<0.01, 
significantly different from control. ##P<0.01 and ###P<0.001, significantly different from BSA-AGEs 
(50μg/ml). 
 
 
3.4.13 Effect of SAC/NAC on BAEC wound healing 
To examine the inhibitory effect of SAC/NAC on BAEC migration, a wound healing 
assay was performed (Figure 3.66). Representative photomicrographs show the 
migration of untreated cells cultured in 2.5% FBS (1), cells treated with FGF-2 (2) or 
0.01 - 2μg/ml SAC/NAC (3 - 8) are shown. Images were taken at time 0 and then after 
24 hours to capture the differences in the number of cells that had migrated. In 
comparison to the controls, migration of the cells exposed to 0.05μg/ml of SAC/NAC 
showed significant (p<0.05) inhibition and the distance migrated was 8.0  2.0mm. 
SAC/NAC at concentrations of between 0.1 - 2μg/ml significantly suppressed the cell 
migration (p<0.01) where the maximum migrated distance was only 4.0  1.0mm. 
These results suggest that SAC/NAC inhibited cell migration in a dose-dependent 
manner (Figure 3.67). 
 
Chapter 3 
 
 
157 
 
 
Figure 3.66: Photomicrographic showing the effect of SAC/NAC on BAEC wound healing. 
Photomicrographs 24 hours following wounding showing the effect of SAC/NAC on BAEC (1 × 
106/ml) migration were taken using phase contrast microscopy (magnification × 100). Untreated cells 
cultured in 2.5% FBS (1), FGF-2 (25ng/ml) used as a positive control (2), or areas (3 – 8) show cells 
exposed to different concentrations of SAC/NAC (0.01 - 2μg/ml). The number of migrated cells in the 
denuded area was counted in 5 random areas per slide and averaged accordingly. This panel is 
representative of at least two independent experiments. 
 
.  
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Figure 3.67: Effect of SAC/NAC on BAEC wound healing. 
Bar graph showing the effect of different concentrations of SAC/NAC on BAEC migration. The number 
of migrated cells in the denuded area was counted in 5 random areas per slide and averaged accordingly. 
The results are presented as mean ± S.D. (n=3), *P<0.01 and **P<0.01, significantly different from 
control. 
 
 
3.4.14 Effect of SAC/NAC on BAEC tube formation 
Using the Matrigel assay system, the influence of SAC/NAC on BAEC tube formation 
was investigated, and the results are highlighted in Figure 3.68. Representative 
photomicrographs of the tube formation in untreated cells without FBS (1), untreated 
cells cultured in 2.5% FBS (2), cells treated with FGF-2 (3) or 0.01 - 2μg/ml 
SAC/NAC (4 - 9) are shown. Compared to the untreated cells (negative control), FGF-
2 used as a positive control to improve the cells ability to respond. Images were taken 
after 7 hours to capture the differences in the number of tubes formed. The results 
showed that tube formation was significantly inhibited (p<0.05), as seen by the 
reduction in tubule-like structures. Thus, the cells were unable to migrate to form new 
capillary structures in the presence of SAC/NAC at concentration of 0.01μg/ml with 
inhibition of 82% and the results showed more significant inhibition (p<0.01) was seen 
at a concentrations of  between 0.05 - 2μg/ml with inhibition ranges between 84% - 
59%. The results indicated that SAC/NAC inhibited tube formation and the inhibition 
was dose-dependent (Figure 3.69).    
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Figure 3.68: Photomicrographic showing the effect of SAC/NAC on BAEC tube formation. 
Photomicrographs showing the effect of SAC/NAC on BAEC (1 × 106/ml) tube formation in Matrigel 
(magnification × 100). Negative control (untreated cells) without FBS (1), untreated cells cultured in 
2.5% FBS (2), FGF-2 (25ng/ml) used as a positive control (3) or areas (4 – 9) show cells exposed to 
different concentrations of SAC/NAC (0.01 - 2μg/ml). After 7 hours, tubes had formed and the number 
of closed areas was counted from 5 random fields of 3 wells of a 96-well plate. This panel is a 
representative example of at least two independent experiments. 
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Figure 3.69: Effect of SAC/NAC on BAEC tube formation. 
Bar graph showing the effect of different concentrations of SAC/NAC on BAEC tube formation. The 
results are presented as mean ± S.D. (n=3), *P<0.05 and **P<0.01 significantly different from control. 
 
 
3.4.15 Effect of compound A on BAEC wound healing 
As shown in Figure 3.70, there are representative photomicrographs of the migration 
of untreated cells cultured in 2.5% FBS (1), cells treated with FGF-2 (2) or 0.01 - 
2μg/ml compound A (3 - 8) are shown. Images were taken at time 0 and then after 24 
hours to capture the differences in the number of cells that had migrated. Migration of 
the cells exposed to 0.05μg/ml of compound A  showed significant (p<0.05) inhibition, 
while the migration of cells exposed in compound A at concentrations of between 0.1 
- 2μg/ml were decreased (p<0.01) and the maximum migrated distance was only 4.0 
 2.0mm, respectively. Compound A inhibited wound healing in BAECs in a dose-
dependent manner (Figure 3.71).    
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Figure 3.70: Photomicrographic showing the effect of compound A on BAEC wound healing. 
Photomicrographs 24 hours following wounding showing the effect of compound A on BAEC (1 × 
106/ml) migration were taken using phase contrast microscopy (magnification × 100). Untreated cells 
cultured in 2.5% FBS (1), FGF-2 (25ng/ml) used as a positive control (2), or areas (3 – 8) show cells 
exposed to different concentrations of compound A (0.01 - 2μg/ml). The number of migrated cells in 
the denuded area was counted in 5 random areas per slide and averaged accordingly. This panel is 
representative of at least two independent experiments.  
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Figure 3.71: Effect of compound A on BAEC wound healing. 
Bar graph showing the effect of different concentrations of compound A on BAEC migration. The 
number of migrated cells in the denuded area was counted in 5 random areas per slide and averaged 
accordingly. The results are presented as mean ± S.D. (n=3), *P<0.05, and **P<0.01, significantly 
different from control. 
 
 
3.4.16 Effect of compound A on BAEC tube formation 
Using the Matrigel assay system, the influence of compound A on endothelial cells 
tube formation was investigated (Figure 3.72). Representative photomicrographs of 
the tube formation in untreated cells without FBS (1), untreated cells cultured in 2.5% 
FBS (2), cells treated with FGF-2 (3) or 0.01 - 2μg/ml compound A (4 - 9) are shown. 
Compared to the untreated cells (negative control), FGF-2 used as a positive control 
to prove the cells’ ability to respond. Images were taken after 7 hours to capture the 
differences in the number of tubes formed. The results showed that compound A 
significantly (p<0.01) reduced the tube formation as seen by the reduction in tube-like 
structures. Thus, the cells were unable to migrate to form new capillary structures in 
the presence of compound A at concentrations of between 0.01 - 0.1μg/ml. In addition, 
the results showed more significant (p<0.001) in the reduction of the tube formation 
at concentrations of between 0.5 - 2μg/ml, with 90% as the maximum percentage 
inhibition. The inhibition was dose-dependent (Figure 3.73).    
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Figure 3.72: Photomicrographic showing the effect of compound A on BAEC tube formation. 
Photomicrographs showing the effect of compound A on BAEC (1 × 106/ml) tube formation in Matrigel 
(magnification × 100). Negative control (untreated cells) without FBS (1), untreated cells cultured in 
2.5% FBS (2), FGF-2 (25ng/ml) used as a positive control (3) or areas (4 – 9) show cells exposed to 
different concentrations of compound A (0.01 - 2μg/ml). After 7 hours, tubes had formed and the 
number of closed areas was counted from 5 random fields of 3 wells of a 96-well plate. This panel is a 
representative example of at least two independent experiments. 
 
 
 
 
Chapter 3 
 
 
164 
 
 
Figure 3.73: Effect of compound A on BAEC tube formation. 
Bar graph showing the effect of different concentrations of compound A on BAECs tube formation. 
The results are presented as mean ± S.D. (n=3), **P<0.01 and ***P<0.001, significantly different from 
control. 
 
 
3.4.17 Effect of SAC/NAC-loaded hADMSCs CM on BEAC wound healing  
This study designed to evaluate the therapeutic effect of SAC/NAC-loaded hADMSCs 
CM on BAEC wound healing (Figure 3.74). Representative photomicrographs show 
the migration of treated cells cultured in SCM (1), 2μg/ml SAC/NAC cultured in SCM 
(2), cells treated with CM- day 1 alone used as control (3), cells treated with CM- day 
2 alone used as control (4), 500μg/ml SAC/NAC-loaded hADMSCs CM- day 1 (5) or 
day 2 (6) are shown. Images were taken at time 0 and then after 24 hours to capture 
the differences in the number of cells that had migrated. The results show that 
500μg/ml SAC/NAC-primed hADMSCs CM- days 1 and 2 significantly (p< 0.05) 
induced the cell migration compared to control with distance migrated increasing to 
27.0  2.0mm and 25.0  1.0mm, respectively. In addition, compared to 2μg/ml 
SAC/NAC treatment with SCM, 500μg/ml SAC/NAC-primed hADMSCs CM- days 
1 and 2 significantly (p< 0.05) increased tube formation (Figure 3.75). 
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Figure 3.74: Photomicrographic showing the effect of SAC/NAC-loaded hADMSCs CM on 
BAEC wound healing. 
Photomicrographs 24 hours following wounding showing the effect of SAC/NAC-loaded hADMSCs 
CM (24 - 48 h) on BAEC (1 × 106/ml) migration were taken using phase contrast microscopy 
(magnification × 100). Untreated cells cultured in SCM (1), 2μg/ml SAC/NAC cultured in SCM (2), 
CM-day 1 (3), CM-day 2 (4), SAC/NAC-loaded hADMSCs CM-day 1 (5) or day 2 (6). The number of 
migrated cells in the denuded area was counted in 5 random areas per slide and averaged accordingly. 
This panel is representative of at least two independent experiments. SCM= stem cells medium, CM-
day 1= conditioned medium alone after 24h, CM- day 2= conditioned medium alone after 48h.  
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Figure 3.75: The effect of SAC/NAC-loaded hADMSCs CM on BAEC wound healing. 
Bar graph showing the effect of SAC/NAC-loaded hADMSCs CM on BAEC migration. The number 
of migrated cells in the denuded area was counted in 5 random areas per slide and averaged accordingly. 
The results are presented as mean ± S.D. (n=3), *P<0.05, significantly different from control. #P<0.05, 
significantly different from 2μg/ml SAC/NAC-treated cells.  
 
 
3.4.18 Effect of SAC/NAC-loaded hADMSCs CM on BAEC tube formation 
Using the Matrigel assay system, to evaluate the therapeutic effect of SAC/NAC-
primed hADMSCs CM on endothelial cells tube formation was investigated (Figure 
3.76). Representative photomicrographs show tube formation in cells cultured in SCM 
(1), 2μg/ml SAC/NAC cultured in SCM (2), cells treated with CM- day 1 alone used 
as control (3), cells treated with CM- day 2 alone used as control (4), 500μg/ml 
SAC/NAC-primed hADMSCs CM- day 1 (5) or day 2 (6) are shown. Images were 
taken after 7 hours to capture the differences in the number of tubes formed. The 
results showed that 500μg/ml SAC/NAC-loaded hADMSCs, CM- days 1 and 2 
significantly (p<0.05) induced cell tube formation compared to control. In addition, 
compared to 2μg/ml SAC/NAC treatment with SCM, 500μg/ml SAC/NAC-primed 
hADMSCs CM significantly promotes tube formation at days 1 (p< 0.01)  and 2 (p< 
0.05) (Figure 3.77). 
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Figure 3.76: Photomicrographic showing the effect of SAC/NAC-loaded hADMSCs CM on 
BAEC tube formation. 
Photomicrographs showing the effect of SAC/NAC-loaded hADMSCs CM (24 - 48 h) on BAEC (1 × 
106/ml) tube formation in Matrigel (magnification × 100). Untreated cells cultured in SCM (1), 2μg/ml 
SAC/NAC cultured in SCM (2), CM-day 1 (3), CM-day 2 (4), SAC/NAC-loaded hADMSCs CM-day 
1 (5) or day 2 (6). After 7 hours, tubes had formed and the number of closed areas was counted from 5 
random fields of 3 wells of a 96-well plate. This panel is a representative example of at least two 
independent experiments. SCM= stem cells medium, CM-day 1= stem cells conditioned medium alone 
after 24h, CM- day 2= stem cells conditioned medium alone after 48h. 
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Figure 3.77: Effect of SAC/NAC-loaded hADMSCs CM on BAEC tube formation. 
Bar graph showing the effect of SAC/NAC-loaded hADMSCs CM on BAEC tube formation. The 
results are presented as mean ± S.D. (n=3), *P<0.05, significantly different from control. #P<0.05 and 
##P<0.01, significantly different from 2μg/ml SAC/NAC-treated cells.  
 
 
3.4.19 Effect of compound A-loaded hADMSCs CM on BAEC wound healing  
To evaluate the therapeutic effect of compound A-primed hADMSCs CM on wound 
healing (Figure 3. 78).  Representative photomicrographs  are shown of the migration 
of cells cultured in SCM (1), 2μg/ml compound A cultured in SCM (2), cells treated 
with CM- day 1 alone used as control (3), cells treated with CM- day 2 alone used as 
control (4), 500μg/ml compound A-loaded hADMSCs CM- day 1 (5) or day 2 (6) are 
shown. Pictures were taken at time 0 and then after 24 hours to capture the differences 
in the number of cells migrated. The results show that 250μg/ml compound A-loaded 
hADMSCs CM significantly promoted cell migration at days 1 (p<0.01) and 2 
(p<0.05) compared to control. In addition, compared to 2μg/ml compound A treatment 
with SCM, 250μg/ml compound A-primed hADMSCs CM- days 1 and 2 a 
significantly (p< 0.01) increased cell migration (Figure 3.79). 
 
 
Chapter 3 
 
 
169 
 
 
Figure 3.78: Photomicrographic showing the effect of compound A-loaded hADMSCs CM on 
BAEC wound healing. 
Photomicrographs 24 hours following wounding showing the effect of compound A-loaded hADMSCs 
CM (24 - 48 h) on BAEC (1 × 106/ml) migration were taken using phase contrast microscopy 
(magnification × 100). Untreated cells cultured in SCM (1), 2μg/ml compound A (2), CM-day 1 (3), 
CM-day 2 (4), compound A-loaded hADMSCs CM-day 1 (5) or day 2 (6). The number of migrated 
cells in the denuded area was counted in 5 random areas per slide and averaged accordingly. This panel 
is representative of at least two independent experiments. SCM= stem cells medium, CM1-day 1= stem 
cells conditioned medium alone after 24h, CM2= stem cells conditioned medium alone after 48h.  
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Figure 3.79: Effect of compound A-loaded hADMSCs CM on BAEC wound healing. 
Bar graph showing the effect of compound A-loaded hADMSCs CM on BAEC migration. The results 
are presented as mean ± S.D. (n=3), *P<0.05, **P<0.01, significantly different from control. ##P<0.01, 
significantly different from 2μg/ml compound A-treated cells.  
 
 
3.4.20 Effect of compound A-loaded hADMSCs CM on BAEC tube formation  
To evaluate the therapeutic effect of compound A-primed hADMSCs CM on 
endothelial cells tube formation was investigated (Figure 3.80). Representative 
photomicrographs are shown of the tube formation in cells cultured with SCM (1), 
2μg/ml compound A cultured with SCM (2), cells treated with CM- day 1 alone used 
as control (3), cells treated with CM- day 2 alone used as control (4), 500μg/ml 
compound A-primed hADMSCs CM- day 1 (5) or day 2 (6) are shown. Images were 
taken after 7 hours to capture the differences in the number of tubes formed. The 
results show that 250μg/ml compound A-primed hADMSCs CM- days 1 and 2 
significantly (p<0.05) induced the cell tube formation compared to control. In 
addition, compare to 2μg/ml compound A treatment with SCM, 250μg/ml mimic 
compound A-primed hADMSCs CM- significantly (p<0.001) promotes tube 
formation at days 1 and 2 (Figure 3.81). 
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Figure 3.80: Photomicrographic showing the effect of compound A-loaded hADMSCs CM on 
BAEC tube formation. 
Photomicrographs showing the effect of compound A-loaded hADMSCs CM (24 - 48 h) on BAEC (1 
× 106/ml) tube formation in Matrigel (magnification × 100). Untreated cells cultured with SCM (1), 
2μg/ml compound A cultured with SCM (2), CM-day 1 (3), CM-day 2 (4), compound A-loaded 
hADMSCs CM-day 1 (5) or day 2 (6). After 7 hours, tubes had formed and the number of closed areas 
was counted from 5 random fields of 3 wells of a 96-well plate. This panel is a representative example 
of at least two independent experiments. SCM= stem cells medium, CM1-day 1= stem cells conditioned 
medium alone after 24h, CM2-day 2= stem cells conditioned medium alone after 48h.  
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Figure 3.81: The effect of compound A-loaded hADMSCs CM on BAEC tube formation. 
Bar graph showing the effect of compound A-loaded hADMSCs CM on BAEC tube formation. The 
results are presented as mean ± S.D. (n=3), *P<0.05, significantly different from control. #P<0.05 and 
##P<0.01, significantly different from 2μg/ml mimic compound A-treated cells.  
 
3.5 Analysis of hADMSCs-loaded CM with high performance liquid 
chromatography (HPLC)  
3.5.1 HPLC method development and optimisation 
For quantification with increased sensitivity, NAC was studied using the application 
of HPLC. According to the literature review, there are no reported methods for the 
estimation of NAC-loaded hADMSCs CM by HPLC. Hence, it was necessary to 
develop an accurate and selective HPLC method for the determination of NAC-loaded 
hADMSCs CM. In this experiment, an HPLC method with post-column NPM 
derivatisation was used as the starting point. Initially, using an HPLC column 
(Hypersil Elite. C18, 3.0mm x 100cm, particle size: 3μm) packing material. The 
injection volume was 10μl and fluorimetric detection was with an excitation 
wavelength of 330nm and an emission wavelength of 380nm. The reaction appeared 
as broad peaks (Figure 3.82, A). Increasing the length of the column was not preferred, 
as an increase in retention time gave increased peak broadening and a lower column 
temperature would exhibit poor separation and peak shape problems. In this case, it 
was desirable to decrease the plate height equivalent of a theoretical plate by 
decreasing the particle size of the stationary phase, which leads to an increase of the 
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separation efficiency of the HPLC column and the column temperature was increased 
to 60ºC to accelerate the degradation of the stationary phase. In addition, the injection 
volume was reduced to 1μl from 10μl to work with small volumes. Chromatographic 
separation of derivatised NAC was conducted on a C-18 column (4.6mm x 25cm, 3μm 
particle size) and NPM derivatives’ detection wavelength was measured by a 
fluorescence detector (FID) (λ ex = 330 nm and λ em = 376 nm) (Figure 3.82, B) 
(Lindsay, 1992).  
 
Figure 3.82: Chromatograms representing the specificity of the developed HPLC method. 
(A) Column used (Hypersil Elite. C18, 3.0mm x 100cm, particle size: 3μm), injection volume was 10μl 
and the column temperature was 25ºC, (B) Column used (Eclipsex DB. C18, 4.6mm x 25cm, particle 
size: 3μm), injection volume of 1μl and the column temperature increased to 60ºC. The NPM 
derivatives were measured by a fluorescence detector (FID) (λ ex = 330nm and λ em = 376nm).  
 
 
3.5.2 Calibration curves 
As shown in Figure 3.83, a calibration curve was constructed by plotting integrated 
peak areas versus standard NAC concentrations (100, 200, 300, 400 and 500μg/ml). 
Linearity for NAC standards was obtained only between 100-300μg/ml (r=0.9871). 
 
Chapter 3 
 
 
174 
 
 
Figure 3.83: Calibration curves of NAC with water. 
Column used (Eclipsex DB. C18, 4.6mm x 25cm, particle size: 3μm) with injection volume of 1μl and 
column temperature 60ºC. NAC concentrations were measured by a fluorescence detector (FID) (λ ex 
= 330nm and λ em = 376nm).  
 
3.5.3 Detection of NAC by UV-DAD  
The UV-DAD (photodiode array detection) spectra of aqueous solutions of NAC alone 
were recorded in the wavelength of Sig=230 and Ref=360nm. As compared to blank 
(Figure 3.84, A), the solution of NAC showed a peak at RT of 2.383min (Figure 3.84, 
B). Unfortunately, analysis of NAC without derivatisation did not permit a satisfactory 
separation and absorption at the ultraviolet wavelengths, nor did they exhibit 
fluorescence. Hence, NPM has been used as the fluorescent derivatising agent for 
many thiol compounds. 
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Figure 3.84: HPLC-DAD. 
(A) Blank (no peaks), (B) 500μg/ml NAC alone at RT of 2.383min. The column used (Eclipsex DB. 
C18, 4.6mm x 25cm, particle size: 3μm) with an injection volume of 1μl and column temperature of 
60ºC. NAC concentrations were measured by photodiode array detection (UV-DAD) (Sig=230, 
Ref=360 nm).  
 
 
3.5.4 HPLC analysis of NAC   
In order to quantify the NAC released by SAC/NAC- loaded hADMSCs, this 
experiment tested NAC by FID (flame ionisation detection) (λ ex = 330 nm and λ em 
= 376 nm) HPLC analysis. NAC was extracted using C18 solid phase extraction 
cartridges in cell media. These samples were then run through the HPLC to identify 
whether NAC was successfully extracted from the cell media and that there was a high 
enough recovery after the extraction process. In this study, SAC and mimic compound 
A were not analysed due to limited time and the unavailability of a detector for both 
of them.  In situ derivatisation of biological samples with NPM produced, an NPM-
NAC adduct which was rapidly separated by the HPLC system employed for this 
study. The chromatogram pictured in Figure 3.85 confirms that adequate separation of 
the NPM-NAC adduct from the hydrolysis peaks. When the analytical column was 
introduced into the system, the RT of NAC-NPM was approximately 6.34/6.393 min 
while NPM alone exhibited a peak at RT of 8.133/8.208min. After 24 hours, the 
500μg/ml NAC standard showed that the average peak area at RT of 5.647 min was 
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135.1LU (Figure 3.85, A). CM alone release by hADMSCs showed only the NPM 
peak and the average peak area was 7.668LU (Figure 3.85, B). The average peak area 
for CM from 500μg/ml SAC/NAC-primed hADMSCs collected on days 1 and 2 from 
3 tests at RT of 6.345 and 6.346min, respectively, were for both of them 110.1LU and 
NAC concentration was 149.75 and 124.21μg/ml, respectively (Figure 3.85, C and D). 
The results indicated that HPLC analysis could quantify NAC.  
 
 
Figure 3.85: Chromatograms of derivative samples. 
(A) Chromatogram of NAC 500μg/ml in water standard with NPM derivatives showing a NAC peak at 
RT of 5.647min, (B) Chromatogram of CM alone released by hADMSCs showing NMP peak at RT of 
7.66min (no NAC-NPM peak), (C) Chromatogram of 500μg/ml SAC/NAC-primed hADMSCs CM 
after 24hours, showing NAC-NPM peak at RT of 6.345min and calculated NAC concentration was 
149.75μg/ml and (D) Chromatogram of 500μg/ml SAC/NAC-primed hADMSCs CM after 48 hours, 
showing NAC-NPM peak at RT of 6.346min and the calculated NAC concentration was 124.21μg/ml. 
The column used (Eclipsex DB. C18, 4.6mm x 25cm, particle size: 3μm) with an injection volume of 
1μl and the column temperature was 60ºC. The NAC-NPM derivatives were measured by a fluorescence 
detector (FID) (λ ex = 330nm and λ em = 376nm)
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Chapter 4 - Discussion 
4.1 Detection of AGEs 
Advanced glycation end products can be generated from the amino residues of 
proteins, lipids and DNA through several different mechanisms. Such mechanisms 
include non-enzymatic glycation by glucose and reactions with metabolic 
intermediates and reactive dicarbonyl intermediates (MG and glyoxal). Consequently, 
these reactions not only alter the form and structure of the proteins but also lead to 
intramolecular and intermolecular cross-link production. The accumulation of cross-
linked AGEs in biological compartments such as tissues and plasma plays a vital role 
in long-term complications associated with diabetes mellitus  (Wu et al., 2009; Genuth 
et al., 2015).  
 
Several studies have highlighted the benefits of using medicinal plants for inhibiting 
AGE formation, and may, therefore, provide protection to alleviate the development 
of such complications (Kaewkamson et al., 2007; Wang et al., 2009; Parveen et al., 
2017). In addition, these naturally derived chemicals also contribute to improved 
intercellular drug delivery, which is considered an important factor in attaining good 
therapeutic effects (Jeetah et al., 2014). In this regard, extensive studies were carried 
out on garlic, which has a very long history of use as both a food and medicinal plant 
(Rivlin, 2001; Bozin et al., 2008; Cardelle-Cobas et al., 2010). Notably, garlic is 
available in different formulations, with one such preparation being aged garlic extract 
(Agarwal et al., 2004; Cardelle-Cobas et al., 2010; Arreola et al., 2015).  
 
In this study, protein glycation was established in vitro by incubation of proteins with 
a reducing sugar (MG) at physiological pH for various time intervals. Lysozyme is a 
popular protein for the detection of cross-linked AGE production, as oligomerisation 
occurs readily and is easily measurable by SDS-PAGE techniques. A number of 
researchers have examined the glycation of lysozyme in vitro (Kislinger et al., 2004; 
Muthenna et al., 2012; Adisakwattana et al., 2012; Mariño et al., 2017). Lysozyme 
consists of 6 lysines and 11 arginines per molecule, and modifications of these residues 
can be achieved by both glucose and MG. The results of SDS-PAGE illustrate that 
elevated cross-linked AGE formation is correlated with glucose concentration and the 
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period of incubation. This finding is consistent with a previous study which found that 
high AGE cross- link  formation was correlated with increased glucose levels and 
incubation time (Mashilipa et al., 2011). 
 
Like other workers, this study has also demonstrated that exposure of proteins to MG 
reacts relatively rapidly with proteins and induces crosslinking to form AGEs. It was 
suggested that glycation by MG is increased disproportionately compared to the 
increase in glucose concentration in experimental and clinical diabetes (Ahmed, 
2005). This may be attributed to the formation of MG from triosephosphate 
accumulation in vascular cells suffering cytosolic hyperglycaemia (Brownlee, 2001;  
Thornalley, 2008; Gaens et al., 2013). Moreover, the other important features of MG 
are its ability to bind with sulphydryl, amino, lysine and arginine functional groups in 
protein molecules (Richarme et al., 2015). In this respect, MG-induced generation of 
AGEs has contributed to the progression and development of diabetic microvascular 
complications such as neuropathy, retinopathy and atherosclerosis (Chawla et al., 
2016) and the concentration of MG is elevated during diabetes (Kong et al., 2014; 
Moraru et al., 2018). Moreover, MG is recognised as a toxic agent (Lee and Park, 
2017) and its toxicity is mainly associated with cell apoptosis (Di Loreto et al., 2008) 
in a variety of cells, including endothelial cells, epithelial cells, human leukaemia 
cells, Schwann cells, osteoblasts and rat hippocampal cells (Kim et al., 2014; Seo et 
al., 2014; Tajes et al., 2014; Chan et al., 2016).  
 
During this study, the potential benefits of using SAC and/or NAC derived from 
natural sources were assessed in a lysozyme-MG system in vitro. The formation of 
cross-linked AGEs was induced by incubation of proteins with MG (Klöpfer et al., 
2010). The results obtained from cross-linking assays suggested that cross-linking 
between the binding of reducing sugars to protein occurred during AGE formation. 
Using SAC and/or NAC displayed potent inhibitory effects on AGE formation. 
Furthermore, findings from the present study also indicate that these inhibitors have 
the potent ability to prevent protein glycation by MG. The inhibition of MG-derived 
AGEs by SAC/NAC produce a synergistic effect when compared with SAC or NAC 
alone. This inhibitory effect may occur at any stage in the glycation reaction such as 
to compete for the amino groups on the protein, bind to the protein or to the glycation 
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intermediates to stop the progression up to the AGE formation stage (Brownson and 
Hipkiss, 2000; Harding and Ganea, 2006; Younus and Anwar, 2016). This is in 
agreement with previous work by Ahmad et al. (2007) who demonstrated that aged 
garlic extract and SAC effectively inhibit AGEs formation in vitro.  
 
In this study, synthetic mimic compounds A, B and C were tested for their 
antiglycation activates. These compounds are small molecules inhibitor- mimics of 
SAC and NAC. This is the first study to evaluate the effect of these compounds on 
AGE formation. Incubation of lysozyme glycated with MG in the presence and /or 
absence of compounds A, B and C showed potent inhibitory effect on the formation 
of AGEs. The basic structure of compounds A, B and C have many functional groups. 
Therefore, they may have excellent antiglycation and MG trapping ability. 
 
Structurally, compound A [(R) S-Benzyl-L-cysteine] with one benzene ring, an amino 
group and carbonyl group showed better ability to inhibit AGE formation than 
compounds B and C. However, its antiglycation ability may have been dependent upon 
its unique phenolic structure and the number and position of the hydroxyl and amino 
groups. Despite the fact that compound B does not possess the essential functional 
groups like benzene ring, its antiglycation activity was stronger than compound C.  
Compound C [(R) S-triphenylmethyl cysteine] is more fat-soluble compound than 
compound A. Theoretically, compound C with three benzene rings, amino group and 
carbonyl group should produce the highest antiglycation activity. Therefore, it may be 
that the three benzene rings in compound C do not have the required structure, which 
attributed to these results. In addition, it is thought that acidic and /or basic amino 
acids play an important role in the antiglycation activity and different positions of the 
carboxylic group may produce different effects. Therefore, compound A was used in 
future experiments. However, to our knowledge, this is the first study demonstrating 
the ability of SAC/NAC as a mixture and compound A to inhibit the formation of 
cross-linked AGE in vitro. 
 
The detection of fluorescence to study the effects of different glucose concentrations 
on AGE production also confirmed the previous findings with SDS-PAGE techniques. 
The measurement of fluorescence intensity as a parameter to study the effects of 
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SAC/NAC on cross-linked AGE formation was not possible because SAC/NAC do 
not exhibit satisfactory absorption at visible or ultraviolet wavelengths, nor do they 
exhibit fluorescence (Lee et al., 2014). Other limitations are in terms of sensitivity or 
procedures being time-consuming (Ercal et al., 1996). Therefore, other methods were 
used to study the effects of SAC/NAC on the formation of cross-linked AGEs. 
Furthermore, comparative studies were conducted between SAC/NAC and compound 
A using ELISA. Since MG is an important reactive intermediate of AGEs’ generation, 
its elimination may hinder AGE production in biological systems.  
 
As shown in the ELISA assay, after BAECs were exposed to 300μΜ MG, the AGEs 
formation was significantly increased in the cell medium. However, the MG-induced 
AGE formation was markedly inhibited by the treatment with SAC/NAC and 
compound A, with the results being comparable to the positive control. Furthermore, 
a recent study tested the effect of 200μM NAC on HaCaT exposed to 400μM MG for 
48 hours, and showed that NAC inhibited MG-induced AGE formation (Yang et al., 
2017). 
  
Different strategies have been proposed to reverse the effect of AGEs, focusing on the 
prevention of the formation of AGE cross-links or even the development of AGEs 
(Elosta et al., 2012). The results obtained from both SDS-PAGE-silver stain and 
Western blot assays showed that SAC/NAC and compound A inhibited the formation 
of AGEs and this is in agreement with previous studies demonstrating that aged garlic 
extract and SAC effectively inhibit AGE formation in vitro in dose-dependent (Ahmad 
et al., 2007).  
 
Analysis of SDS-PAGE revealed the abilities of SAC/NAC and compound A to inhibit 
AGE formation decreased in the order of compound A> SAC/NAC > SAC > NAC. In 
all tested concentrations, compound A has more potent effects when compared with 
SAC/NAC against glycation-derived protein cross-linking. These results suggest that 
other functional groups may be present in compound A, which gives its antiglycation 
activity, although these groups have not yet been determined.  
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It was further suggested that the antiglycation activity of aged garlic extract is mainly 
due to its organosulphur compounds. The latter is derived from garlic; 
DAS, SEC, SAC and NAC, and have been found to protect LDL against oxidation and 
glycation. This may, therefore, explain why garlic protects against cardiovascular 
disease in healthy individuals (Ou et al., 2003). 
 
In addition, organosulphur compounds, including SAC and NAC, are well known to 
exhibit free-radical scavenging effects (Colín-González et al., 2012,; Dewi et al., 
2017). This antioxidant property of aged garlic extract may be, at least in part, involved 
in the AGE-inhibitory mechanisms. For this reason, various comparative studies 
between SAC, NAC and compound A were conducted in this study. However, the 
antioxidant properties of SAC, NAC and compound A have not been elucidated in this 
study. Chemically, NAC is derived from L-cysteine, whose amino-group is acetylated. 
It was reported that L-cysteine, as well as its metabolite H2S, is decreased in African 
Americans with Type 2 DM (Jain et al., 2015). Although NAC is a well-known thiol 
compound used in chronic obstructive pulmonary disease because it possesses a free 
sulphydryl group through which it reduces disulfide bonds conferring antioxidant 
effects; NAC possesses other beneficial effects on glucose and lipid metabolism 
(Yongjie Ma et al., 2016). 
 
The possible reason for the inhibition of AGE formation in samples treated with 
different concentrations of SAC/NAC and compound A was that such inhibitors might 
have the ability to modify the carbonyl or amino groups in the glycation reaction, 
which therefore results in the inhibition of AGE formation.  
 
4.2 Angiogenesis 
The angiogenic process is tightly regulated and can be triggered by some pathological 
processes such as diabetic angiogenesis. The prevalence of diabetes mellitus and 
diabetic vascular complications are largely associated with mortality and disability. 
The formation of tube-like structures in endothelial cells is another crucial step of 
angiogenesis (Xie et al., 2016). The tube formation assay is a rapid and quantitative 
method for determining genes or pathways involved in angiogenesis. In the later stages 
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of angiogenesis, endothelial cells differentiate into tubular-like structures, which 
eventually form the lumen of new blood vessels. Tube formation occurs quickly with 
most tubes forming in this assay within 2 - 6 hours, depending on the quantity and 
type of angiogenic stimuli (DeCicco-Skinner et al., 2014). 
 
This study has mainly examined the effect of glucose, AGEs, SAC/NAC and 
compound A on the paradoxical phenomena of angiogenesis and its underlying 
mechanism of migration and capillary loop formation of endothelial cells. FGF-2 is a 
pro-angiogenic factor that stimulates the proliferation, migration and tube formation 
of the endothelial cell at the concentration of 25ng/ml (Hussain et al., 2009). Hence, 
in the current study, it was used as a positive control. Although the migration and tube 
formation results show that FGF-2 greatly increased cell invasion compared to 
untreated cells, its effect has not been examined in the presence of the inhibitors 
including, glucose, AGEs, SAC/NAC and compound A. 
 
It is well established in DM, that hyperglycaemia usually ranges from 6 to 30mM 
glucose and, in severe conditions the levels may reach at 55mM (Facchiano et al., 
2006). In this study, concentrations of 15 - 100mM of glucose have been chosen to 
represent a range corresponding to moderate to severe diabetic conditions (J. Zhang et 
al., 2006). Although these concentrations approach the upper limit of those seen in 
physiological conditions, this takes into account that the normal ideal growth 
conditions for endothelial cells in vitro include medium supplementation with 25mM 
glucose. This concentration is similar to that used in similar studies investigating the 
effects of glucose on protein glycation and oxidative stress in macrovessel and 
microvessel endothelial cells (Paget et al., 1998; Padayatti et al., 2001).   
 
The effect of high glucose on BAEC migration was evaluated using the in vitro wound 
healing assay. The results demonstrated that 25 - 100mM glucose inhibits the 
migratory abilities of endothelial cells and that these effects occurred in a dose-
dependent manner compared to controls (Fig. 3.42). The effect of glucose on BAEC 
may induce oxidative stress through inactivation of antioxidant enzymes and glycation 
(Buranasin et al., 2018). Moreover, these results were in agreement with those of other 
studies showing that high glucose concentration (75mM) significantly inhibited cell 
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migration (Buranasin et al., 2018). However, Lamers et al. (2011) found that glucose, 
at lower concentration 25mM, impairs cell migration in Chinese hamster 
ovary (CHO) cells (CHO.K1) and mouse embryonic fibroblasts (NIH-3T3) due to an 
increase in oxidative stress that causes polarity loss, deficient adhesion and protrusion.  
 
Sustained high glucose environments can cause abrogation of the cell migration and 
tube formation as well (Qiu et al., 2018). In accordance with previous studies, this 
work also showed that glucose inhibits tube formation by endothelial cells in vitro. 
When BAECs were cultured on polymerised Matrigel, they were organised into such 
tube like-structures. However, when BAECs were cultured on polymerised Matrigel 
in the presence of glucose (25 - 100mM), the cells failed to organise into capillary-
like structures. These effects occurred in a dose-dependent manner compared to 
controls. Song et al. (2017) found that the ability of HUVECs to form vascular-like 
structures was inhibited under high glucose or in the presence of AGEs. By mean of 
RNA interference, the expression of inhibitory genes can promote neovascularisation 
in the diabetic environment. The abnormal activation mechanism of barriers to 
angiogenesis in refractory diabetic wounds. 
  
The migration of endothelial cells is one of the critical features in the formation of 
new blood vessels and in the repair of injured vessels. Therefore, another approach in 
this study was to determine whether SAC/NAC and compound A induce or inhibit the 
migration process of BAECs. The in vitro wound-healing assay showed that both 
SAC/NAC and compound A, at concentrations of between 0.1 - 2μg/ml, inhibited 
BAEC migration in a dose-response manner. The involvement of aged garlic extract 
in cell migration had already investigated by Nariaki Matsuura et al. (2006)  who 
tested its effects on cell functions associated with migration. Their data showed that 
aged garlic extract is able to enhance the adhesion of endothelial cells to collagen and 
fibronectin. Furthermore, suppressed cell motility and invasion in the wound-healing 
assay. SAC suppressed the migration of human epithelial ovarian cancer cell line 
A2780 in a dose-dependent manner (Xu et al., 2014), HUVEC (Lee et al., 2015) and 
T24 bladder cancer cells (Supabphol et al., 2009). 
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Aged garlic extract produces several pharmacological effects, including the inhibition 
of tumour cell growth and chemopreventive effects (Kyo et al., 2001). It could prevent 
tumour formation by inhibiting angiogenesis through the suppression of endothelial 
cell motility, proliferation, and tube formation (Matsuura et al., 2006). This study 
found that in the in vitro tube formation assay, SAC/NAC and compound A, at 
concentrations of between 0.1 - 2μg/ml, are also capable of destroying vascular 
networks formed on Matrigel.  Recently, SAC (100μM) was found to enhance the 
formation of new blood vessels derived from EPCs (Syu et al., 2017). Alliin was 
shown to induced-tube formation and angiogenesis in HUVECs and ex vivo in the 
CAM assay (Matsuura et al., 2006). NAC reduced VEGF-induced tube formation of 
endothelial cells (Lee et al., 2015). However, previous studies showed that SAC 
(Matsuura et al., 2006; Pandrangi, 2015; Haghi et al., 2017) and NAC (Cai et al., 
1999; Zafarullah et al., 2003; Zhang et al., 2018) promote cellular migration. Thus, 
further studies are required to determine the underlying mechanisms of these 
inhibitors.   
 
In this study, SAC/NAC and compound A (0.01 - 2μg/ml) incubated with glucose 
(75mM) were found to dramatically inhibit BAECs to undergo cell migration at all 
concentrations in vitro. Lamers et al. (2011) showed that the 25mM glucose effects 
were partially or completely reversed in CHO.K1and NIH-3T3 cell migration by 
treatment with 10mM NAC.  These results could be due to the high NAC concentration 
used and the concentration at which NAC is effective, varying on the cell type 
(Sadowska et al., 2007; Buranasin et al., 2018). Exposure of HaCaT cells to 400μM 
MG markedly suppressed cell migration. However, this was alleviated by pretreatment 
with 200μM NAC (Yang et al., 2017).  
 
It has been reported that hyperglycaemia-induced oxidative stress increases ROS 
formation in type 2 diabetic mouse model (Furukawa et al., 2017). Furthermore, It has 
been shown that treatment with a high concentration of NAC (1mM) could restore cell 
migration and proliferation in human gingival fibroblast cells (HGFs) grown at high 
glucose concentrations (50mM), while lower concentrations of NAC (100μM and 
500μM) produce the opposite effects (Buranasin et al., 2018). However, the 
mechanism through which excess glucose results in endothelial damage has not been 
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well elucidated. Incubation of SAC/NAC and compound A (0.01-2μg/ml) with 
glucose (75mM) was found to inhibit BAEC tube formation in vitro. This study has 
shown that prolonged exposure to elevated glucose reduced endothelial-dependent 
relaxation and delayed cell migration in cultured endothelial cells. This was coincident 
to other findings in normal blood vessels (Control and Group, 1993; Guo et al., 2000; 
J. Zhang et al., 2006). The results obtained from cell migration and tube formation 
showed that SAC/NAC and compound A in combination with glucose showed more 
inhibition effect than glucose alone.  
 
Increasing evidence from in vitro and in vivo studies have shown that the biochemical 
process of AGE formation, which is accelerated in diabetes as a result of chronic 
hyperglycaemia, is responsible for the development of diabetic complications 
(Yamagishi and Imaizumi, 2005; Goh and Cooper, 2008; Saeidnia and Abdollahi, 
2013; Aljohi et al., 2018; Rhee and Kim, 2018). This has, accordingly, led to the 
hypothesis that protein glycation, through the formation of AGEs, may play a role in 
angiogenesis (Stitt et al., 2005; Oak et al., 2009). AGE-modified BSA (BSA-AGE) 
has been used for studying AGE toxicity on a number of cell types (McCarthy et al., 
1997; Yui et al., 1994)  and shown to be toxic to mesangial cells (Trachtman et al., 
1994), BAECs (Duraisamy et al., 2003)  and retinal pericytes (Yamagishi et al., 1995). 
This toxicity is mediated via the production of free radicals, particularly when AGEs 
interact with their receptors on the cell surface (Naka et al., 2004; Rojas and Morales, 
2004).  
 
In the present study, the results showed that BSA-AGEs at concentrations of 15 – 
50μg/ml, inhibited the number of migrated cells. This range was selected as it may 
represent the lowest plasma AGE level found in diabetic patients (Xu et al., 2003). 
BSA-AGEs were used at 50μg/ml for the study, which is considered not toxic to 
BAECs, in agreement with Chibber et al. (1997) who show that BSA-AGEs are toxic 
to BAECs only at concentrations higher than 62.5µg/ml. Also, Makita et al. (1992) 
stated that human serum AGE levels were elevated more than two-fold in diabetic 
patients (~25μg/ml), and almost eight-fold in diabetic patients on haemodialysis 
(~80μg/ml) in comparison with normal patients. Moreover, BSA-AGEs have been 
used extensively in order to study the changes induced by protein glycation on several 
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cell lines and tissues (McCance et al., 1993; McCarthy et al., 1997; Franke et al., 
2009). In addition, a recent study showed that high concentrations of BSA-AGEs have 
been reported to impair cell migration by bone marrow-derived endothelial progenitor 
cells (Aljohi et al., 2018). Another study by Sharaf et al. (2015) showed that the 
concentration range between 25–200μg/ml of MG-BSA-AGEs significantly increased 
the distance of cell migration of the MDA-MB-231 breast cancer cell line in a dose-
dependent manner, with a peak at 50μg/ml. 
 
AGEs have been observed to accumulate around vessels in the skin, which leads to 
impaired angiogenesis. Angiogenesis, including endothelial proliferation, migration 
and capillary tube-like formation, is regulated by many angiogenic factors (Song et 
al., 2017). HUVECs exposed to high glucose and AGE concentration, have an 
impaired ability to form capillary-like assemblies in the tube formation assay was 
observed (Song et al., 2017; Wang et al., 2017). This study confirms that a high 
concentration of BSA-AGEs has been reported to inhibit tube formation. This is in 
agreement with previous studies who showed the same inhibitory effect of BSA-AGEs 
on tube formation  (Wang et al., 2005; Aljohi et al., 2018). 
  
The angiogenic effect of AGEs on ECs has been elucidated for several decades. It has 
been shown that the accumulation of serum AGEs in diabetes increases the severity of 
vascular complications (Goh and Cooper, 2008). Previous studies have confirmed that 
the interaction of AGEs and receptor RAGE is correlated with angiogenesis 
(Yamagishi et al., 2008; Ko et al., 2014). However, previous reports have debated 
whether AGEs exert pro-angiogenic or anti-angiogenic effects. Devi and Sudhakaran 
(2011) have demonstrated that different cell environments exert opposite effects on 
AGE-induced angiogenesis, while Wang et al. (2016) confirmed pro-angiogenic 
effects of AGEs in HUVECs by showing that BSA-AGEs induced increased 
angiogenesis.   
 
In the present study, it has been shown that 25 - 50μg/ml of BSA-AGEs inhibited tube 
formation by BAECs. Moreover, BSA-AGEs caused a modest, but consistent, 
decrease in tube formation, the same BSA-AGEs concentration (50μg/ml) giving a 
maximal effect. This concentration of BSA-AGEs was comparable with that of the in 
Chapter 4 
 
 
187 
 
vivo situation in diabetes (Chen et al., 2009). Reduced formation of tube-like structures 
by BAECs incubated under hyperglycaemic conditions suggests that the endothelial 
cell dysfunction in hyperglycaemia may contribute to decreased angiogenesis, which 
is mediated by glycation of cellular proteins (Ahmed et al., 2008). The inhibition of 
tube formation in BAECs clearly shows that the effects observed with BSA-AGEs are 
due to their glycated moiety (Gallicchio et al., 2006).  
 
Previous studies report that BSA-AGEs may produce several biological effects in 
terms of the cultured cell including endothelial cell migration and tube formation 
(Tezuka et al., 1993). Different cell environments exert opposite effects on AGE-
induced angiogenesis. In a study by Wang et al. (2016) on HUVECs, they confirmed 
the pro-angiogenic effects of AGEs by showing that BSA-AGEs induced increased 
angiogenesis. The increase of hydroimidazolone, one of the components of AGEs, in 
the vitreous humour and serum has been demonstrated to be associated with 
proliferative diabetic retinopathy (PDR). In addition,  Matsuura et al. (2006) reported 
that AGEs potently inhibited the tube formation of endothelial cells. The ability of 
HUVECs to form vascular-like structures was inhibited under high glucose and AGEs 
environments. The inhibition is relative to the factors Ang-2 and VEGF; Tie-2 receptor 
differential expression in cells also has a certain effect on the regulation of 
angiogenesis under high glucose and AGEs environments (Song et al., 2017). 
 
Surprisingly, this study also illustrated that the addition of 1-2μg/ml SAC/NAC and 
0.5-2μg/ml compound A reversed the BSA-AGE anti-angiogenic effect on cell 
migration. This reactivity is justified because the AGE formation’s being arrested by 
SAC/NAC and compound A may occur through blocking of AGE formation. A similar 
finding was obtained when the Momordica charantia (MC)  was used in combination 
with AGEs  (Aljohi et al., 2018). NAC, an intracellular radical scavenger, completely 
prevented the inhibitory effects of AGEs on protein synthesis (Yamagishi et al., 2003). 
 
Similarly, the addition of 0.5-2μg/ml SAC/NAC and 0.5-2μg/ml compound A, 
combined with BSA-AGEs in BAEC showed an increase in angiogenesis. They 
formed short, thick capillary-like networks that seemed to be indicative of an early 
stage of angiogenic development. One explanation for these speculative results may 
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be that SAC/NAC and compound A act as AGE inhibitors by blocking AGE 
formation. A  similar finding using MC was illustrated by Aljohi et al. (2018). The in 
vitro administration of NAC inhibited MG-induced AGE generation in skin 
keratinocytes. Importantly, the treatment with NAC significantly reduced MG-
triggered inflammatory injury, mitochondrial dysfunction and impairment of cellular 
behavioural action. Further results revealed that the blockage of NAC on MG-induced 
inflammatory injury was mediated by RAGE, which indicates that the administration 
of NAC can attenuate DM-related dermal injury through the inhibition of AGE/RAGE 
signals (Yang et al., 2017). 
 
In the present study, the results demonstrated that SAC/NAC (500μg/ml) and 
compound A (250μg/ml) were not toxic and induced hADMSCs to release these 
inhibitory drugs in the dosage sufficient to inhibit the glycation induced by MG in 
endothelial cells. Therefore, SAC/NAC- and compound A-loaded hADMSCs CM 
might be employed to protect endothelial cells from AGE hyperactivity-induced 
toxicity caused by intracellular AGEs under the exposure to stress, such as oxidative 
stress and inflammation. 
 
 4.3 HPLC 
Several studies have focused on HPLC with the fluorometric detection of derivatives 
of NAC (Gabard and Mascher, 1991). Several methods have been proposed for the 
measurement of NAC, but they have practical limitations in terms of sensitivity or 
time-consuming procedures (Ercal et al., 1996). In this study, the development of a 
new HPLC method for measuring biological thiols, which incorporated the 
derivatising agent NMP (Winters et al., 1995). NPM readily reacts with free 
sulphydryl groups to form fluorescent derivatives. This method afforded substantial 
improvements in rapidity of analysis and ease of use. However, the NAC assay 
described in the present study may prove useful to the extent that it can be run under 
ambient conditions, requires only about 18 min per sample to run, is susceptible to 
automation being an HPLC method, but linearity for the NAC standards was obtained 
only between 100-300μg/ml (r=0.9871). The results obtained from HPLC indicated 
the quantity of NAC released from hADMSCs were enough for the protection against 
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the ECs damage from AGEs. However, the HPLC method to detect NAC still needs 
to be developed for further study. 
  
The use of hADMSCs as an active targeted-delivery vehicle for therapeutic agents is 
especially attractive because they have proven to be permissive to small compound 
incorporation, and are immune-protective and pathotrophic. Considering the limited 
number of hADMSCs which can be delivered in vivo, it is important to have enough 
drug incorporated into them in order to achieve a therapeutic drug concentration in the 
targeted tissues (Janowski et al., 2015). Numerous studies on the uptake of 
nanoparticles in hADMSCs have shown that the internalisation of nanoparticles can 
be improved by their modification, size control, proper incubation time and 
concentration (Auffinger et al., 2013). To be effective, a therapeutic vehicle must 
primarily be stably loaded inside the cell carrier and then be released into the 
extracellular space gradually and steadily, instead of instant release into the systemic 
circulation prior to the cells’ reaching the target site. Thereby, it gives time for the cell 
carrier to migrate towards the wound regions and reach as many target cells as possible 
after the systemic delivery.  
 
It is also critical to ensure that drug loading does not affect the viability of hADMSCs 
and endothelial cells or their native properties, especially their pathotrophic ones. 
Several studies have proved that loading anticancer-drug nanoparticles, or even 
chemotherapeutic drugs, does not affect the short-term or long-term viability of MSCs 
(Auffinger et al., 2013; Pascucci et al., 2014; Fang et al., 2016). This work also 
confirmed that neither SAC/NAC nor compound A loading affects the viability of 
hADMSCs. In vitro transwell experiments have demonstrated that nanoparticle- 
loaded MSCs still possess the migration capacity towards chemoattractant and 
endothelial cells (Huang et al., 2013; Landázuri et al., 2013; Sadhukha et al., 2014; 
Fang et al., 2016).  
 
In the present study, the combination of SAC/NAC, compound A, SAC/NAC- and 
compound A-loaded hADMSCs CM were examined by SDS-PAGE-silver stain and 
Western blot to show whether these inhibited the glycation activity in endothelial cells. 
The results showed that SAC/NAC, compound A, SAC/NAC- and compound A-
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loaded hADMSCs CM potent effective at inhibiting the formation of cross-linked 
AGEs in vitro. In addition, the uptake of SAC/NAC and compound A in hADMSCs 
increased in a time-dependent manner, starting from 24-hour incubation and gradually 
enriching the cytoplasm up to 48 hours of priming. After internalisation, SAC/NAC 
and compound A-loaded hADMSCs continuously released SAC/NAC and compound 
A into the medium for 4 days, with the peak release within the first 24 hours. The 
incorporation and release kinetics of nanoparticles in MSCs for the treatment of 
malignant glioma revealed that nanoparticles demonstrated an initial burst of release 
from cells within the first 4 hours followed by a steady release over 9 days (Sadhukha 
et al., 2014). These findings were supported by a previous study conducted on BAECs 
to determine the effect of another inhibitor, P5, and P5-primed MSCs. The results from 
this study showed that the P5 was able to significantly inhibit calcium-induced CDK5 
activity, reduce cell number and apoptosis markers (Fang et al., 2016). In addition, a 
recent study tested the effect of 200μM NAC on HaCaT cells exposed to 400μM MG 
for 48 hours showed that NAC inhibited MG-induced AGE (Yang et al., 2017). 
 
Parekkadan and Milwid (2010) confirmed the therapeutic hypothesis that collection 
of bioactive molecules could be used as treatment. This can be done by collecting the 
molecules secreted in MSC-conditioned medium (MSC-CM) and administering them 
intravenously in a concentrated form in a single bolus dose to animals after the 
induction of disease. They also engineered a delivery platform for the continuous and 
dynamic administration of these molecules into the bloodstream.  It was found that 
this treatment method provided an improved survival benefit of 71% compared with 
14% in controls. In addition, other studies have suggested that pre-treatment of target 
cells, such as by gene editing, can change the secretion characteristics and function of 
the exosomes. It is believed that, after pre-treatment, MSCs may be the ideal drug or 
gene delivery media (Kim et al., 2007; Yu et al., 2013). 
 
The important novel findings from the current study demonstrate that SAC/NAC- and 
compound A-loaded hADMSCs CM was able to promote cell migration and tube 
formation considerably. This could mean that the secretions from hADMSCs contain 
diverse cytokines, such as EGF, VEGF, HGF, bFGF, GDNF, angiogenin and IL-8, 
which have shown their capabilities in promoting angiogenesis (Du et al., 2016). 
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Notably, drugs released from hADMSCs are capable of keeping their bioactivities. 
The findings described herein make these cells interesting candidates for drug delivery 
vehicles. Also, they are able to play protective roles against endothelial cell damage 
by AGEs under specific culture condition in vitro. In addition, SAC/NAC and 
compound A incubated with SCM have been shown to induce the migration and tube 
formation abilities of endothelial cells compared to control. In this study, used 
hADMSCs as a drug carrier in order to release SAC/NAC and compound A which 
provide to protect the cells against AGEs damage.  
   
Wu et al. (2007) reported that injection of BMSCs significantly enhanced the wound 
closure and strength in a diabetic mouse model for wound healing. PARK et al. (2008) 
showed that used ASC-CM increased collagen synthesis leading to improve the 
outcome of wound healing. Further analysis revealed increased collagen production 
and altered gene expression with CM obtained from ASCs (Kim et al., 2007; Lee et 
al., 2009). Barcelos et al. (2009) demonstrated the efficacy of local therapy with 
human fetal aorta-derived CD133₊  progenitor cells and their CM in a preclinical 
model of DFU. Taken together, the above findings indicate that ASCs release effective 
factors and can stimulate recruitment, migration, and proliferation of endogenous cells 
in the wound environment. Consequently, Paracrine factors’ secretion from ASCs was 
related to promote angiogenesis, epithelialization, and tissue remodelling through 
during wound repair (Hassan et al., 2014). 
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Chapter 5 – Conclusion and Future work 
5.1 Conclusion 
The findings of the current study have demonstrated that protein glycation causes 
cross-linked that fundamentally influence the physical and chemical properties of 
proteins. The degree of protein glycation is concentration-dependent. These data 
support the contribution of protein glycation in the development of diabetic 
complications. However, the process of glycation and the damage caused by AGEs 
may be reduced with the use of antiglycation agents. The present study was conducted 
to evaluate the antiglycation activities of several inhibitors including SAC, NAC and 
compound A. The data presented in this study clearly indicate that both SAC/NAC 
and compound A can effectively protect against MG-mediated protein modification in 
vitro, possibly due to their interaction with α-oxoaldehydes generated during the 
glycation process. The work contained within this thesis has highlighted the potential 
of hADMSCs as an applied therapy for wound healing.  
The most promising area of this section of the study is the development towards a 
successful methodology for the quantification of drug release from hADMSCs by 
HPLC. If this methodology can be finalised, the possible applications in the 
development of stem cells as a means of drug delivery would be extremely significant.  
In conclusion, hADMSCs provide a highly attractive option for the treatment of 
diabetic wound healing due to their many natural characteristics and their potential to 
be applied as a combinational therapy. The successful delivery of drugs such as 
SAC/NAC and compound A in combination and using a target method, could be an 
effective way to stimulate wound healing.  
5.2 Limitations 
1. An in vivo study on the effect of SAC/NAC and compound A on diabetic patients 
wound healing was not included. Further investigation into the effect of 
SAC/NAC and compound A in vivo is certainly required  
2. Unavailable detector for SAC and compound A  
3. To our limited knowledge, there has been no report relevant to the effects of 
SAC/NAC- loaded hADMSCs CM on wound healing  
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5.3 Future work 
1. Further studies relating to the current work that can be pursued include: 
 New techniques, such as mass spectrometry or nuclear magnetic resonance, 
may be used for the structural determination of AGEs 
 The bioavailability of SAC/NAC and compound A, and their ability to inhibit 
AGE formation require further investigation using specific biomarkers 
 The examination of the effects of BSA-AGEs, SAC/NAC and compound A 
on FGF-2-induced BAEC modification 
 A further, more in-depth, study with greater focus on the quantification of 
AGEs in diabetic tissues, and their functional effects on cell signalling 
 Further HPLC methodology for NAC development 
 SAC/NAC, compounds A, B and C could be further studied for their 
antioxidant activity 
2. Investigate the anti-inflammation of IL-1RA-primed MSCs 
 Assess the mRNA and protein synthesis of cytokines and chemokines (IL-
1β, TNFα, CRP, IL-6, IL-10, MCP) in monocytes and macrophages by real-
time PCR and Western blotting 
 Analyse the release of cytokines and chemokines by monocytes and 
macrophages using ELISA 
3.  Investigate the effectiveness of dressing coated with drug-primed MSCs 
 Optimise the dressing conditions, including materials, the amounts of drug-
primed MSCs 
 Investigate the effectiveness of the dressing coated with drug-primed MSCs 
on wound healing
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Klöpfer, A., Spanneberg, R. and Glomb, M. A. (2010) 'Formation of arginine modifications in 
a model system of N α-tert-butoxycarbonyl (Boc)-arginine with methylglyoxal.' Journal of 
Agricultural and Food Chemistry, 59(1) pp. 394-401. 
 
Ko, S.-Y., Ko, H.-A., Shieh, T.-M., Chang, W.-C., Chen, H.-I., Chang, S.-S. and Lin, I.-H. (2014) 
'Cell migration is regulated by AGE-RAGE interaction in human oral cancer cells in vitro.' PLoS 
One, 9(10) p. e110542. 
 
Kodera, Y., Ushijima, M., Amano, H., Suzuki, J.-i. and Matsutomo, T. (2017) 'Chemical and 
Biological Properties of S-1-Propenyl-ʟ-Cysteine in Aged Garlic Extract.' Molecules, 22(4) p. 
570. 
 
Kolaczkowska, E. and Kubes, P. (2013) 'Neutrophil recruitment and function in health and 
inflammation.' Nature Reviews Immunology, 13(3) p. 159. 
 
  
209 
 
Kolset, S., Reinholt, F. and Jenssen, T. (2012) 'Diabetic nephropathy and extracellular matrix.' 
Journal of Histochemistry & Cytochemistry, 60(12) pp. 976-986. 
 
Kong, X., Ma, M. z., Huang, K., Qin, L., Zhang, H. m., Yang, Z., Li, X. y. and Su, Q. (2014) 
'Increased plasma levels of the methylglyoxal in patients with newly diagnosed type 2 
diabetes 初诊 2 型糖尿病患者血浆甲基乙二醛水平升高.' Journal of Diabetes, 6(6) pp. 
535-540. 
 
Kraehenbuehl, K., Davidek, T., Devaud, S. and Mauroux, O. (2008) Basic and acidic sugars as 
flavour precursors in the Maillard reaction. Institut Für Chemie und Biologische Chemie. 
 
Kyo, E., Uda, N., Kasuga, S. and Itakura, Y. (2001) 'Immunomodulatory effects of aged garlic 
extract.' The Journal of Nutrition, 131(3) pp. 1075S-1079S. 
 
Laakso, M. (2010) 'Cardiovascular disease in type 2 diabetes from population to man to 
mechanisms: the Kelly West Award Lecture 2008.' Diabetes Care, 33(2) pp. 442-449. 
 
Laemmli, U. K. (1970) 'Cleavage of structural proteins during the assembly of the head of 
bacteriophage T4.' Nature, 227 pp. 680-685. 
 
Lamers, M. L., Almeida, M. E., Vicente-Manzanares, M., Horwitz, A. F. and Santos, M. F. 
(2011) 'High glucose-mediated oxidative stress impairs cell migration.' PloS one, 6(8) p. 
e22865. 
 
Landázuri, N., Tong, S., Suo, J., Joseph, G., Weiss, D., Sutcliffe, D. J., Giddens, D. P., Bao, G. 
and Taylor, W. R. (2013) 'Magnetic targeting of human mesenchymal stem cells with 
internalized superparamagnetic iron oxide nanoparticles.' Small, 9(23) pp. 4017-4026. 
 
Landén, N. X., Li, D. and Ståhle, M. (2016) 'Transition from inflammation to proliferation: a 
critical step during wound healing.' Cellular and Molecular Life Sciences, 73(20) pp. 3861-
3885. 
 
Lee, C. and Park, C. (2017) 'Bacterial responses to glyoxal and methylglyoxal: reactive 
electrophilic species.' International Journal of Molecular Sciences, 18(1) p. 169. 
 
Lee, D.-H., Kim, Y.-J., Kim, H.-H., Cho, H.-J., Ryu, J.-H., Rhee, M. H. and Park, H.-J. (2013) 
'Inhibitory effects of epigallocatechin-3-gallate on microsomal cyclooxygenase-1 activity in 
platelets.' Biomolecules & Therapeutics, 21(1) p. 54. 
 
Lee, D. E., Ayoub, N. and Agrawal, D. K. (2016) 'Mesenchymal stem cells and cutaneous 
wound healing: novel methods to increase cell delivery and therapeutic efficacy.' Stem Cell 
Research & Therapy, 7(1) p. 37. 
 
  
210 
 
Lee, E. Y., Xia, Y., Kim, W. S., Kim, M. H., Kim, T. H., Kim, K. J., Park, B. S. and Sung, J. H. (2009) 
'Hypoxia‐enhanced wound‐healing function of adipose‐derived stem cells: Increase in stem 
cell proliferation and up‐regulation of VEGF and bFGF.' Wound Repair and Regeneration, 
17(4) pp. 540-547. 
 
Lee, K. Y. and Yuk, S. H. (2007) 'Polymeric protein delivery systems.' Progress in Polymer 
Science, 32(7) pp. 669-697. 
 
Lee, P. C., Yang, Y. Y., Huang, C. S., Hsieh, S. L., Lee, K. C., Hsieh, Y. C., Lee, T. Y. and Lin, H. C. 
(2015) 'Concomitant inhibition of oxidative stress and angiogenesis by chronic hydrogen‐rich 
saline and N‐acetylcysteine treatments improves systemic, splanchnic and hepatic 
hemodynamics of cirrhotic rats.' Hepatology Research, 45(5) pp. 578-588. 
 
Lee, S., Yoo, M., Kim, S. and Shin, D. (2014) 'Identification and quantification of S-allyl-l-
cysteine in heated garlic juice by HPLC with ultraviolet and mass spectrometry detection.' 
LWT-Food Science and Technology, 57(2) pp. 516-521. 
 
Lee, S. H., Jeong, S. K. and Ahn, S. K. (2006) 'An update of the defensive barrier function of 
skin.' Yonsei Medical Journal, 47(3) pp. 293-306. 
 
Lee, S. H., Jin, S. Y., Song, J. S., Seo, K. K. and Cho, K. H. (2012) 'Paracrine effects of adipose-
derived stem cells on keratinocytes and dermal fibroblasts.' Annals of Dermatology, 24(2) 
pp. 136-143. 
 
Levinson, H. (2013) 'A paradigm of fibroblast activation and dermal wound contraction to 
guide the development of therapies for chronic wounds and pathologic scars.' Advances in 
Wound Care, 2(4) pp. 149-159. 
 
Li, M. D., Atkins, H. and Bubela, T. (2014) 'The global landscape of stem cell clinical trials.' 
Regenerative Medicine, 9(1) pp. 27-39. 
 
Li, P., Gong, Z., Shultz, L. D. and Ren, G. (2019) 'Mesenchymal stem cells: From regeneration 
to cancer.' Pharmacology & Therapeutics,  
 
Lim, A. K. (2014) 'Diabetic nephropathy–complications and treatment.' International Journal 
of Nephrology and Renovascular Disease, 7 p. 361. 
 
Lin, C.-Y., Chen, C.-S., Shieh, M.-S., Wu, C.-H. and Lee, H.-M. (2002) 'Development of an 
automated immunoassay for advanced glycosylation end products in human serum.' Clinical 
Biochemistry, 35(3) pp. 189-195. 
 
Lindsay, S. (1992) Analytical Chemistry by Open Learning High Performance Liquid 
Chromatography. John Willey and Sons, London. 
 
  
211 
 
Liu, L., Yu, Y., Hou, Y., Chai, J., Duan, H., Chu, W., Zhang, H., Hu, Q. and Du, J. (2014) 'Human 
umbilical cord mesenchymal stem cells transplantation promotes cutaneous wound healing 
of severe burned rats.' PloS one, 9(2) p. e88348. 
 
Lobmann, R., Ambrosch, A., Schultz, G., Waldmann, K., Schiweck, S. and Lehnert, H. (2002) 
'Expression of matrix-metalloproteinases and their inhibitors in the wounds of diabetic and 
non-diabetic patients.' Diabetologia, 45(7) pp. 1011-1016. 
 
Lobo Júnior, J. P., Brescansin, C. P., Santos-Weiss, I. C., Welter, M., Souza, E. M. d., Rego, F. 
G. d. M., Picheth, G. and Alberton, D. (2017) 'Serum Fluorescent Advanced Glycation End (F-
AGE) products in gestational diabetes patients.' Archives of Endocrinology and Metabolism, 
61(3) pp. 233-237. 
 
Lu, F., Mizuno, H., Uysal, C. A., Cai, X., Ogawa, R. and Hyakusoku, H. (2008) 'Improved viability 
of random pattern skin flaps through the use of adipose-derived stem cells.' Plastic and 
Reconstructive Surgery, 121(1) pp. 50-58. 
 
Luevano-Contreras, C. and Chapman-Novakofski, K. (2010) 'Dietary advanced glycation end 
products and aging.' Nutrients, 2(12) pp. 1247-1265. 
 
Lukomska, B., Stanaszek, L., Zuba-Surma, E., Legosz, P., Sarzynska, S. and Drela, K. (2019) 
'Challenges and controversies in human mesenchymal stem cell therapy.' Stem Cells 
International, 2019 
 
Luo, G., Cheng, W., He, W., Wang, X., Tan, J., Fitzgerald, M., Li, X. and Wu, J. (2010) 'Promotion 
of cutaneous wound healing by local application of mesenchymal stem cells derived from 
human umbilical cord blood.' Wound Repair and Regeneration, 18(5) pp. 506-513. 
 
Ma, T. (2010) 'Mesenchymal stem cells: From bench to bedside.' World Journal of Stem Cells, 
2(2) p. 13. 
 
Ma, Y., Gao, M. and Liu, D. (2016) 'N-acetylcysteine protects mice from high fat diet-induced 
metabolic disorders.' Pharmaceutical Research, 33(8) pp. 2033-2042. 
 
Ma, Y., Song, D., Wang, Z., Jiang, J., Jiang, T., Cui, F. and Fan, X. (2011) 'Effect of ultrahigh 
pressure treatment on volatile compounds in garlic.' Journal of Food Process Engineering, 
34(6) pp. 1915-1930. 
 
MacLeod, A. S., Rudolph, R., Corriden, R., Ye, I., Garijo, O. and Havran, W. L. (2014) 'Skin-
resident T cells sense ultraviolet radiation–induced injury and contribute to DNA repair.' The 
Journal of Immunology,  p. 1303297. 
 
Macpherson, L. J., Geierstanger, B. H., Viswanath, V., Bandell, M., Eid, S. R., Hwang, S. and 
Patapoutian, A. (2005) 'The pungency of garlic: activation of TRPA1 and TRPV1 in response 
to allicin.' Current Biology, 15(10) pp. 929-934. 
  
212 
 
 
Maggini, J., Mirkin, G., Bognanni, I., Holmberg, J., Piazzón, I. M., Nepomnaschy, I., Costa, H., 
Cañones, C., Raiden, S. and Vermeulen, M. (2010) 'Mouse bone marrow-derived 
mesenchymal stromal cells turn activated macrophages into a regulatory-like profile.' PloS 
one, 5(2) p. e9252. 
 
Majors, R. E. and Przybyciel, M. (2002) 'Columns for reversed-phase LC separations in highly 
aqueous mobile phases.' LC GC NORTH AMERICA, 20(7) pp. 584-593. 
 
Makita, Z., Vlassara, H., Cerami, A. and Bucala, R. (1992) 'Immunochemical detection of 
advanced glycosylation end products in vivo.' Journal of Biological Chemistry, 267(8) pp. 
5133-5138. 
 
Mallipattu, S. K. and Uribarri, J. (2014) 'Advanced glycation end product accumulation: a new 
enemy to target in chronic kidney disease?' Current opinion in nephrology and hypertension, 
23(6) p. 547. 
 
Mane, P., Mayee, R. and Atre, K. (2011) 'Medicinal properties of allium sativum (garlic): A 
review.' International Journal of Pharma Research and Development, 3(2) pp. 17-27. 
 
Mariño, L., Maya-Aguirre, C. A. s., Pauwels, K., Vilanova, B., Ortega-Castro, J., Frau, J., 
Donoso, J. and Adrover, M. (2017) 'Glycation of Lysozyme by Glycolaldehyde Provides New 
Mechanistic Insights in Diabetes-Related Protein Aggregation.' ACS Chemical Biology, 12(4) 
pp. 1152-1162. 
 
Martins, S. I. and Van Boekel, M. A. (2005a) 'Kinetics of the glucose/glycine Maillard reaction 
pathways: influences of pH and reactant initial concentrations.' Food Chemistry, 92(3) pp. 
437-448. 
 
Martins, S. I. and Van Boekel, M. A. (2005b) 'A kinetic model for the glucose/glycine Maillard 
reaction pathways.' Food Chemistry, 90(1-2) pp. 257-269. 
 
Maruyama, K., Asai, J., Ii, M., Thorne, T., Losordo, D. W. and D'Amore, P. A. (2007) 'Decreased 
macrophage number and activation lead to reduced lymphatic vessel formation and 
contribute to impaired diabetic wound healing.' The American Journal of Pathology, 170(4) 
pp. 1178-1191. 
 
Mashilipa, C., Wang, Q., Slevin, M. and Ahmed, N. (2011) 'Antiglycation and antioxidant 
properties of soy sauces.' Journal of Medicinal Food, 14(12) pp. 1647-1653. 
 
Matsuura, N., Miyamae, Y., Yamane, K., Nagao, Y., Hamada, Y., Kawaguchi, N., Katsuki, T., 
Hirata, K., Sumi, S.-I. and Ishikawa, H. (2006) 'Aged garlic extract inhibits angiogenesis and 
proliferation of colorectal carcinoma cells.' The Journal of Nutrition, 136(3) pp. 842S-846S. 
 
  
213 
 
Matthay, M. A., Goolaerts, A., Howard, J. P. and Lee, J. W. (2010) 'Mesenchymal stem cells 
for acute lung injury: preclinical evidence.' Critical Care Medicine, 38(10 Suppl) p. S569. 
 
Maxson, S., Lopez, E. A., Yoo, D., Danilkovitch-Miagkova, A. and LeRoux, M. A. (2012) 'Concise 
review: role of mesenchymal stem cells in wound repair.' Stem Cells Translational Medicine, 
1(2) pp. 142-149. 
 
Mayadas, T. N., Cullere, X. and Lowell, C. A. (2014) 'The multifaceted functions of 
neutrophils.' Annual Review of Pathology: Mechanisms of Disease, 9 pp. 181-218. 
 
McCance, D. R., Dyer, D. G., Dunn, J. A., Bailie, K. E., Thorpe, S. R., Baynes, J. W. and Lyons, T. 
J. (1993) 'Maillard reaction products and their relation to complications in insulin-dependent 
diabetes mellitus.' The Journal of Clinical Investigation, 91(6) pp. 2470-2478. 
 
McCarthy, A. D., Etcheverry, S. B., Bruzzone, L. and Cortizo, A. M. (1997) 'Effects of advanced 
glycation end-products on the proliferation and differentiation of osteoblast-like cells.' 
Molecular and Cellular Biochemistry, 170(1-2) pp. 43-51. 
 
Mei, S. H., Haitsma, J. J., Dos Santos, C. C., Deng, Y., Lai, P. F., Slutsky, A. S., Liles, W. C. and 
Stewart, D. J. (2010) 'Mesenchymal stem cells reduce inflammation while enhancing 
bacterial clearance and improving survival in sepsis.' American Journal of Respiratory and 
Critical Care Medicine, 182(8) pp. 1047-1057. 
 
Mittal, R. (2011) 'Mesenchymal stem cells: the new players in the pathogenesis of 
tuberculosis.' J Microbial Biochem Technol, 3(3) 
 
Morais, M. P. P., Marshall, D., Flower, S. E., Caunt, C. J., James, T. D., Williams, R. J., 
Waterfield, N. R. and Van Den Elsen, J. M. (2013) 'Analysis of protein glycation using 
fluorescent phenylboronate gel electrophoresis.' Scientific Reports, 3 p. 1437. 
 
Moraru, A., Wiederstein, J., Pfaff, D., Fleming, T., Miller, A. K., Nawroth, P. and Teleman, A. 
A. (2018) 'Elevated levels of the reactive metabolite methylglyoxal recapitulate progression 
of type 2 diabetes.' Cell Metabolism, 27(4) pp. 926-934. e928. 
 
Murray, P. J. and Wynn, T. A. (2011) 'Protective and pathogenic functions of macrophage 
subsets.' Nature Reviews Immunology, 11(11) p. 723. 
 
Mustoe, T. A., O'shaughnessy, K. and Kloeters, O. (2006) 'Chronic wound pathogenesis and 
current treatment strategies: a unifying hypothesis.' Plastic and Reconstructive Surgery, 
117(7S) pp. 35S-41S. 
 
Muthenna, P., Akileshwari, C. and Reddy, G. B. (2012) 'Ellagic acid, a new antiglycating agent: 
its inhibition of Nϵ-(carboxymethyl) lysine.' Biochemical Journal, 442(1) pp. 221-230. 
 
  
214 
 
Naka, Y., Bucciarelli, L. G., Wendt, T., Lee, L. K., Rong, L. L., Ramasamy, R., Yan, S. F. and 
Schmidt, A. M. (2004) 'RAGE axis: animal models and novel insights into the vascular 
complications of diabetes.' Arteriosclerosis, Thrombosis, and Vascular Biology, 24(8) pp. 
1342-1349. 
 
Neeper, M., Schmidt, A., Brett, J., Yan, S., Wang, F., Pan, Y., Elliston, K., Stern, D. and Shaw, 
A. (1992) 'Cloning and expression of a cell surface receptor for advanced glycosylation end 
products of proteins.' Journal of Biological Chemistry, 267(21) pp. 14998-15004. 
 
Newman, R. E., Yoo, D., LeRoux, M. A. and Danilkovitch-Miagkova, A. (2009) 'Treatment of 
inflammatory diseases with mesenchymal stem cells.' Inflammation & Allergy-Drug Targets 
(Formerly Current Drug Targets-Inflammation & Allergy), 8(2) pp. 110-123. 
 
Newton, A. E., Fairbanks, A. J., Golding, M., Andrewes, P. and Gerrard, J. A. (2012) 'The role 
of the Maillard reaction in the formation of flavour compounds in dairy products–not only a 
deleterious reaction but also a rich source of flavour compounds.' Food & Function, 3(12) pp. 
1231-1241. 
 
Nie, C., Yang, D., Xu, J., Si, Z., Jin, X. and Zhang, J. (2011) 'Locally administered adipose-derived 
stem cells accelerate wound healing through differentiation and vasculogenesis.' Cell 
Transplantation, 20(2) pp. 205-216. 
 
Nishikawa-Ogawa, M., Wanibuchi, H., Morimura, K., Kinoshita, A., Nishikawa, T., Hayashi, S., 
Yano, Y. and Fukushima, S. (2005) 'N-acetylcysteine and S-methylcysteine inhibit MeIQx rat 
hepatocarcinogenesis in the post-initiation stage.' Carcinogenesis, 27(5) pp. 982-988. 
 
Nita, M. and Grzybowski, A. (2016) 'The role of the reactive oxygen species and oxidative 
stress in the pathomechanism of the age-related ocular diseases and other pathologies of 
the anterior and posterior eye segments in adults.' Oxidative Medicine and Cellular 
Longevity, 2016 
 
Novak, M. L. and Koh, T. J. (2013) 'Macrophage phenotypes during tissue repair.' Journal of 
leukocyte Biology, 93(6) pp. 875-881. 
 
Nursten, H. E. (2005) The Maillard reaction: chemistry, biochemistry, and implications. Royal 
Society of Chemistry. 
 
O’sullivan, E. P. and Dinneen, S. F. (2009) 'Benefits of early intensive glucose control to 
prevent diabetes complications were sustained for up to 10 years.' Evidence-Based Medicine, 
14(1) p. 9. 
 
Oak, J.-H., Youn, J.-Y. and Cai, H. (2009) 'Aminoguanidine inhibits aortic hydrogen peroxide 
production, VSMC NOX activity and hypercontractility in diabetic mice.' Cardiovascular 
Diabetology, 8(1) p. 65. 
 
  
215 
 
Ogony, J., Mare, S., Wu, W. and Ercal, N. (2006) 'High performance liquid chromatography 
analysis of 2-mercaptoethylamine (cysteamine) in biological samples by derivatization with 
N-(1-pyrenyl) maleimide (NPM) using fluorescence detection.' Journal of Chromatography B, 
843(1) pp. 57-62. 
 
Oh, J. Y., Ko, J. H., Lee, H. J., Yu, J. M., Choi, H., Kim, M. K., Wee, W. R. and Prockop, D. J. 
(2014) 'Mesenchymal stem/stromal cells inhibit the NLRP3 inflammasome by decreasing 
mitochondrial reactive oxygen species.' Stem Cells, 32(6) pp. 1553-1563. 
 
Ojeh, N. O. and Navsaria, H. A. (2014) 'An in vitro skin model to study the effect of 
mesenchymal stem cells in wound healing and epidermal regeneration.' Journal of 
Biomedical Materials Research Part A, 102(8) pp. 2785-2792. 
 
Omar, S. and Al-Wabel, N. (2010) 'Organosulfur compounds and possible mechanism of garlic 
in cancer.' Saudi Pharmaceutical Journal, 18(1) pp. 51-58. 
 
Ott, C., Jacobs, K., Haucke, E., Santos, A. N., Grune, T. and Simm, A. (2014) 'Role of advanced 
glycation end products in cellular signaling.' Redox biology, 2 pp. 411-429. 
 
Ou, C.-c., Tsao, S.-m., Lin, M.-c. and Yin, M.-c. (2003) 'Protective action on human LDL against 
oxidation and glycation by four organosulfur compounds derived from garlic.' Lipids, 38(3) 
pp. 219-224. 
 
Ourouadi, S., Moumene, H., Zaki, N., Boulli, A.-A., Ouatmane, A. and Hasib, A. (2016) 'Garlic 
(Allium Sativum): A Source of Multiple Nutraceutical and Functional Components.' Journal of 
Chemical, Biological and Physical Sciences (JCBPS), 7(1) p. 9. 
 
Ozougwu, J., Obimba, K., Belonwu, C. and Unakalamba, C. (2013) 'The pathogenesis and 
pathophysiology of type 1 and type 2 diabetes mellitus.' Journal of Physiology and 
Pathophysiology, 4(4) pp. 46-57. 
 
Padayatti, P. S., Jiang, C., Glomb, M. A., Uchida, K. and Nagaraj, R. H. (2001) 'High 
concentrations of glucose induce synthesis of argpyrimidine in retinal endothelial cells.' 
Current Eye Research, 23(2) pp. 106-115. 
 
Paget, C., Lecomte, M., Ruggiero, D., Wiernsperger, N. and Lagarde, M. (1998) 'Modification 
of enzymatic antioxidants in retinal microvascular cells by glucose or advanced glycation end 
products.' Free Radical Biology and Medicine, 25(1) pp. 121-129. 
 
Panche, A., Diwan, A. and Chandra, S. (2016) 'Flavonoids: an overview.' Journal of Nutritional 
Science, 5 
 
Pandrangi, A. (2015) 'Cancer chemoprevention by garlic-A review.' Hereditary Genet, 4(2) pp. 
1-7. 
  
216 
 
 
Pang, C., Ibrahim, A., Bulstrode, N. W. and Ferretti, P. (2017) 'An overview of the therapeutic 
potential of regenerative medicine in cutaneous wound healing.' International Wound 
Journal, 14(3) pp. 450-459. 
 
Parekkadan, B. and Milwid, J. M. (2010) 'Mesenchymal stem cells as therapeutics.' Annual 
Review of Biomedical Engineering, 12 pp. 87-117. 
 
PARK, B. S., Jang, K. A., SUNG, J. H., PARK, J. S., Kwon, Y. H., Kim, K. J. and KIM, W. S. (2008) 
'Adipose‐derived stem cells and their secretory factors as a promising therapy for skin aging.' 
Dermatologic Surgery, 34(10) pp. 1323-1326. 
 
Parsons, J., Sparrow, K., Ismail, K., Hunt, K., Rogers, H. and Forbes, A. (2018) 'Experiences of 
gestational diabetes and gestational diabetes care: a focus group and interview study.' BMC 
Pregnancy and Childbirth, 18(1) p. 25. 
 
Parveen, A., Jin, M. and Kim, S. Y. (2017) 'Bioactive phytochemicals that regulate the cellular 
processes involved in diabetic nephropathy.' Phytomedicine,  
 
Pascucci, L., Coccè, V., Bonomi, A., Ami, D., Ceccarelli, P., Ciusani, E., Viganò, L., Locatelli, A., 
Sisto, F. and Doglia, S. M. (2014) 'Paclitaxel is incorporated by mesenchymal stromal cells and 
released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery.' 
Journal of Controlled Release, 192 pp. 262-270. 
 
Pastar, I., Stojadinovic, O., Yin, N. C., Ramirez, H., Nusbaum, A. G., Sawaya, A., Patel, S. B., 
Khalid, L., Isseroff, R. R. and Tomic-Canic, M. (2014) 'Epithelialization in wound healing: a 
comprehensive review.' Advances in Wound Care, 3(7) pp. 445-464. 
 
Penn, J. W., Grobbelaar, A. O. and Rolfe, K. J. (2012) 'The role of the TGF-β family in wound 
healing, burns and scarring: a review.' International Journal of Burns and Trauma, 2(1) p. 18. 
 
Pescosolido, N., Barbato, A., Giannotti, R., Komaiha, C. and Lenarduzzi, F. (2016) 'Age-related 
changes in the kinetics of human lenses: prevention of the cataract.' International Journal of 
Ophthalmology, 9(10) p. 1506. 
 
Poulsen, M. W., Hedegaard, R. V., Andersen, J. M., de Courten, B., Bügel, S., Nielsen, J., 
Skibsted, L. H. and Dragsted, L. O. (2013) 'Advanced glycation endproducts in food and their 
effects on health.' Food and Chemical Toxicology, 60 pp. 10-37. 
 
Prasad, V. K., Lucas, K. G., Kleiner, G. I., Talano, J. A. M., Jacobsohn, D., Broadwater, G., 
Monroy, R. and Kurtzberg, J. (2011) 'Efficacy and safety of ex vivo cultured adult human 
mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute 
graft-versus-host disease in a compassionate use study.' Biology of Blood and Marrow 
Transplantation, 17(4) pp. 534-541. 
 
  
217 
 
Procházka, V., Gumulec, J., Jalůvka, F., Šalounová, D., Jonszta, T., Czerný, D., Krajča, J., 
Urbanec, R., Klement, P. and Martinek, J. (2010) 'Cell therapy, a new standard in 
management of chronic critical limb ischemia and foot ulcer.' Cell Transplantation, 19(11) 
pp. 1413-1424. 
 
Qader, S. W., Abdulla, M. A., Chua, L. S., Najim, N., Zain, M. M. and Hamdan, S. (2011) 
'Antioxidant, total phenolic content and cytotoxicity evaluation of selected Malaysian 
plants.' Molecules, 16(4) pp. 3433-3443. 
 
Qi, Y., Jiang, D., Sindrilaru, A., Stegemann, A., Schatz, S., Treiber, N., Rojewski, M., 
Schrezenmeier, H., Vander Beken, S. and Wlaschek, M. (2014) 'TSG-6 released from 
intradermally injected mesenchymal stem cells accelerates wound healing and reduces 
tissue fibrosis in murine full-thickness skin wounds.' Journal of Investigative Dermatology, 
134(2) pp. 526-537. 
 
Qiu, F., Tong, H., Wang, Y., Tao, J., Wang, H. and Chen, L. (2018) 'Recombinant human maspin 
inhibits high glucose-induced oxidative stress and angiogenesis of human retinal 
microvascular endothelial cells via PI3K/AKT pathway.' Molecular and Cellular Biochemistry,  
pp. 1-10. 
 
Quittet, M.-S., Touzani, O., Sindji, L., Cayon, J., Fillesoye, F., Toutain, J., Divoux, D., Marteau, 
L., Lecocq, M. and Roussel, S. (2015) 'Effects of mesenchymal stem cell therapy, in association 
with pharmacologically active microcarriers releasing VEGF, in an ischaemic stroke model in 
the rat.' Acta Biomaterialia, 15 pp. 77-88. 
 
Rahman, K. (2007) 'Effects of garlic on platelet biochemistry and physiology.' Molecular 
nutrition & Food Research, 51(11) pp. 1335-1344. 
 
Rai, A. K., Chandra, S., Singh, S. P. and Parveen, A. (2016) 'Atherosclerosis: a life changing 
phenomenon.' Pharmaceutical and Biological Evaluations, 3(2) pp. 154-164. 
 
Raman, B., Krishna, N., Rao, N., Saradhi, P. and Rao, B. (2012) 'Plants with antidiabetic 
activities and their medicinal values.' Int Res J Pharm, 3(3) pp. 11-15. 
 
Raposeiras-Roubín, S., Rodiño-Janeiro, B. K., Paradela-Dobarro, B., Grigorian-Shamagian, L., 
García-Acuña, J. M., Aguiar-Souto, P., Jacquet-Hervet, M., Reino-Maceiras, M. V., González-
Juanatey, J. R. and Álvarez, E. (2013) 'Fluorescent advanced glycation end products and their 
soluble receptor: the birth of new plasmatic biomarkers for risk stratification of acute 
coronary syndrome.' PLoS One, 8(9) p. e74302. 
 
Rhee, S. Y. and Kim, Y. S. (2018) 'The Role of Advanced Glycation End Products in Diabetic 
Vascular Complications.' Diabetes & Metabolism Journal, 42(3) pp. 188-195. 
 
Richarme, G., Mihoub, M., Dairou, J., Bui, L. C., Leger, T. and Lamouri, A. (2015) 
'Parkinsonism-associated protein DJ-1/Park7 is a major protein deglycase that repairs 
  
218 
 
methylglyoxal-and glyoxal-glycated cysteine, arginine, and lysine residues.' Journal of 
Biological Chemistry, 290(3) pp. 1885-1897. 
 
Rivlin, R. S. (2001) 'Historical perspective on the use of garlic.' The Journal of Nutrition, 131(3) 
pp. 951S-954S. 
 
Roby, M. H. H., Sarhan, M. A., Selim, K. A.-H. and Khalel, K. I. (2013) 'Evaluation of antioxidant 
activity, total phenols and phenolic compounds in thyme (Thymus vulgaris L.), sage (Salvia 
officinalis L.), and marjoram (Origanum majorana L.) extracts.' Industrial Crops and Products, 
43 pp. 827-831. 
 
Rodriguez-Menocal, L., Shareef, S., Salgado, M., Shabbir, A. and Van Badiavas, E. (2015) 'Role 
of whole bone marrow, whole bone marrow cultured cells, and mesenchymal stem cells in 
chronic wound healing.' Stem Cell Research & Therapy, 6(1) p. 24. 
 
Rojas, A. and Morales, M. A. (2004) 'Advanced glycation and endothelial functions: a link 
towards vascular complications in diabetes.' Life Sciences, 76(7) pp. 715-730. 
 
Rustad, K. C., Wong, V. W., Sorkin, M., Glotzbach, J. P., Major, M. R., Rajadas, J., Longaker, 
M. T. and Gurtner, G. C. (2012) 'Enhancement of mesenchymal stem cell angiogenic capacity 
and stemness by a biomimetic hydrogel scaffold.' Biomaterials, 33(1) pp. 80-90. 
 
Saad, B. and Said, O. (2011) Greco-Arab and Islamic herbal medicine: Traditional System, 
Ethics, Safety, Efficacy, and Regulatory Issues. John Wiley & Sons. 
 
Saap, L. J. and Falanga, V. (2002) 'Debridement performance index and its correlation with 
complete closure of diabetic foot ulcers.' Wound Repair and Regeneration, 10(6) pp. 354-
359. 
 
Sadhukha, T., O'brien, T. D. and Prabha, S. (2014) 'Nano-engineered mesenchymal stem cells 
as targeted therapeutic carriers.' Journal of Controlled Release, 196 pp. 243-251. 
 
Sadowska, A., Manuel-Y-Keenoy, B. and De Backer, W. (2007) 'Antioxidant and anti-
inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-
effects: a review.' Pulmonary Pharmacology & Therapeutics, 20(1) pp. 9-22. 
 
Saeidnia, S. and Abdollahi, M. (2013) 'Toxicological and pharmacological concerns on 
oxidative stress and related diseases.' Toxicology and Applied Pharmacology, 273(3) pp. 442-
455. 
 
Samakradhamrongthai, R. (2017) 'Effect of drying condition of Thai garlic (Allium sativum L.) 
on physicochemical and sensory properties.'  
 
  
219 
 
Santhosha, S. G., Jamuna, P. and Prabhavathi, S. N. (2013) 'Bioactive components of garlic 
and their physiological role in health maintenance: A review.' Food Bioscience, 3 pp. 59-74. 
 
Schäfer, M. and Werner, S. (2008) 'Oxidative stress in normal and impaired wound repair.' 
Pharmacological Research, 58(2) pp. 165-171. 
 
Sen, C. K., Gordillo, G. M., Roy, S., Kirsner, R., Lambert, L., Hunt, T. K., Gottrup, F., Gurtner, G. 
C. and Longaker, M. T. (2009) 'Human skin wounds: a major and snowballing threat to public 
health and the economy.' Wound Repair and Regeneration, 17(6) pp. 763-771. 
 
Seo, K., Ki, S. and Shin, S. (2014) Methylglyoxal induces mitochondrial dysfunction and cell 
death in liver. Toxicol Res 30: 193–198. doi: 10.5487. TR. 2014.30. 3.193.  
 
Serra, M. B., Barroso, W. A., Silva, N. N. d., Silva, S. d. N., Borges, A. C. R., Abreu, I. C. and 
Borges, M. O. d. R. (2017) 'From inflammation to current and alternative therapies involved 
in wound healing.' International Journal of Inflammation, 2017 
 
Sharaf, H., Matou-Nasri, S., Wang, Q., Rabhan, Z., Al-Eidi, H., Al Abdulrahman, A. and Ahmed, 
N. (2015) 'Advanced glycation endproducts increase proliferation, migration and invasion of 
the breast cancer cell line MDA-MB-231.' Biochimica et Biophysica Acta (BBA)-Molecular 
Basis of Disease, 1852(3) pp. 429-441. 
 
Sharma, C., Kaur, A., Thind, S., Singh, B. and Raina, S. (2015) 'Advanced glycation end-
products (AGEs): an emerging concern for processed food industries.' Journal of Food Science 
and Technology, 52(12) pp. 7561-7576. 
 
Sharma, G. and Prasad, S. (2006) 'Optimization of process parameters for microwave drying 
of garlic cloves.' Journal of Food Engineering, 75(4) pp. 441-446. 
 
Shimomura, H. and Spiro, R. G. (1987) 'Studies on macromolecular components of human 
glomerular basement membrane and alterations in diabetes: decreased levels of heparan 
sulfate proteoglycan and laminin.' Diabetes, 36(3) pp. 374-381. 
 
Singh, V. P., Bali, A., Singh, N. and Jaggi, A. S. (2014) 'Advanced glycation end products and 
diabetic complications.' The Korean Journal of Physiology & Pharmacology, 18(1) pp. 1-14. 
 
Siviero, F. (2013) 'Biologia celular: bases moleculares e metodologia de pesquisa.' In Biologia 
Celular: Bases Moleculares e Metodologia de Pesquisa.  
 
Slavich, G. M. and Irwin, M. R. (2014) 'From stress to inflammation and major depressive 
disorder: a social signal transduction theory of depression.' Psychological Bulletin, 140(3) p. 
774. 
 
  
220 
 
Smith, A. N., Willis, E., Chan, V. T., Muffley, L. A., Isik, F. F., Gibran, N. S. and Hocking, A. M. 
(2010) 'Mesenchymal stem cells induce dermal fibroblast responses to injury.' Experimental 
Cell Research, 316(1) pp. 48-54. 
 
Snyder, L. R., Kirkland, J. J. and Glajch, J. L. (2012) Practical HPLC method development. John 
Wiley & Sons. 
 
Sollazzo, V., Palmieri, A., Girardi, A., Farinella, F. and Carinci, F. (2011) 'Trabecular titanium 
induces osteoblastic bone marrow stem cells differentiation.' J Biotechnol Biomaterial, 
1(102) p. 2. 
 
Soloviev, A., Stefanov, A., Tishkin, S., Khromov, A., Parshikov, A., Ivanova, I. and Gurney, A. 
(2002) 'SALINE CONTAINING PHOSPHATIDYLCHOLINE LIPOSOMES.' Journal of physiology and 
pharmacology, 53(4) pp. 701-712. 
 
Song, F., Yuan, B., Li, X., Huang, X., Zhou, Z., Dong, J., Yang, H. and Qiao, L. (2017) 'High glucose 
and AGEs inhibit tube formation of vascular endothelial cells by sustained Ang-2 production.' 
International Journal of Clinical and Experimental Pathology, 10(3) pp. 3786-3793. 
 
Sottile, V., Halleux, C., Bassilana, F., Keller, H. and Seuwen, K. (2002) 'Stem cell characteristics 
of human trabecular bone-derived cells.' Bone, 30(5) pp. 699-704. 
 
Squillaro, T., Peluso, G. and Galderisi, U. (2016) 'Clinical trials with mesenchymal stem cells: 
an update.' Cell Transplantation, 25(5) pp. 829-848. 
 
Srikanth, V., Maczurek, A., Phan, T., Steele, M., Westcott, B., Juskiw, D. and Münch, G. (2011) 
'Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease.' 
Neurobiology of Aging, 32(5) pp. 763-777. 
 
Stadler, R. H., Blank, I., Varga, N., Robert, F., Hau, J., Guy, P. A., Robert, M.-C. and Riediker, S. 
(2002) 'Acrylamide from Maillard reaction products.' Nature, 419, 10/03/online, p. 449. 
 
Steiner, M. and Li, W. (2001) 'Aged garlic extract, a modulator of cardiovascular risk factors: 
a dose-finding study on the effects of AGE on platelet functions.' The Journal of Nutrition, 
131(3) pp. 980S-984S. 
 
Stinghen, A. E., Massy, Z. A., Vlassara, H., Striker, G. E. and Boullier, A. (2015) 'Uremic toxicity 
of advanced glycation end products in CKD.' Journal of the American Society of Nephrology,  
p. ASN. 2014101047. 
 
Stitt, A. W., McGoldrick, C., Rice-McCaldin, A., McCance, D. R., Glenn, J. V., Hsu, D. K., Liu, F.-
T., Thorpe, S. R. and Gardiner, T. A. (2005) 'Impaired retinal angiogenesis in diabetes: role of 
advanced glycation end products and galectin-3.' Diabetes, 54(3) pp. 785-794. 
 
  
221 
 
Stitt, A. W., Curtis, T. M., Chen, M., Medina, R. J., McKay, G. J., Jenkins, A., Gardiner, T. A., 
Lyons, T. J., Hammes, H.-P. and Simo, R. (2016) 'The progress in understanding and treatment 
of diabetic retinopathy.' Progress in Retinal and Eye Research, 51 pp. 156-186. 
 
Stojadinovic, O., Brem, H., Vouthounis, C., Lee, B., Fallon, J., Stallcup, M., Merchant, A., 
Galiano, R. D. and Tomic-Canic, M. (2005) 'Molecular pathogenesis of chronic wounds: the 
role of β-catenin and c-myc in the inhibition of epithelialization and wound healing.' The 
American Journal of Pathology, 167(1) pp. 59-69. 
 
Supabphol, A., Muangman, V., Chavasiri, W., Supabphol, R. and Gritsanapan, W. (2009) 'N-
acetylcysteine inhibits proliferation, adhesion, migration and invasion of human bladder 
cancer cells.' Medical Journal of the Medical Association of Thailand, 92(9) p. 1171. 
 
Syu, J.-N., Yang, M.-D., Tsai, S.-Y., Chiang, E.-P. I., Chiu, S.-C., Chao, C.-Y., Rodriguez, R. L. and 
Tang, F.-Y. (2017) 'S-allylcysteine Improves Blood Flow Recovery and Prevents Ischemic Injury 
by Augmenting Neovasculogenesis.' Cell Transplantation, 26(10) pp. 1636-1647. 
 
Tadokoro, M., Kanai, R., Taketani, T., Uchio, Y., Yamaguchi, S. and Ohgushi, H. (2009) 'New 
bone formation by allogeneic mesenchymal stem cell transplantation in a patient with 
perinatal hypophosphatasia.' The Journal of pediatrics, 154(6) pp. 924-930. 
 
Tajes, M., Eraso-Pichot, A., Rubio-Moscardó, F., Guivernau, B., Bosch-Morató, M., Valls-
Comamala, V. and Munoz, F. J. (2014) 'Methylglyoxal reduces mitochondrial potential and 
activates Bax and caspase-3 in neurons: Implications for Alzheimer's disease.' Neuroscience 
letters, 580 pp. 78-82. 
 
Takahashi, H., Sakata, N., Yoshimatsu, G., Hasegawa, S. and Kodama, S. (2019) 'Regenerative 
and Transplantation Medicine: Cellular Therapy Using Adipose Tissue-Derived Mesenchymal 
Stromal Cells for Type 1 Diabetes Mellitus.' Journal of Clinical Medicine, 8(2) p. 249. 
 
Tang, W., Martin, K. A. and Hwa, J. (2012) 'Aldose reductase, oxidative stress, and diabetic 
mellitus.' Frontiers in pharmacology, 3 p. 87. 
 
Tezuka, M., Koyama, N., Morisaki, N., Saito, Y., Yoshida, S., Araki, N. and Horiuchi, S. (1993) 
'Angiogenic effects of advanced glycation end products of the Maillard reaction on cultured 
human umbilical cord vein endothelial cells.' Biochemical and Biophysical Research 
Communications, 193(2) pp. 674-680. 
 
Thornalley, P. J. (2008) 'Protein and nucleotide damage by glyoxal and methylglyoxal in 
physiological systems-role in ageing and disease.' Drug Metabolism and Drug Interactions, 
23(1-2) pp. 125-150. 
 
Todd, G. P., LeRoux, M. A. and Danilkovitch-Miagkova, A. (2011) 'Mesenchymal stem cells as 
vehicles for targeted therapies.' In Drug Discovery and Development-Present and Future. 
InTech,  
  
222 
 
 
Torres, C., Picó, Y. and Manes, J. (1996) 'Determination of pesticide residues in fruit and 
vegetables.' Journal of Chromatography A, 754(1-2) pp. 301-331. 
 
Towbin, H., Staehelin, T. and Gordon, J. (1979) 'Electrophoretic transfer of proteins from 
polyacrylamide gels to nitrocellulose sheets: procedure and some applications.' Proceedings 
of the National Academy of Sciences, 76(9) pp. 4350-4354. 
 
Trachtman, H., Futterweit, S., Prenner, J. and Hanon, S. (1994) 'Antioxidants reverse the 
antiproliferative effect of high glucose and advanced glycosylation end products in cultured 
rat mesangial cells.' Biochemical and Biophysical Research Communications, 199(1) pp. 346-
352. 
 
Troise, A. D. and Fogliano, V. (2013) 'Reactants encapsulation and Maillard reaction.' Trends 
in Food Science & Technology, 33(1) pp. 63-74. 
 
Tsekovska, R., Sredovska-Bozhinov, A., Niwa, T., Ivanov, I. and Mironova, R. (2016) 'Maillard 
reaction and immunogenicity of protein therapeutics.' World, 1 p. 003. 
 
Uribarri, J. (2017) Dietary AGEs and Their Role in Health and Disease. CRC Press. 
 
Velnar, T., Bailey, T. and Smrkolj, V. (2009) 'The wound healing process: an overview of the 
cellular and molecular mechanisms.' Journal of International Medical Research, 37(5) pp. 
1528-1542. 
 
Villa, M., Parravano, M., Micheli, A., Gaddini, L., Matteucci, A., Mallozzi, C., Facchiano, F., 
Malchiodi-Albedi, F. and Pricci, F. (2017) 'A quick, simple method for detecting circulating 
fluorescent advanced glycation end-products: Correlation with in vitro and in vivo non-
enzymatic glycation.' Metabolism, 71 pp. 64-69. 
 
Walter, M., Wright, K. T., Fuller, H., MacNeil, S. and Johnson, W. E. B. (2010) 'Mesenchymal 
stem cell-conditioned medium accelerates skin wound healing: an in vitro study of fibroblast 
and keratinocyte scratch assays.' Experimental Cell Research, 316(7) pp. 1271-1281. 
 
Wang, I.-H., Moorman, R. and Burleson, J. (2003) 'Isocratic reversed-phase liquid 
chromatographic method for the simultaneous determination of (S)-methoprene, MGK264, 
piperonyl butoxide, sumithrin and permethrin in pesticide formulation.' Journal of 
Chromatography A, 983(1-2) pp. 145-152. 
 
Wang, J., Sun, B., Cao, Y. and Tian, Y. (2009) 'Protein glycation inhibitory activity of wheat 
bran feruloyl oligosaccharides.' Food Chemistry, 112(2) pp. 350-353. 
 
Wang, Q., Fan, A., Yuan, Y., Chen, L., Guo, X., Huang, X. and Huang, Q. (2016) 'Role of moesin 
in advanced glycation end products-induced angiogenesis of human umbilical vein 
endothelial cells.' Scientific Reports, 6 p. 22749. 
  
223 
 
 
Wang, X., Ackermann, M., Neufurth, M., Wang, S., Li, Q., Feng, Q., Schröder, H. C. and Müller, 
W. E. (2017) 'Restoration of Impaired Metabolic Energy Balance (ATP Pool) and Tube 
Formation Potential of Endothelial Cells under “high glucose”, Diabetic Conditions by the 
Bioinorganic Polymer Polyphosphate.' Polymers, 9(11) p. 575. 
 
Wang, Y., Friedrichs, U., Eichler, W., Hoffmann, S. and Wiedemann, P. (2005) 'Advanced 
glycation endproducts enhance pro-liferation, but not tube formation in choroidal 
microvascular endothelial cells.' International Journal of Ophthalmology, 5(2) 
 
Waterman, R. and Betancourt, A. (2011) 'Treating chronic pain with mesenchymal stem cells: 
A therapeutic approach worthy of continued investigation.' J Stem Cell Res Ther,  p. S2. 
 
Wikramanayake, T. C., Stojadinovic, O. and Tomic-Canic, M. (2014) 'Epidermal differentiation 
in barrier maintenance and wound healing.' Advances in Wound Care, 3(3) pp. 272-280. 
 
Wilgus, T. A., Roy, S. and McDaniel, J. C. (2013) 'Neutrophils and wound repair: positive 
actions and negative reactions.' Advances in Wound Care, 2(7) pp. 379-388. 
 
Williamson, J. and Ido, Y. (2012) 'Linking diabetic complications to sorbitol oxidation, 
oxidative stress and metabolic suppression.' Journal of Diabetes Metabolism, 3 
 
Winters, R. A., Zukowski, J., Ercal, N., Matthews, R. H. and Spitz, D. R. (1995) 'Analysis of 
glutathione, glutathione disulfide, cysteine, homocysteine, and other biological thiols by 
high-performance liquid chromatography following derivatization by n-(1-pyrenyl) 
maleimide.' Analytical Biochemistry, 227(1) pp. 14-21. 
 
Wu, J.-W., Hsieh, C.-L., Wang, H.-Y. and Chen, H.-Y. (2009) 'Inhibitory effects of guava 
(Psidium guajava L.) leaf extracts and its active compounds on the glycation process of 
protein.' Food Chemistry, 113(1) pp. 78-84. 
 
Wu, S. C., Marston, W. and Armstrong, D. G. (2010) 'Wound care: the role of advanced 
wound-healing technologies.' Journal of the American Podiatric Medical Association, 100(5) 
pp. 385-394. 
 
Wu, Y., Chen, L., Scott, P. G. and Tredget, E. E. (2007) 'Mesenchymal stem cells enhance 
wound healing through differentiation and angiogenesis.' Stem Cells, 25(10) pp. 2648-2659. 
 
Wu, Y., Ding, Y., Tanaka, Y. and Zhang, W. (2014) 'Risk factors contributing to type 2 diabetes 
and recent advances in the treatment and prevention.' International Journal of Medical 
Sciences, 11(11) p. 1185. 
 
Xie, C., Liu, N., Long, J., Tang, C., Li, J., Huo, L., Wang, X., Chen, P. and Liang, S. (2011) 'Blue 
native/SDS‐PAGE combined with iTRAQ analysis reveals advanced glycation end‐product‐
  
224 
 
induced changes of synaptosome proteins in C57 BL/6 mice.' Electrophoresis, 32(16) pp. 
2194-2205. 
 
Xie, D., Ju, D., Speyer, C., Gorski, D. and Kosir, M. A. (2016) 'Strategic Endothelial Cell Tube 
Formation Assay: Comparing Extracellular Matrix and Growth Factor Reduced Extracellular 
Matrix.' Journal of Visualized Experiments: JoVE, (114) 
 
Xu, B., Chibber, R., Ruggiero, D., Kohner, E., Ritter, J. and Ferro, A. (2003) 'Impairment of 
vascular endothelial nitric oxide synthase activity by advanced glycation end products.' The 
FASEB journal, 17(10) pp. 1289-1291. 
 
Xu, J., Wu, W., Zhang, L., Dorset-Martin, W., Morris, M. W., Mitchell, M. E. and Liechty, K. W. 
(2012) 'The role of microRNA-146a in the pathogenesis of the diabetic wound-healing 
impairment: correction with mesenchymal stem cell treatment.' Diabetes, 61(11) pp. 2906-
2912. 
 
Xu, Y.-s., Feng, J.-g., Zhang, D., Zhang, B., Luo, M., Su, D. and Lin, N.-m. (2014) 'S-allylcysteine, 
a garlic derivative, suppresses proliferation and induces apoptosis in human ovarian cancer 
cells in vitro.' Acta Pharmacologica Sinica, 35(2) p. 267. 
 
Yagihashi, S., Mizukami, H. and Sugimoto, K. (2011) 'Mechanism of diabetic neuropathy: 
where are we now and where to go?' Journal of Diabetes Investigation, 2(1) pp. 18-32. 
 
Yamagishi, S.-i. (2011) 'Role of advanced glycation end products (AGEs) and receptor for AGEs 
(RAGE) in vascular damage in diabetes.' Experimental Gerontology, 46(4) pp. 217-224. 
 
Yamagishi, S.-i. and Imaizumi, T. (2005) 'Diabetic vascular complications: pathophysiology, 
biochemical basis and potential therapeutic strategy.' Current Pharmaceutical Design, 11(18) 
pp. 2279-2299. 
 
Yamagishi, S.-I., Inagaki, Y., Okamoto, T., Amano, S., Koga, K. and Takeuchi, M. (2003) 
'Advanced glycation end products inhibit de novo protein synthesis and induce TGF-β 
overexpression in proximal tubular cells.' Kidney International, 63(2) pp. 464-473. 
 
Yamagishi, S.-i., Matsui, T., Nakamura, K., Inoue, H., Takeuchi, M., Ueda, S., Fukami, K., 
Okuda, S. and Imaizumi, T. (2008) 'Olmesartan blocks advanced glycation end products 
(AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression.' 
Microvascular Research, 75(1) pp. 130-134. 
 
Yamagishi, S., Hsu, C.-C., Taniguchi, M., Harada, S., Yamamoto, Y., Ohsawa, K., Kobayashi, K. 
and Yamamoto, H. (1995) 'Receptor-mediated toxicity to pericytes of advanced glycosylation 
end products: a possible mechanism of pericyte loss in diabetic microangiopathy.' 
Biochemical and Biophysical Research Communications, 213(2) pp. 681-687. 
 
  
225 
 
Yan, L.-J. (2014) 'Pathogenesis of chronic hyperglycemia: from reductive stress to oxidative 
stress.' Journal of Diabetes Research, 2014 
 
Yang, C.-t., Meng, F.-h., Chen, L., Li, X., Cen, L.-J., Wen, Y.-h., Li, C.-c. and Zhang, H. (2017) 
'Inhibition of methylglyoxal-induced AGEs/RAGE expression contributes to dermal 
protection by N-acetyl-L-cysteine.' Cellular Physiology and Biochemistry, 41(2) pp. 742-754. 
 
Yazdanpanah, L., Nasiri, M. and Adarvishi, S. (2015) 'Literature review on the management 
of diabetic foot ulcer.' World Journal of Diabetes, 6(1) p. 37. 
 
Yin, M.-c. and Cheng, W.-s. (2003) 'Antioxidant and antimicrobial effects of four garlic-
derived organosulfur compounds in ground beef.' Meat Science, 63(1) pp. 23-28. 
 
Yolanda, M.-M., Maria, A.-V., Amaia, F., Marcos, P., Silvia, P., Dolores, E. and Jesús, O. (2014) 
'Adult stem cell therapy in chronic wound healing.' J Stem Cell Res Ther, 4(162) p. 2. 
 
You, H.-J. and Han, S.-K. (2014) 'Cell therapy for wound healing.' Journal of Korean Medical 
Science, 29(3) pp. 311-319. 
 
Younus, H. and Anwar, S. (2016) 'Prevention of non-enzymatic glycosylation (glycation): 
Implication in the treatment of diabetic complication.' International Journal of Health 
Sciences, 10(2) p. 261. 
 
Yu, A.-N. and Zhang, A.-D. (2010) 'The effect of pH on the formation of aroma compounds 
produced by heating a model system containing L-ascorbic acid with L-threonine/L-serine.' 
Food Chemistry, 119(1) pp. 214-219. 
 
Yu, L., Yang, F., Jiang, L., Chen, Y., Wang, K., Xu, F., Wei, Y., Cao, X., Wang, J. and Cai, Z. (2013) 
'Exosomes with membrane‐associated TGF‐β1 from gene‐modified dendritic cells inhibit 
murine EAE independently of MHC restriction.' European Journal of Immunology, 43(9) pp. 
2461-2472. 
 
Yui, S., Sasaki, T., Araki, N., Horiuchi, S. and Yamazaki, M. (1994) 'Induction of macrophage 
growth by advanced glycation end products of the Maillard reaction.' The Journal of 
Immunology, 152(4) pp. 1943-1949. 
 
Zafarullah, M., Li, W., Sylvester, J. and Ahmad, M. (2003) 'Molecular mechanisms of N-
acetylcysteine actions.' Cellular and Molecular Life Sciences CMLS, 60(1) pp. 6-20. 
 
Zhang, J., Slevin, M., Duraisamy, Y., Gaffney, J., Smith, C. A. and Ahmed, N. (2006) 
'Comparison of protective effects of aspirin, D-penicillamine and vitamin E against high 
glucose-mediated toxicity in cultured endothelial cells.' Biochimica et Biophysica Acta (BBA)-
Molecular Basis of Disease, 1762(5) pp. 551-557. 
 
  
226 
 
Zhang, P., Zhong, S., Wang, G., Zhang, S.-y., Chu, C., Zeng, S., Yan, Y., Cheng, X., Bao, Y. and 
Hocher, B. (2018) 'N-Acetylcysteine Suppresses LPS-Induced Pathological Angiogenesis.' 
Cellular Physiology and Biochemistry, 49(6) pp. 2483-2495. 
 
Zhao, Y., Vanhoutte, P. M. and Leung, S. W. (2015) 'Vascular nitric oxide: Beyond eNOS.' 
Journal of Pharmacological Sciences, 129(2) pp. 83-94. 
 
Zvaifler, N. J., Marinova-Mutafchieva, L., Adams, G., Edwards, C. J., Moss, J., Burger, J. A. and 
Maini, R. N. (2000) 'Mesenchymal precursor cells in the blood of normal individuals.' Arthritis 
Research & Therapy, 2(6) p. 477. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
227 
 
Appendices  
Appendix A 
 
1. AGE formation of lysozyme induced by MG 
Lysozyme glycation by MG after 24 hours 
 
 
Lysozyme glycation by MG after 72 hours  
 
 
 
 
 
 
 
 
 
 
Compartion between stains 
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2. Detection of AGEs by SDS-PAGE-silver stain 
 
The effect of SAC on MG-derived AGE formation 
 
 
 
The effect of NAC on MG-derived AGE formation 
 
 
 
 
The effect of SAC/NAC on the cross-linked AGE formation 
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Comparison between mimic compounds A, B and C on MG-induced AGE formation 
 
 
 
 
The effect of SAC/NAC on MG-induced AGE formation 
  
 
 
 
 
The effect of compound A on MG-induced AGE formation 
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Effect of SAC/NAC and compound A on MG-induced AGE formation 
 
 
 
 
 
Effect of SAC/NAC-primed hADMSCs CM on MG-induced AGE formation 
 
 
 
Effect of compound A-primed hADMSCs CM on MG-induced AGE formation 
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Effect of SAC/NAC- and compound A-loaded hADMSCs CM on MG-induced AGE 
formation 
 
 
 
3. Detection of AGEs by Western blot 
Protein determination 
 
 
 
 
 
The effect of MG on BAEC glycation after 1 day 
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The effect of MG on BAEC glycation after 72 hours. 
 
 
 
The effect of MG on BAEC glycation after 5days. 
 
 
 
 
The effect of compound A on BAEC glycation.  
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The effect of SAC/NAC on BAEC glycation.  
 
 
 
 
The effect SAC/NAC and compound A of BAEC glycation.  
 
 
 
 
 
The effect of (SAC/NAC and compound A) - loaded hADMSCs CM 
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Appendix B: Angiogenesis 
 
Effect of glucose on BAEC wound healing 
 
 
 
 
 
Effect of glucose on tube formation  
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Effect of SAC/NAC pre-incubation in the presence of glucose on BAECs wound 
healing 
 
 
 
 
Effect of compound A pre-incubation in the presence of glucose on BAECs wound 
healing 
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Effect of SAC/NAC in the presence of glucose on BAECs tube formation 
 
 
 
 
Effect of compound A pre-incubation in the presence of glucose on BAECs tube 
formation 
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Effect of BSA-AGE on BAECs wound healing 
 
 
 
 
 
 
Effect of BSA-AGEs on BAEC tube formation 
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Effect of SAC/NAC in presence of BSA-AGE on BAEC wound healing 
 
 
 
 
 
 
Effect of compound A in presence of BSA-AGE on BAEC wound healing 
 
 
 
 
 
 
 
 
  
239 
 
Effect of SAC/NAC in presence of BSA-AGE on BAEC tube formation 
 
 
 
 
 
 
Effect of compound A in presence of BSA-AGE on BAEC tube formation 
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Effect of SAC/NAC on BAEC wound healing 
 
 
 
 
 
 
Effect of compound A on BAEC wound healing 
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Effect of SAC/NAC on BAEC tube formation 
 
 
 
 
 
Effect of compound A on BAEC tube formation 
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Effect of SAC/NAC- and compound A-loaded hADMSCs CM on BEAC wound 
healing  
 
 
 
 
 
Effect of SAC/NAC- and compound A-loaded hADMSCs CM on BAEC tube 
formation 
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Appendix C: HPLC 
 
Analysis of NAC hADMSCs-loaded CM with high performance liquid 
chromatography (HPLC)  
 
 
 
 
 
 
Detection of NAC by UV –DAD 
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HPLC analysis of NAC   
 
 
 
 
